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Background: Only one-third of patients with depression respond fully to treatment with antidepressant
medication. However, there is little robust evidence to guide the management of those whose symptoms
are ‘treatment resistant’.
Objective: The CoBalT trial examined the clinical effectiveness and cost-effectiveness of
cognitive behavioural therapy (CBT) as an adjunct to usual care (including pharmacotherapy) for primary
care patients with treatment-resistant depression (TRD) compared with usual care alone.
Design: Pragmatic, multicentre individually randomised controlled trial with follow-up at 3, 6, 9 and
12 months. A subset took part in a qualitative study investigating views and experiences of CBT, reasons
for completing/not completing therapy, and usual care for TRD.vii
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ABSTRACT
viiiSetting: General practices in Bristol, Exeter and Glasgow, and surrounding areas.
Participants: Patients aged 18–75 years who had TRD [on antidepressants for ≥ 6 weeks, had adhered to
medication, Beck Depression Inventory, 2nd version (BDI-II) score of ≥ 14 and fulﬁlled the International
Classification of Diseases and Related Health Problems, Tenth edition criteria for depression].
Individuals were excluded who (1) had bipolar disorder/psychosis or major alcohol/substance abuse
problems; (2) were unable to complete the questionnaires; or (3) were pregnant, as were those currently
receiving CBT/other psychotherapy/secondary care for depression, or who had received CBT in the
past 3 years.
Interventions: Participants were randomised, using a computer-generated code, to usual care or CBT
(12–18 sessions) in addition to usual care.
Main outcome measures: The primary outcome was ‘response’, deﬁned as ≥ 50% reduction in
depressive symptoms (BDI-II score) at 6 months compared with baseline. Secondary outcomes included
BDI-II score as a continuous variable, remission of symptoms (BDI-II score of < 10), quality of life, anxiety
and antidepressant use at 6 and 12 months. Data on health and social care use, personal costs, and time
off work were collected at 6 and 12 months. Costs from these three perspectives were reported using a
cost–consequence analysis. A cost–utility analysis compared health and social care costs with quality
adjusted life-years.
Results: A total of 469 patients were randomised (intervention: n = 234; usual care: n = 235), with
422 participants (90%) and 396 (84%) followed up at 6 and 12 months. Ninety-ﬁve participants (46.1%)
in the intervention group met criteria for ‘response’ at 6 months compared with 46 (21.6%) in the
usual-care group {odds ratio [OR] 3.26 [95% conﬁdence interval (CI) 2.10 to 5.06], p < 0.001}. In repeated
measures analyses using data from 6 and 12 months, the OR for ‘response’ was 2.89 (95% CI 2.03 to
4.10, p < 0.001) and for a secondary ‘remission’ outcome (BDI-II score of < 10) 2.74 (95% CI 1.82 to 4.13,
p < 0.001). The mean cost of CBT per participant was £910, the incremental health and social care cost
£850, the incremental QALY gain 0.057 and incremental cost-effectiveness ratio £14,911. Forty
participants were interviewed. Patients described CBT as challenging but helping them to manage their
depression; listed social, emotional and practical reasons for not completing treatment; and described
usual care as mainly taking medication.
Conclusions: Among patients who have not responded to antidepressants, augmenting usual care with
CBT is effective in reducing depressive symptoms, and these effects, including outcomes reﬂecting
remission, are maintained over 12 months. The intervention was cost-effective based on the National
Institute for Health and Care Excellence threshold. Patients may experience CBT as difﬁcult but effective.
Further research should evaluate long-term effectiveness, as this would have major implications for the
recommended treatment of depression.
Trial registration: Current Controlled Trials ISRCTN38231611.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 18, No. 31. See the NIHR Journals Library website
for further project information.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Many patients with depression who are prescribed antidepressants by their doctor do not get betterafter 6 weeks of treatment. Cognitive behavioural therapy (CBT) is a type of ‘talking therapy’ that has
been shown to help patients with previously untreated depression but there is little evidence about its
effectiveness as a ‘next-step’ treatment for those patients whose depression has not responded to
medication. To answer this question we studied 469 patients with depression who had been taking
antidepressants for at least 6 weeks and who had not got better. All continued with usual care from their
general practitioner, including medication, but half (234) received CBT in addition. We followed up
participants for 1 year and found that those who had CBT as well as usual care were approximately three
times more likely to have fewer depressive symptoms than those in the usual-care group. The treatment
was good value for money over the 12 months. Participants sometimes found therapy to be a challenging
and difﬁcult process, but felt that the techniques learned from CBT helped them better manage their
depression. This study has provided high-quality evidence that receiving CBT, in addition to continuing on
antidepressants as part of usual care, is an effective treatment for patients with depression who have not
got better on medication alone.xxv
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Depression is ranked among the top ﬁve contributors to the global burden of disease, and by 2030 is
predicted to be the leading cause of disability in high-income countries. Antidepressants are often the
ﬁrst-line treatment for depression and the number of prescriptions for antidepressants has risen
dramatically in recent years in the UK and elsewhere. Over 46 million prescriptions were issued in England
in 2011, at a cost of more than £27M. However, the recent STAR*D study (Sequenced Treatment
Alternatives to Relieve Depression) found that only one-third of patients responded fully to
pharmacotherapy and that half did not experience at least a 50% reduction in depressive symptoms
following 12–14 weeks of antidepressant medication. The reasons for this non-response are complex but
include treatment resistance (when an adequate dose and duration of treatment has been given).
Many deﬁnitions of treatment resistance have been proposed. These cover a broad spectrum, ranging
from failure to respond to at least 4 weeks of antidepressant medication given at an adequate dose to
classiﬁcation systems based on non-response to multiple courses of treatment. Irrespective of the deﬁnition
used, it is clear that treatment-resistant depression (TRD) has a considerable impact on individuals, health
services and society.
There is no standard approach to the management of TRD. ‘Next-step’ options include increasing
the dose of pharmacotherapy, switching to a different antidepressant or augmentation with another
pharmacological or psychological treatment. However, there is little robust evidence that these approaches
improve outcome.
There is good evidence that cognitive behavioural therapy (CBT), the most widely available structured
psychotherapy for depression, is effective for previously untreated episodes of depression. However, limited
access to psychological treatment in the UK and elsewhere has meant that, in clinical practice, CBT has
often been reserved for those who have not responded to antidepressants. CBT has been shown to
reduce rates of relapse, including among those with residual depressive symptoms, and combined
pharmacological and psychological treatment has been found to be more effective than either component
alone for patients with chronic depression, who are likely to include non-responders to medication.
However, to date, no large-scale randomised controlled trials (RCTs) have evaluated the effectiveness of
augmenting antidepressant medication with CBT following non-response to pharmacotherapy compared
with continuing pharmacotherapy as part of usual care as a ‘next-step’ option for patients with TRD.
Similarly, robust evidence regarding cost-effectiveness is lacking.Objectives
Amongst patients with TRD (deﬁned as those who have signiﬁcant depressive symptoms following at
least 6 weeks’ treatment with antidepressant medication at an adequate dose) in primary care, to
determine (1) the effectiveness of CBT in addition to pharmacotherapy in reducing depressive symptoms
and improving quality of life over the following 12 months (compared with usual care that includes
pharmacotherapy) and (2) the cost-effectiveness of this intervention.
In addition, this study incorporated a qualitative study to: (1) explore patients’ views and experiences of
CBT; (2) identify patients’ reasons for completing or not completing therapy; and (3) describe ‘usual care’
for this patient group.xxvii
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xxviiiMethods
This was an individually randomised, two-parallel group, pragmatic, multicentre RCT. Patients with TRD
were recruited from general practices in Bristol, Exeter and Glasgow, and surrounding areas.
Eligible patients were those who (1) were aged 18–75 years; (2) were currently taking antidepressants and
had done so for at least 6 weeks, and who had adhered to their medication; (3) had a Beck Depression
Inventory, 2nd version (BDI-II) score of at least 14; and (4) fulﬁlled International Classification of Diseases
and Related Health Problems, Tenth Edition (ICD-10) criteria for depression. Excluded were those who had
bipolar disorder, psychosis or major alcohol/substance abuse; those who were unable to complete the
questionnaires; and women who were pregnant. Also excluded were those who were currently receiving
psychotherapy (including CBT and counselling) or secondary care for their depression, and those who had
received CBT in the past 3 years.
A three-stage recruitment process was used to identify those who were eligible to participate in the trial.
Initially, general practices conducted a search of their computerised records to identify all patients who
had received repeated prescriptions for an antidepressant during the previous 4 months and who were
currently being prescribed an antidepressant at an adequate dose for depression. General practitioners
(GPs) then screened this list of patients and excluded those patients who fulﬁlled any of the exclusion
criteria described above. A letter of invitation and brief information leaﬂet about the study was sent by the
general practice to the potentially eligible participants. This letter sought permission for the research team
to contact them and to send a questionnaire asking about their depressive symptoms and adherence to
antidepressant medication. Patients replied directly to the study team, indicating whether or not they
agreed to be contacted.
General practitioners could also invite patients to take part in the study during a consultation. In such
cases, the GP provided the patient with an information leaﬂet about the study and obtained permission
from the patient to pass their contact details to the research team.
All those who agreed to be contacted by the research team (either in response to the postal invitation or
to a direct invitation from their GP during the consultation) were sent a postal questionnaire. This included
questions about their depressive symptoms (BDI-II) and use of antidepressants.
Those who met the deﬁnition of TRD [based on severity of depressive symptoms (BDI-II score of ≥14) and
adherence to antidepressants at an adequate dose for at least 6 weeks] were contacted by a researcher by
telephone to ascertain their eligibility with respect to current/past psychological treatment and current
secondary care for depression. Those who were not currently receiving (or scheduled to start) CBT or
secondary care for their depression, and who had not received CBT in the past 3 years, were invited to
attend a face-to-face appointment with a researcher to discuss participating in the trial and to assess
their eligibility.
Baseline assessments to establish eligibility were conducted in the patients’ own homes, at their GP
surgeries or at nearby NHS/University premises. Only those patients who fulﬁlled ICD-10 criteria (category
F32) for their current depressive episode (assessed using the revised Clinical Interview Schedule), had a
BDI-II score of ≥14 and who were continuing to take the prescribed antidepressants at an adequate dose
were eligible to participate in the trial.
Those who were eligible and gave written informed consent were randomised, using a
computer-generated code, to one of two groups: ‘usual care’ or ‘CBT in addition to usual care’.
Randomisation was carried out using a remote automated telephone system, and was stratiﬁed by centre
and minimised on baseline BDI-II score (mild 14–19; moderate 20–28; severe ≥ 29), whether the general
practice had a counsellor (yes/no), prior treatment with antidepressants (yes/no) and duration of theNIHR Journals Library www.journalslibrary.nihr.ac.uk
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were taking antidepressant medication and expected to continue to do so as part of usual care.
Those allocated to the intervention group received a course of individual face-to-face CBT comprising
12 sessions, with (up to) a further six sessions if deemed clinically appropriate by the therapist. There were
no restrictions on the treatment options for those randomised to continue with usual care from their GP.
Participants were followed up at 3, 6, 9 and 12 months. To maximise response rates, follow-up
assessments at 6 and 12 months were conducted at a face-to-face appointment with a researcher, with
the 3- and 9-month follow-up data collected over the telephone.
The primary outcome was ‘response’, deﬁned as at least a 50% reduction in depressive symptoms (BDI-II
score) at 6 months compared with baseline. Secondary outcomes included the BDI-II score as a continuous
variable, remission of symptoms (BDI-II score of < 10), quality of life [European Quality of Life-5
Dimensions-3 Levels (EQ-5D-3)], anxiety and antidepressant use at 6 and 12 months. Data on health and
social care use, personal expenditure including private treatments and complementary/alternative
therapies, and time off work were also collected at 6 and 12 months.
The primary comparative analyses of clinical effectiveness were conducted according to the principle of
intention-to-treat without imputation of missing data.
Costs from the three perspectives (health and social care, patients, and lost productivity) were reported
using a cost–consequence analysis. A cost–utility analysis compared health and social care costs with
quality-adjusted life-years (QALYs). Discounting was not applied.
Patients were contacted about taking part in the qualitative study after they had completed their primary
outcome measures for the trial at 6 months post randomisation. A purposeful sampling strategy was used
to ensure interviews were held with individuals in both arms of the trial and, within the intervention arm,
with patients who had and had not completed therapy.
Interviews were held face to face, audio-taped and fully transcribed. Data were analysed thematically to
allow comparisons to be made within and across the interviews, and to highlight patients’ views on
speciﬁc issues, for example, their experiences of CBT. The software package Atlas.ti was used to aid data
management. Data collection ended when data saturation had been reached.Results
In total, 73 general practices agreed to take part in the study and 749 baseline assessments were
conducted. Four hundred and sixty-nine patients were eligible and gave written informed consent for trial
participation, and were randomised, with 234 allocated to receive the intervention and 235 to continue
with usual care. Ninety per cent of participants (n = 422) were followed up at 6 months and 396 (84%)
were followed up at 12 months.
The average duration of the intervention (from randomisation) was 6.3 months (standard deviation 3.0).
Twenty participants (8.5%) did not attend any therapy sessions. In total, 74 participants (31.6%) either
withdrew from therapy (n = 47) or were discharged, having repeatedly not attended appointments
(n = 27). A further 23 participants reached an ‘agreed end’ in less than 12 sessions.
By 6 months, those randomised to the intervention had received a median of 11 sessions of CBT
[interquartile range (IQR) 5–13] and 62% (n = 144) had received at least nine sessions. By 12 months,
the median was 12 (IQR 6–17) and 141 participants had received at least 12 sessions.xxix
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xxxNinety-ﬁve participants (46.1%) in the intervention group met criteria for ‘response’ at 6 months
compared with 46 (21.6%) in the usual-care group {odds ratio [OR] 3.26 [95% conﬁdence interval (CI)
2.10 to 5.06], p < 0.001}. In repeated measures analyses using data from 6 and 12 months, the OR for
‘response’ was 2.89 (95% CI 2.03 to 4.10), p < 0.001, and for a secondary ‘remission’ outcome
(BDI-II score of < 10) the OR was 2.74 (95% CI 1.82 to 4.13), p < 0.001. Those in the intervention group
were also more likely to report greater improvements in quality of life over the 12 months [difference in
mean Short-Form questionnaire-12 items (SF-12) mental health subscale scores between treatment groups:
4.8 (95% CI 2.7 to 6.9) p < 0.001].
The mean cost of CBT per participant was £910. The cost of the intervention was slightly offset by the
higher cost (£59) of health and social care in the usual-care group, giving an incremental cost of £850. In
line with the clinical outcomes, participants receiving the intervention experienced a better health-related
quality of life as measured by QALYs (0.61 vs. 0.55), giving a cost per QALY over the 12 months of
£14,911 (incremental cost-effectiveness ratio).
If society is willing to pay £20,000 per QALY, the net monetary beneﬁt (NMB) per patient per year is £289
(95% CI –£603 to £1182) and the probability that the intervention is cost-effective is 0.74. At a threshold
of £30,000 per QALY, the NMB increases to £859 (95% CI –£455 to £2179), with a commensurate
increase in the probability that the intervention is cost-effective (0.91).
In total, 40 interviews were conducted for the nested qualitative study. Twenty-six of these interviews were
with patients in the intervention arm, nine of whom had not completed therapy within the trial. On
average, the interviews lasted about an hour. Participants who had been allocated to receive the
intervention reported that CBT had given them techniques to help them better manage their symptoms.
Patients described components of CBT that they struggled with, or were a barrier to them completing the
therapy, but still felt they had beneﬁted from the sessions. Patients’ accounts of usual care indicated that
this mainly consisted of taking antidepressants.ConclusionsImplications for health carel CBT given as an adjunct to usual care (that includes pharmacotherapy) was found to be an effective
‘next-step’ treatment (when compared with usual care alone) for primary care patients with depression,
who had not responded to treatment with pharmacotherapy alone. The intervention was effective in
both reducing depressive symptoms and improving quality of life, and these beneﬁts were maintained
over 12 months.
l The economic evaluation showed that the intervention was cost-effective over 12 months, based
on the threshold of £20,000 per QALY used by the National Institute for Health and Care Excellence.
l The qualitative ﬁndings suggested that practitioners referring patients for CBT, for example GPs, should
discuss the potential challenges of this therapy with patients to help them make an informed choice
about referral for CBT.Future research implications (in order of priority)l Further research needs to evaluate effectiveness of this intervention over the long term. CBT has the
potential to produce a more sustainable improvement than pharmacotherapy alone. If this intervention
was found to be cost-effective over the long term, this would have major implications for
recommendations as to how depression should be managed.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31l Although nearly half of those in the intervention group met the criteria for response, 54% did not.
Therefore, it is a priority that the evidence base for the effectiveness of a range of ‘next-step’
treatments for those who do not respond to medication alone is expanded. Although many different
strategies have been evaluated, to date there is little robust evidence regarding the effectiveness of
many of these strategies. Only by obtaining robust evidence on the effectiveness and cost-effectiveness
of a range of ‘next-step’ psychological and pharmacological interventions will it be possible to reduce
the considerable burden to patients, the NHS and society, which is associated with non-response to the
most common ﬁrst-line treatment for depression in primary care.Trial registration
This trial is registered as ISRCTN38231611.Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.xxxi
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Depression is ranked among the top ﬁve contributors to the global burden of disease, and by 2030 ispredicted to be the leading cause of disability in high-income countries.1 Antidepressants are often
the ﬁrst-line treatment for depression and the number of prescriptions for antidepressants has risen
dramatically in recent years in the UK2 and elsewhere.3,4 Over 46 million prescriptions were issued in
England in 2011, at a cost of more than £270M.5 However, the recent STAR*D (Sequenced Treatment
Alternatives to Relieve Depression) study found that only one-third of patients responded fully to
pharmacotherapy and that half did not experience at least a 50% reduction in depressive symptoms
following 12–14 weeks of antidepressant medication.6 The reasons for this non-response are complex but
include (1) intolerance to medication; (2) treatment resistance (when an adequate dose and duration of
treatment has been given) and (3) non-adherence to the treatment regime (both in terms of adherence to
medication and failure to attend follow-up). Under-treatment of depression is also a recognised problem.7
The high prevalence of depression means that effective interventions have the potential to substantially
impact on the economic cost of this condition (to the NHS, patients and society).8Deﬁning treatment resistanceIt is important to separate treatment resistance from a lack of tolerance of medication. For the latter, the
clinician’s ‘next step’ would be to switch the patient to a different antidepressant to ﬁnd one that could be
tolerated and determine the outcome for an adequate trial of such medication before seeking alternative
treatment options based on the problem of resistance.
Many deﬁnitions of treatment resistance have been proposed. These deﬁnitions cover a broad spectrum
ranging from failure to respond to at least 4 weeks of antidepressant medication given at an adequate
dose9 to classiﬁcation systems based on non-response to multiple courses of treatment.10,11 Irrespective of
the deﬁnition used, it is clear that treatment-resistant depression (TRD) has a considerable impact on
individuals, health services and society.
In the 2004 depression guidelines,12 the National Institute for Health and Care Excellence (NICE) deﬁned
TRD as failure to respond ‘to two or more antidepressants given sequentially at an adequate dose for
an adequate time’, but this could include individuals who have failed to respond to two different
antidepressants that have the same pharmacological action. More recent guidance advocates that general
practitioners (GPs) should reconsider treatment options if there has been little or no response after
4–6 weeks of antidepressant medication.13 Options for the ‘next-step’ treatment include increasing the
dose of medication, switching to a different antidepressant (either within or across pharmacological class)
or augmentation with another pharmacological or psychological treatment.13 However, there is currently
little evidence to guide management after the initial 6 weeks of treatment. Hence for the research
reported here we propose a more inclusive deﬁnition of TRD, directly relevant to UK primary care, given
the uncertainty about what course of action to recommend to patients who have not responded to at
least 6 weeks of antidepressant medication. These patients will be heterogeneous in terms of prior
treatment, but all will have not responded to at least 6 weeks’ medication, thus ensuring trial results
are generalisable.Existing evidence on the management of treatment-resistant
depressionThe evidence from randomised controlled trials (RCTs) investigating pharmacological and psychological
interventions for patients with TRD was summarised up to January 2001.14 This systematic review included
all studies in which patients with unipolar depression had not responded to at least 4 weeks of1
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Wiles et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
INTRODUCTION
2antidepressant medication at an adequate dose. Despite the broad inclusion criteria, the authors
concluded that there was little evidence to guide the management of this patient group. Augmentation of
pharmacotherapy was the most common treatment approach for such patients, but the RCTs were very
small and of poor methodological quality and hence no precise treatment effects could be obtained. At
that time, no RCTs had examined a psychological intervention for TRD. In December 2004, NICE published
guidelines for the management of depression suggesting that ‘the combination of antidepressant
medication with [face-to-face] cognitive behavioural therapy (CBT) should be considered’ for patients with
TRD.12 However, this report acknowledged ‘signiﬁcant limitations to the current evidence base’ [grade B
evidence (no RCTs)]12 and there are few data on what constitutes ‘usual care’ for this patient group.
A review on the evidence for the effectiveness of psychological interventions for adults with TRD is
currently being prepared for publication in The Cochrane Library (www.thecochranelibrary.com). In short,
despite 10 years having elapsed since the earlier publication by Stimpson et al.,14 the evidence base for this
area remains weak. Three small studies (n < 50) of CBT have been published. One was our pilot study
(n = 25) for the present CoBalT (Cognitive behavioural Therapy as an adjunct to pharmacotherapy for
primary care patients with treatment resistant depression) RCT.15 The second (n = 44) examined the effect
of augmentation with CBT among partial responders to antidepressants16 and the third study (n = 36),
conducted among inpatients, was published only as a conference abstract.17 Neither of the last two studies
included a group who remained on antidepressants in order to evaluate the effectiveness of CBT as an
adjunct to antidepressant medication (comparators: lithium augmentation16 and augmentation with
supportive therapy17).
The REVAMP (Research Evaluating the Value of Augmenting Medication with Psychotherapy) trial18 recruited
patients with chronic depression (deﬁned as persistent depressive symptoms for > 2 years), who had not
responded or only partially responded to 12 weeks of antidepressant medication. However, they found no
difference in depression outcomes (symptoms, ‘response’ or ‘remission’) between those who switched to the
next step in a medication algorithm and those who received psychotherapy [cognitive behavioural analysis
system of psychotherapy (CBASP) or brief supportive psychotherapy (BSP)], and no difference in outcomes
between the two different psychotherapies (CBASP vs. BSP).18
The large US STAR*D study recruited 2876 patients with depression, and invited those who failed to
respond to up to 14 weeks’ treatment with citalopram (Celexa®, Forest Laboratories Inc.) to take part in a
RCT of various treatment options, including switching or augmenting with either antidepressants or
CBT.19–21 However, the STAR*D RCT included patients who could not tolerate citalopram, as well as those
who were treatment resistant. This makes it difﬁcult to apply the ﬁndings to clinical practice because, in
practice, the clinician would try to ﬁnd an antidepressant that the patient could tolerate and prescribe this
for an appropriate interval at an adequate dose before deciding that the patient was treatment resistant
and seeking alternative treatment options. However, more importantly, in STAR*D there was no
comparison group of patients who continued on citalopram, so the effect of augmenting antidepressant
medication with CBT as a ‘next-step’ treatment option cannot be ascertained from the STAR*D RCT. Given
frequent patient preference for ‘talking therapy’,22 the lack of evidence of effectiveness of psychological
interventions in this patient group is an important deﬁcit. Furthermore, it is important that such trials are
conducted in the UK, as data from other countries may not generalise to UK primary care owing to
differences in health services and the clinical characteristics of patients presenting therein. Moreover, the
UK needs information on cost-effectiveness that can be applied to the NHS. While it has become more
commonplace for an economic evaluation to run alongside a RCT, this has not been the case historically.
There are currently few data on the cost-effectiveness of CBT interventions. Those that exist relate to CBT
for relapse prevention23 or CBT delivered in ‘real time’ over the internet using an instant messaging
service.24 Other reports on cost-effectiveness of CBT, for example, Durham et al.,25 are conﬁned to
different patient populations (anxiety/psychosis) and varied CBT interventions (including low-intensity
interventions comprising, on average, four sessions with a contact time of just 2.6 hours) and cannot be
generalised more widely.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31Ongoing studiesThere are two small studies of CBT for TRD that are registered as ongoing on the clinical trials registers
[‘www.controlled-trials.com’ and ‘www.clinicaltrials.gov’, searched 21 February 2013 (search terms:
CBT/cognitive therapy and depression)]. The ﬁrst, a UK-based study, aimed to recruit 24 patients
from secondary care to determine the effectiveness of CBT compared with usual care for TRD
(ISRCTN53305823). The study commenced in 2006 but was not completed owing to unexpected stafﬁng
changes (Stephen Barton, Newcastle University, 14 March 2012, personal communication). In addition, a
US pilot study (n = 30) aimed to examine the effectiveness of CBT and desipramine compared with
medication alone in outpatients with TRD (NCT00000376: anticipated start/end dates: 03/1996–02/1999).
Although the anticipated end date of the trial was given as February 1999, no results have been published
to date.
In addition, there are a number of ongoing studies of other psychological interventions for patients
with TRD. For example, the Tavistock Adult Depression Study is examining the effectiveness of
60 sessions of weekly psychoanalytic psychotherapy compared with usual care in 90 patients with TRD
(www.tavistockandportman.nhs.uk/adultdepressionstudy, ISRCTN40586372). The REFRAMED trial
(www.reframed.org.uk, anticipated start/end dates: 1 January 2012 to 1 September 2014;
ISRCTN85784627) is evaluating the effectiveness of Dialectical Behaviour Therapy (DBT) for TRD. A
Canadian study (NCT01141426), currently in set-up, will evaluate the effectiveness of intensive short-term
dynamic psychotherapy (ISTDP) compared with usual care in patients with an inadequate response to at
least 6 weeks’ antidepressant medication. Others are recruiting to a RCT to examine the clinical
effectiveness and cost-effectiveness of a specialist expert mood disorder team for refractory unipolar
depressive disorder (NCT01047124).26 CBT will be provided as part of the treatment offered by this
specialist team to secondary care patients. Finally, the PATH-D study (NCT01021254) will examine the
effectiveness of mindfulness-based cognitive therapy (MBCT) compared with a health-enhancement
programme for patients with TRD.Cognitive behavioural therapy for treatment-resistant
depressionMany patients with depression express a preference for ‘talking therapies’,22 and some have estimated a
need for 250 psychological treatment centres.8 In England,27,28 and elsewhere,29,30 there have been
initiatives to improve access to psychological therapies. CBT is the most widely available structured
psychotherapy for depression in specialist mental health services in the NHS, and has been shown to be
more effective than other psychotherapies in improving outcome in depression.31 Nonetheless, although
CBT is an effective treatment for previously untreated episodes of depression,31 this evidence is not speciﬁc
to patients with TRD. Yet, in practice in the NHS, CBT is often reserved for those who have not responded
to pharmacotherapy in primary care (i.e. those who are treatment resistant). The roll-out of the Improving
Access to Psychological Therapies (IAPT) project27,28,32,33 means that it is important (and timely) to examine
the effectiveness of CBT for patients with TRD.
Cognitive behavioural therapy has been proposed as an adjunct to pharmacotherapy in patients with TRD.
Although there is currently no evidence for the effectiveness of CBT in this group, there are indications
that psychological treatments may be effective. In patients with residual depressive symptoms, who were
randomised to receive CBT (16 sessions over 20 weeks), the relapse rate was signiﬁcantly reduced (after
68 weeks) compared with usual care.34 This beneﬁt was lost fully only 3–4 years after the end of
treatment.35 There is also an increasing literature on the use of combination therapy for depression, which
suggests that there is a small beneﬁt of combination therapy compared with medication alone in reducing
depressive symptoms,36,37 although the evidence base for patients with TRD is lacking. Furthermore, others
have noted some beneﬁt of combined treatment for those with chronic depression (deﬁned as at least
2 years’ duration). For example, Keller et al.38 found that the combination of nefazodone (now withdrawn)3
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INTRODUCTION
4and psychotherapy was more effective than either component alone in reducing depressive symptoms
after 12 weeks.
From clinical practice it is known that not all patients who are offered psychotherapy will complete the
course. Although no ﬁgures speciﬁc to this patient group and intervention are available, it has been
estimated that around 47% of individuals do not complete a course of psychotherapy.39 Quantitative
studies have suggested that non-completion is more common among those of lower socioeconomic
background, but there are few other consistent predictors.39 Importantly, as there has been little qualitative
research in this area, there is only limited understanding of why patients adhere to psychotherapy or not,
and, likewise, for the rationale behind their decisions. Researchers have used qualitative methods to
explore people’s experiences of CBT40,41 and their work shows the value of listening to patients, particularly
in relation to better understanding patients’ views on both the therapeutic process and outcomes of
therapy. To our knowledge, to date no one has focused speciﬁcally on the views and experiences of
patients with TRD who have received CBT.
Qualitative research methods are increasingly being used within RCTs to investigate patients’ experiences
of participation and trial processes (e.g. how interventions are implemented and delivered42,43) and the UK
Medical Research Council (MRC) recommends that both qualitative and quantitative methods are used to
evaluate complex interventions.44 Data collected during in-depth interviews or focus groups with trial
participants can provide detailed insight into their experiences of the trial and intervention, and the extent
to which they view a particular treatment as acceptable and effective. Such data can also illuminate
possible reasons for the quantitative ﬁndings and give another viewpoint from which to evaluate the
treatment being delivered.Summary of rationale for randomised controlled trialIn summary, given the frequently expressed patient preference for talking therapies, the recent initiatives
to widen access to ‘talking therapies’27–30 and the paucity of evidence for interventions for patients
with TRD, there is clearly a need for a large-scale pragmatic RCT to examine the effectiveness and
cost-effectiveness of CBT as an adjunct to pharmacotherapy, as a ‘next-step’ option for patients who have
not responded to antidepressant medication. As indicated earlier, there are reasons to believe that a CBT
intervention may be effective and such a trial would make a major contribution to the evidence base for
the ‘next-step’ options for the treatment of depression. It is important that any such trial uses an inclusive
deﬁnition of treatment resistance (based on non-response to at least 6 weeks of antidepressant
medication) that is directly relevant to the manner in which depression is typically treated in UK
primary care.13
Given the high prevalence of depression in primary care, an effective intervention has the potential to have
a substantial impact on the economic burden associated with this patient group. Currently, the lack of
evidence means that clinicians are increasingly faced with a dilemma as to what action to recommend to
patients who do not respond to antidepressants.Research objectivesAmongst patients with TRD (deﬁned as those who have signiﬁcant depressive symptoms following at
least 6 weeks’ treatment with antidepressant medication at an adequate dose) in primary care, to
determine (1) the effectiveness of CBT in addition to pharmacotherapy in reducing depressive symptoms
and improving quality of life over the following 12 months (compared with usual care that includes
pharmacotherapy) and (2) the cost-effectiveness of this intervention. In addition, this study will incorporate
a qualitative study to (1) explore patients’ views and experiences of CBT; (2) identify patients’ reasons
for completing or not completing therapy and (3) describe ‘usual care’ for this patient group.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31Chapter 2 MethodsStudy designThe CoBalT study was a multicentre, pragmatic RCT with two treatment groups: a usual-care group and
an intervention group. The intervention consisted of 12–18 sessions of CBT in addition to usual care.
For both groups, usual care included antidepressant medication as well as continued support and advice
from the GP.
An economic evaluation was conducted alongside the RCT in order to evaluate the cost-effectiveness of
the intervention (see Chapter 4). The nested qualitative study is described in more detail (see Chapter 5).
The trial protocol has been published.45Ethical approval and research governanceEthical approval for the study was given by West Midlands Multicentre Research Ethics Committee –
ref. no. NRES/07/H1208/60. Site-speciﬁc approvals were obtained from the relevant Local Research
Ethics Committees and primary care trusts (PCTs)/health boards covering the three study sites (Bristol,
Exeter and Glasgow). In addition, research governance approval was obtained from Avon & Wiltshire
Mental Health Partnership NHS Trust, who were the employers of, and whose premises were used, on
occasion, by the Bristol therapists. The trial was registered with the International Standard Randomised
Controlled Trial Number Register (ISRCTN38231611). A summary of the changes made to the original
protocol is given in Table 1.
Participants
The study sought to recruit patients with TRD from 73 general practices across the three centres.Inclusion criteria
Eligible patients were those aged 18–75 years, who were currently taking antidepressant medication, and
had done so for at least 6 weeks at an adequate dose [based on the British National Formulary (BNF:
www.bnf.org.uk/bnf) and advice from psychopharmacology experts)] (see Appendix 1). In addition, it was
necessary for eligible patients to have adhered to their antidepressant medication, score ≥ 14 on the Beck
Depression Inventory, second version (BDI-II)46 and meet International Classification of Diseases and Related
Health Problems, Tenth Edition (ICD-10), criteria for depression, assessed using the revised Clinical
Interview Schedule (CIS-R).47
It is difﬁcult to measure adherence to medication. Therefore, our deﬁnition of treatment resistance was
operationalised using the Morisky scale, a four-item self-report measure of adherence,48 which had
previously been validated against electronic monitoring medication bottles. A score of ‘0’ (range 0–4) on
this scale was indicative of at least 80% adherence.49 Given the relatively long half-life of antidepressant
medication, an additional item (‘Did you miss 2 days’ antidepressant tablets in a row?’ yes/no) was added
to this scale to ensure that only individuals who had missed more than one consecutive dose
were excluded.5
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TABLE 1 Summary of changes to the original CoBalT trial protocol
Description Submitted Approved
Original submission 19 October 2007 26 February 2008
Amendment 1 (protocol v3)
l Additional/changes to baseline/outcome measures
12 March 2008 15 April 2008
Amendment 2 (protocol v4)
l Alteration of minimisation variables
l Clariﬁcation of excluded psychotherapy treatments
8 August 2008 3 September 2008
Amendment 3 (protocol v5)
l Amendment for those taking part in other research studies
l Letters of invitation to participate v2
l Initial participant information leaﬂet v3
l Screening questionnaire cover letter v2
30 September 2009 14 October 2009
Amendment 4 (protocol v6)
l Permission to conduct qualitative interviews with participants who
decline the baseline assessment
l Change to time frame of data collection from GP notes
l Permission to feedback summary information to GPs on randomised
participants
9 February 2010 28 April 2010
Amendment 5 (protocol v7)
l Extension of window to conduct qualitative interviews from
8–12 months post randomisation
17 July 2010 29 July 2010
Amendment 6 (protocol v8)
l Permission to offer all randomised participants the option of
receiving a £10 gift voucher after completion of 6-month outcome,
as a gesture of goodwill
27 September 2010 10 October 2010
Amendment 7 (protocol v9)
l Permission to extract information on conditional beliefs from
therapist case notes
10 May 2011 20 May 2011
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6Exclusion criteria
General practitioners were asked to exclude those patients who fulﬁlled any of the following exclusion
criteria at the time of the record search:
l patients who had bipolar disorder, psychosis or major alcohol or substance abuse problems
l patients who were not able to complete the study questionnaires
l patients who were currently receiving CBT or other psychotherapy or secondary care for depression, or
who had received CBT in the past 3 years
l women who were pregnant (women who became pregnant during the trial were able to continue to
participate with consent and approval of their GP).
Patients who were currently taking part in another intervention study were excluded, although they were
offered the opportunity to participate in CoBalT once their involvement in the other research study had
ended. In addition, GPs excluded any patients whom they considered it would be inappropriate to invite.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31Recruitment of participantsEligible participants were identiﬁed using a three-stage process (Figure 1).Filter 1: search of general practitioner computerised records to identify
patients being treated for depression
The search of GP computerised records identiﬁed all patients in the appropriate age range who had
received repeated prescriptions for an antidepressant during the previous 4 months, and who were
currently being prescribed an antidepressant medication at an adequate dose for depression.
General practitioners then screened this list of patients and excluded those who fulﬁlled any of the
exclusion criteria listed above. A letter of invitation and brief information leaﬂet about the study was sent
by the general practice to the remaining potential participants. This letter sought permission for the
research team to contact them and to send a questionnaire asking about their depressive symptoms and
adherence to antidepressant medication. Patients replied directly to the study team, indicating whether or
not they agreed to be contacted. One reminder was sent to those who did not respond to the initial letter
of invitation.
On the reply slip, those who did not wish to participate were asked to indicate their age, gender and
reason for non-participation. In addition, non-participants were asked to indicate their willingness to take
part in a brief telephone interview to discuss their reasons for non-participation. This would provide more
detailed insight into the reasons for non-participation and, in particular, the potential demand for CBT by
this patient group.
Anonymised data on age and gender of those patients who were mailed an invitation to participate
but who did not respond (or refused to participate when invited during the consultation) were collected to
assess the generalisability of the study ﬁndings. GPs could also invite patients to take part in the study
during a consultation. In such cases, the GP provided the patient with an information leaﬂet about the
study and obtained permission from the patient to pass their contact details to the research team. The
research team then mailed a questionnaire to the patient asking them about their depressive symptoms
and adherence to antidepressant medication (as earlier).Filter 2: assessment of depressive symptoms and adherence
to antidepressants
All of those who agreed to be contacted by the research team (either in response to the postal invitation
or to a direct invitation from their GP during the consultation) were sent a postal questionnaire. This
questionnaire collected data on the following:
l sociodemographic variables (age, gender, marital status, ethnicity, educational qualiﬁcations,
employment status, home ownership and ﬁnancial difﬁculties)
l severity of depressive symptoms, using the BDI-II46
l duration of antidepressant treatment, dose of medication and adherence to medication.48
One reminder was sent to those individuals who did not return a completed postal questionnaire
within 2 weeks.
Those who met the deﬁnition of TRD (based on severity of depressive symptoms and adherence to
antidepressants at an adequate dose for at least 6 weeks) were contacted by a researcher by telephone to
ascertain their eligibility with respect to current/past psychological treatment and current secondary care
for depression. Those who were not currently receiving (or scheduled to start) CBT or secondary care for
their depression, and who had not received CBT in the past 3 years, were invited to attend a face-to-face
appointment with a researcher to discuss participating in the trial and to assess their eligibility. The date,
time and location of the baseline appointment were conﬁrmed by letter. A detailed patient information7
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Patients on antidepressants at an adequate dose for
depression identified through search of
GP’s computerised records or referred by GP
Patients excluded by GP
Total number of letters of invitations/referrals
Responders to invitation Non-responders to invitation
Declined further contact
Agreed to further contact and screening questionnaire sent
Did not complete assessment screen
• Non-response to postal questionnaire
• Declined questionnaire or telephone screen
Ineligible at assessment screen
• Inadequate dose/duration, non-adherent
   or BDI score < 14
• Other treatment
• Medication change
• Other reason
Eligible for baseline assessment
Declined to take part in baseline assessment
Agreed to eligibility screen
Ineligible to participate in trial
Eligible but declined further participation
Eligible and informed consent obtained (randomised)
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DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31leaﬂet and a leaﬂet that provided an introduction to CBT were also enclosed, and the patient was asked to
read both of these prior to attending the baseline appointment.
Those who were currently receiving non-CBT therapy [e.g. computerised CBT (cCBT) or counselling] were
given the option of being contacted again for a rescreen once their current treatment had ﬁnished. An
‘end of therapy’ date was taken and the patients were mailed a second postal screen after this point to
assess whether they were eligible to participate in the trial.
Those who completed the screening process (postal questionnaire with or without telephone
questionnaire), but were not eligible to participate, received a letter informing them of this and thanking
them for taking part. The letter explained that their GP had also been informed and would continue to
care for them as usual. The GP received a letter that explained that the patient was ineligible as they had
not met one or more of the eligibility criteria, but that the GP could refer the patient back to the trial if
these factors changed. If the patient had given permission in the postal questionnaire, the GP also received
a report that gave more detail about the inclusion criteria that were/were not satisﬁed, as well as the
individual’s score on the BDI-II.Filter 3: baseline assessment
Baseline assessments to establish eligibility were conducted in the patients’ own home, at their GP
surgery or at nearby NHS/university premises. Only those patients who fulﬁlled ICD-10 criteria (F32) for
their current depressive episode (assessed using the CIS-R47), had a BDI-II score of ≥ 14 and who were
continuing to take the prescribed antidepressants at an adequate dose were eligible to participate in
the trial.
As well as completing the CIS-R and BDI-II in order to assess eligibility, the baseline assessment also collected
information on life events, social support, smoking habits and use of alcohol.50 Sociodemographic details
were also recorded (age, gender, ethnicity, marital status), together with information on a number of
socioeconomic markers (including employment status, housing situation, ﬁnancial stress). Questions on
post-traumatic stress disorder (PTSD) (PC-PTSD:51 Primary Care Post-traumatic Stress Disorder) and personality
(Big Five neuroticism scale52) were also collected at baseline. Additional measures such as the Patient Health
Questionnaire-9 items (PHQ-9),53 the Generalised Anxiety Disorder Assessment-7 items (GAD-754), panic
(from the Brief Patient Health Questionnaire),55 the Short-Form questionnaire-12 items (SF-12)56 and
European Quality of Life-5 Dimensions-3 Levels (EQ-5D-3L)57 were collected at baseline and at subsequent
follow-ups, as were measures of dysfunctional attitudes58 and metacognitive awareness59 (see Secondary
outcomes, below, for more detail).
Prior to randomisation, participants were asked to indicate whether or not they had any preference for
treatment (‘prefer CBT (in addition to usual care)’, ‘prefer usual care’ or ‘don’t mind’) and also asked about
whether or not they thought that CBT would help them (based on a list of ﬁve response options: ‘CBT
would deﬁnitely help me’; ‘CBT would probably help me’; ‘I don’t know if CBT would help me’; ‘CBT
would probably not help me’; and ‘CBT would deﬁnitely not help me’). The latter information was used in
an a priori subgroup analysis to examine the inﬂuence of patient expectation of effectiveness of the trial
intervention on outcome.
If a patient was not eligible to take part in the trial, they were informed of this and thanked for their time.
It was explained to them that their GP would also be informed and that a summary giving more detail
about the inclusion criteria that were/were not fulﬁlled, and their depressive symptoms (scores on
the BDI-II at postal screen and baseline) could be fed back to their GP, if they had given permission. If the
patient was eligible to participate, the individual was asked whether or not they were happy to proceed
and, if so, written informed consent was obtained.
Prior to the start of the baseline assessment, patients were asked to provide informed, written consent for
the storage and processing of the data collected at the time of the assessment. This covered the data9
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10collected from both those who were found to be ineligible to participate in the trial as well as those who
were eligible, thus enabling the trial to be reported in line with CONSORT (Consolidated Standards of
Reporting Trials) guidelines.60 Those patients who were identiﬁed as eligible to participate in the trial were
asked to provide additional informed, written consent for this purpose. The original signed and dated
consent forms were held securely as part of the trial site ﬁle, with copies for both the participants and their
GPs for their records.Randomisation, concealment of allocation and blinding
Randomisation was at the level of the individual, with eligible and consenting patients randomised at the
end of their baseline assessment to one of two treatment groups: ‘Usual care’ or ‘Usual care plus CBT’.
At the point of randomisation, all patients were taking antidepressants and had agreed with their GP to
continue with such medication as part of their usual care.
To conceal the allocation of treatment from those conducting the research, randomisation of individual
participants to one of the two treatment arms was undertaken using an automated telephone
randomisation system that was administered remotely and used a computer-generated code. The
randomisation service was provided by the Bristol Randomised Trials Collaboration, a UK Clinical Research
Collaboration-registered trials unit (www.bris.ac.uk/social-community-medicine/centres/brtc). Once the
randomisation procedure had been completed, the outcome and further details about the allocated
treatment was immediately communicated by the researcher to the participant. Given the nature of the
intervention, it was not possible to blind participants, GPs, researchers or the CBT therapists to the
treatment allocation.
Randomisation was stratiﬁed by centre (n = 3), with minimisation used to ensure balance in the
following variables:
l baseline BDI-II score (mild 14–19; moderate 20–28; severe ≥ 29)
l whether the general practice had a counsellor (yes/no)
l prior treatment with antidepressants (yes/no)
l duration of their current episode of depression (< 1 year, 1–2 years, ≥ 2 years).
Minimisation with a probability weighting of 0.8 was used in order to reduce predictability.61Treatment group allocation
Eligible participants were randomised to either ‘usual care’ or ‘usual care plus CBT’.Usual care
There were no restrictions on treatment options for patients randomised to be managed as usual by their
GP. Patients could be referred for counselling or to secondary care (including for CBT) if it was deemed
clinically appropriate by the GP. It was felt unethical to withhold the option of counselling or to restrict
access to secondary care if the GP deemed it appropriate. Although the roll-out of IAPT services had
improved access to psychological therapies in England, there could still be long waiting times (as is the
situation in Scotland), so any such contamination was considered unlikely to substantially inﬂuence the
primary outcome. Nonetheless, such treatments were recorded as part of the follow-up questionnaires.Usual care plus cognitive behavioural therapy
Cognitive behavioural therapy manuals
Therapists used the seminal CBT depression treatment manuals.62,63 Given that the study population had
TRD, where appropriate therapists used elaborations on the manual designed to address treatment
resistance.64 The Moore and Garland manual64 emphasises approaches that overcome cognitive and
behavioural avoidance, and formed the basis for the treatment manual used in an earlier MRC trial that
examined the effectiveness of CBT for patients with residual depression.34 The therapists were ﬂexible inNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31responding to problems raised by the patient, for example by targeting symptoms of anxiety using
appropriate cognitive behavioural models if these were considered important. Emphasis was also given to
formulating the psychopathology in terms of conditional beliefs.Therapy: length and number of sessions
Details of those patients randomised to receive CBT were passed over to the therapy team based in each
centre. The allocated therapist contacted the patient to arrange the ﬁrst appointment at a mutually
convenient time and place.
Patients randomised to CBT received a course of 12 sessions, with (up to) a further six sessions if deemed
clinically appropriate by the therapist. Sessions typically lasted 50–60 minutes. Therapy usually took place
in the patients’ GP surgery, or at nearby NHS premises. In a few exceptional cases the therapy took
place at the patient’s home, or by telephone.Therapists
As this was a pragmatic trial, we aimed to recruit therapists who were representative of CBT
therapists working within NHS psychological therapy services, for example ‘high-intensity’ IAPT
practitioners who had postgraduate CBT qualiﬁcations or equivalent experience, and were accredited
(or eligible for accreditation) by the British Association for Behavioural and Cognitive Psychotherapies
(BABCP: www.babcp.com).
Across the three sites, 11 therapists working part time [ranging from 0.1 full-time equivalent (FTE) to
0.8 FTE] delivered the therapy (Bristol n = 6; Exeter n = 3; Glasgow n = 2). Ten of the eleven (91%)
therapists were female and the mean age of the therapists was 39.2 years [standard deviation (SD) 8.1,
range 27–58 years]. The professional background of the therapists varied: four had a mental health
nursing background, six were clinical psychologists and one had completed a MSc in Psychological
Therapies. On average, the trial therapists had practised as a therapist for 9.7 years (SD 8.1; range 0
(newly qualiﬁed)–30). Before the trial, seven of the therapists had received formal CBT training (Masters or
Postgraduate Certiﬁcate/Diploma) and two of these individuals completed a MSc in CBT during their
employment with the study.Training and supervision of therapists
There were four therapists employed at the start of recruitment, who received 4 days’ training with one of
the authors of the manual designed to address treatment resistance (AG).64 There were ﬁve additional
training days (including 4 days with AG) over the course of the trial. All therapists attended at least one of
these additional training days and received at least 1 day’s training, speciﬁc to the trial, from AG.
Therapists received weekly hourly supervision sessions (in groups of two or three) from an experienced
therapist based at each centre. This arrangement met the standards for clinical supervision set out by
the BABCP (deﬁned as at least 1 hour per month: www.babcp.com/Accreditation/Practitioner/
Practitioner_Accreditation.aspx) and the more stringent requirements set out by IAPT (at least 1 hour of
individual supervision on a weekly basis for full-time staff: www.iapt.nhs.uk/silo/ﬁles/iapt-supervision-
guidance-revised-march-2011.pdf). Therapists in two sites were supervised by two of the principal
investigators (Bristol, GL; Exeter, WK).Fidelity to the cognitive behavioural therapy model
Therapy sessions were recorded, with the patient’s consent, using a digital voice recorder. Individual
permission was sought to use these recordings for teaching and/or research purposes. A random sample of
recordings was selected, and ﬁdelity to the CBT model evaluated by three independent raters from the
Oxford Cognitive Therapy Centre using a recognised CBT rating scale.65 This evaluation was restricted to
the recordings of the CBT sessions for the nine therapists who delivered the majority (97%) of the
intervention. Assessment (session 1) and review sessions (ﬁnal session for those who completed therapy)11
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12were excluded from the pool of potential sessions for selection, as these sessions are different and would
not typically provide a demonstration of competence in CBT.
As three raters were undertaking this evaluation, the ﬁrst step was to demonstrate inter-rater reliability in
Cognitive Therapy Scale-revised (CTS-R) ratings. To ensure an approximately equal distribution between
sessions sampled from earlier or later in therapy, one therapist was selected at random and one session
selected at random from earlier/later sessions of therapy dependent on the frequency distribution of
number of sessions. The remaining eight therapists were then ranked in terms of the number of patients
allocated to them (thus including those who completed therapy as per the study protocol; those who
withdrew from therapy; and those who were discharged for non-compliance). Four therapist pairs were
then deﬁned on the basis of caseload and within each therapist pair, a random number was generated to
determine whether an earlier or later therapy session (selected at random) was evaluated. Across the nine
therapists, this ensured an approximately equal distribution in the number of earlier and later sessions
rated. This process generated one CTS-R rating for each of the nine therapists rated by three independent
raters and these data were used to establish inter-rater reliability. If the audio-recording for the selected
session was missing (either because the audio-ﬁle was missing or the patient withdrew consent for
that session to be recorded) or incomplete (the recording failed for technical reasons) then an alternative
session for the same patient was randomly selected from within the speciﬁed stratum (early/late). If there
were no alternative sessions within the same stratum, another patient was selected at random and an
early/late session sampled at random, as appropriate.
If there was a handover between therapists during the course of therapy and the selected session was one
delivered by the second therapist then the nearest session delivered by the ﬁrst therapist was selected for
evaluation. This corresponded to the therapist who was listed as the allocated therapist and thus
prevented sessions from any individual therapist being over-/under-sampled.
It was speciﬁed in advance that if at least ‘moderate’ reliability [intraclass correlation coefﬁcient (ICC)
> 0.666] between the three raters was observed then each of the three raters would be asked to rate a
further 18 sessions. For each of the nine therapists, six patients would be selected at random. A random
number would be generated to determine whether an earlier or later therapy session (selected at random)
should be evaluated for each of these six patients. This would result in three earlier and three later sessions
being sampled for each of the nine therapists (giving a total of 54 sessions for evaluation). The procedure
for selecting an alternate recording in the event of a missing/incomplete audio-recording or change in
therapists, as outlined earlier, applied.
If there was insufﬁcient inter-rater reliability (ICC ≤ 0.60) then each of the three raters would be asked to
rate the same 18 sessions. In this case, one earlier and one later session would be selected at random for
each of the nine therapists.
A mean CTS-R rating across all therapists is reported accounting for therapist caseload using sampling
weights. For the 12-item CTS-R, a cut-point of ≥ 36 is deemed appropriate, equating to a mean item score
of 3.0 ‘competent’.65Follow-upA ﬂow chart outlining CoBalT follow-up procedures is provided in Figure 2. Follow-up data collection took
place at four time points: 3, 6, 9 and 12 months post randomisation. Measurement of the primary
outcome took place at the 6-month follow-up, as it was expected that most of those in the intervention
group would have attended all (or most) of their CBT sessions by this time. The 12-month follow-up was
designed to enable the investigation of any longer-term effects on study outcomes.NIHR Journals Library www.journalslibrary.nihr.ac.uk
AllocationCBT (
+ UC) UC
Randomised
3-month telephone call
PHQ-9, treatment received, use of medication including adherence to antidepressants
6-month assessment (primary outcome)
BDI-II, PHQ-9, GAD-7, use of medication including adherence to antidepressants,
attitudes to treatment, SF-12, EQ-5D, DAS-SF2, MAQ, mental health literacy
9-month telephone call
PHQ-9, treatment received, use of medication including adherence to antidepressants
12-month assessment
BDI-II, PHQ-9, GAD-7, use of medication including adherence to antidepressants,
attitudes to treatment, SF-12, EQ-5D, DAS-SF2, MAQ, mental health literacy
FIGURE 2 CoBalT trial follow-up stages and data collected. DAS-SF2, Dysfunctional Attitudes Scale-Short Form
(version 2); MAQ, Metacognitive Awareness Questionnaire; UC, usual care.
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31To maximise response rates, wherever possible the researcher arranged to meet the patient at 6- and
12-month follow-up at the participant’s home, in their GP surgery or at university premises. A small
number of participants chose to return the questionnaire(s) by post.
The 3- and 9-month follow-ups were conducted by telephone. These follow-ups were designed to
maintain contact with participants and enable collection of brief outcome data in terms of depressive
symptoms, use of antidepressant medication and receipt of other treatments.Data collection and managementTo standardise processes across the three centres and maximise data quality, researchers were trained to
use detailed standard operating procedures for each stage of data collection. A number of cross-checks
were routinely performed as a means of ensuring that any data inconsistencies arising from either
baseline assessment or follow-up were identiﬁed and resolved at the earliest opportunity. Trial data were
entered into a Microsoft Access 2003 database (Microsoft Corporation, Redmond, WA, USA) at each
centre, before being merged into one central database following the end of data collection. A range of
data validation checks were carried out in both Microsoft Access and Stata 11.2 (StataCorp LP, College
Station, TX, USA) to minimise erroneous or missing data.13
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14Measures
Primary outcome
The primary outcome was the BDI-II score at 6 months post randomisation – speciﬁcally a binary variable
representing response deﬁned as a reduction in depressive symptoms of at least 50% compared with
baseline. A threshold of 50% improvement in symptoms is a widely used deﬁnition of improvement67
and used to compare treatment effects in the systematic review of interventions for TRD.14
The BDI-II is a 21-item self-report instrument to measure the severity of depressive symptoms occurring
over the previous 2 weeks and has been widely used in depression trials. The 21 items are rated on a
four-point severity scale (0–3) and are summed to give a total score (range 0–63). A higher score on the
BDI-II denotes more severe depression.Secondary outcomes
The BDI-II was also completed at 12 months to assess the longer-term effect of the intervention. Secondary
outcomes included the BDI-II as a continuous score, and a further binary version representing remission of
symptoms (deﬁned as a BDI-II score of < 10).
Other outcome measures included at the 6- and 12-month follow-ups assessments are listed below:
l SF-12 (version 2) A 12-item Short Form Health Survey measuring quality of life.56 The SF-12 is an
abbreviated form of the SF-36 (Short Form questionnaire-36 items), a 36-item instrument for
measuring subjective health status. It consists of 12 self-report items, selected from the SF-36.
The CoBalT study used a revised version of the SF-12, the SF-12v2, which was introduced in 2002.
The algorithms used to score data are dependent on the recall period. The CoBalT study used the
acute (1-week recall) survey. Norm-based scores for the physical and mental subscales were calculated.
Higher scores indicate better health and functioning.
l PHQ-9 The Patient Health Questionnaire, a brief nine-item depression scale53 developed for use in a
primary care setting. The questionnaire is designed to assess the patient’s mood over the previous
2 weeks and scores for each of the nine items range from 0 (not at all) to 3 (nearly every day). Items
are summed to give a total score (range 0–27), with a higher score denoting more severe depression.
l GAD-7 The Generalised Anxiety Disorder Assessment – a measure of generalised anxiety disorder
(GAD).54 The GAD-7 is a brief self-report questionnaire designed to detect probable cases of GAD and
to provide a measure of its severity as recalled over the previous 2 weeks. As with the PHQ-9, scores
for each item range from 0 (not at all) to 3 (nearly every day). Items are summed to give a total score
(range 0–21), with a higher score denoting more symptoms of anxiety. The PHQ-9 and GAD-7 form
part of the core IAPT outcome data set (www.iapt.nhs.uk/silo/ﬁles/iapt-outcome-framework-and-data-
collection.pdf) and will enable comparison with national IAPT data.
l Panic (Brief PHQ) The presence of panic disorder was measured using the panic module of the
self-report version of the PRIME-MD questionnaire (Brief PHQ).55 The measure consists of ﬁve items.
The ﬁrst item asks individuals to report whether or not they have experienced an anxiety attack within
the last 4 weeks; if they have they are asked four further questions about their experience.
Each question elicits a response of ‘Yes’ or ‘No’. The total number of panic items endorsed therefore
ranges from 0 to 5.
l EQ-5D-3L A standardised measure of health status developed by the EuroQol Group to provide a
simple, generic measure of health for clinical and economic appraisal.57 The EQ-5D-3L is used in
CoBalT as a measure of health outcome for the economic evaluation. Scores were calculated using
standard algorithms, with higher scores indicating better health.
Bespoke measures relating to patient’s treatment experience and mental health literacy were also recorded
at 6 and 12 months.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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data on antidepressant medication received (additional prescriptions, changes in dose and/or changes in
the antidepressant prescribed) and other medications prescribed during the course of the study were
recorded from GP records, together with details of consultations in primary care. Data on antidepressants
prescribed during the year prior to entry to the study were also recorded, when consent was given to
access medical records. Data on health care utilisation in primary and secondary care, private treatments,
and complementary and alternative treatments were collected as part of the 6- and 12-month follow-up
questionnaires and were used to inform the economic evaluation.
Process measures of dysfunctional attitudes and metacognitive awareness were also collected at the 6- and
12-month assessments:
l Dysfunctional Attitudes Scale-Short Form (version 2) (DAS-SF2) The DAS-SF2 is a self-report
questionnaire containing nine items that was developed from Weissman’s original Dysfunctional
Attitude Scale,68 using item response analysis to provide an efﬁcient and accurate assessment of
dysfunctional attitudes among depressed individuals.58
l Metacognitive Awareness Questionnaire (MAQ) The MAQ59 assessed whether or not patients
with depression view their negative thoughts as reﬂecting reality. The scale consists of nine self-report
items and has the same seven-point response format as the Dysfunctional Attitudes Scale (DAS), with
higher MAQ scores reﬂecting greater metacognitive awareness.
The brief telephone follow-ups at 3 and 9 months comprised the PHQ-9, use of antidepressant
medication, including adherence to antidepressants48 and other treatments received.
Table 2 shows the measures and when they were collected.
Handling missing items
For outcomes on the BDI-II, PHQ-9, GAD-7, DAS-SF2 and MAQ, the trial dealt with any missing data at an
individual item level by adopting the following rule. If > 10% of the items were incomplete then the data
collected on that measure for that participant were disregarded. However, if < 10% of items on a
particular measure were missing, missing item(s) were imputed using the mean of the remaining items
(rounded to an integer). Therefore, when an individual had completed 19 or 20 items for the primary
outcome measure (BDI-II) then the remaining one or two items were imputed. For all other measures
(PHQ-9, GAD-7, DAS-SF2, and MAQ) the 10% rule meant that only a single item would be imputed.
Data were complete for the majority of the sample; the number of cases for which values were imputed
are reported in Table 3.
The scoring manuals for the SF-12 or EQ-5D-3L, which require the application of complex scoring
algorithms, indicated that if any item was missing, the scale score should not be calculated. In the case of
greater item non-response or missing follow-up data, sensitivity analyses were conducted using the
method of multiple imputation by chained equation (MICE) to examine the impact of missing data on the
main ﬁndings (see Sensitivity analyses to examine the impact of missing data, below).Justiﬁcation of sample sizeTo calculate the required sample size, we assumed that usual care would involve GPs acting in line with
NICE guidance,12,13 i.e. increasing the dose of antidepressant, switching to another antidepressant or
augmenting the medication. Data from the large US STAR*D study suggested that, among those who had
not responded to up to 14 weeks treatment with citalopram, only 30% would ‘respond’ when their
antidepressant medication was switched19 or augmented.2015
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Wiles et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
TABLE 2 Measures collected and time point of data collection
Concept Measure
Time points
Screen Baseline
3
months
6
months
9
months
12
months
Sociodemographics a ✓ ✓
Alcohol use AUDIT-PC ✓
ICD-10 diagnosis CIS-R ✓
Depression severity BDI-II ✓ ✓ ✓ ✓
Depression severity PHQ-9 ✓ ✓ ✓ ✓ ✓
Adherence Four-item Morisky
scale
✓ ✓ ✓ ✓ ✓ ✓
Post-traumatic
stress
PC-PTSD ✓
Anxiety GAD-7 ✓ ✓ ✓
Panic Brief PHQ-Panic ✓ ✓ ✓
Quality of Life SF-12 ✓ ✓ ✓
Economic
evaluation
SF-6D ✓ ✓ ✓
Economic
evaluation
EQ-5D-3L ✓ ✓ ✓
Dysfunctional
attitudes
DAS-SF2 ✓ ✓ ✓
Metacognitive
awareness
MAQ ✓ ✓ ✓
Personality Big Five (neuroticism
subscale)
✓
Mental health
awareness
Bespoke
questionnaire
✓ ✓ ✓
Treatment
experience
Bespoke
questionnaire
✓ ✓
AUDIT-PC, Alcohol Use Disorders Identiﬁcation Test Primary Care; SF-6D, Short Form questionnaire-6 Dimensions.
a Screening variables available include age, gender, marital status, ethnic group, highest educational qualiﬁcation,
employment status, housing situation, ﬁnancial well-being. The following additional variables are also available for
randomised participants: caring responsibilities, car ownership, longstanding illness/disability, current and past smoking,
social support score, life event score.
TABLE 3 Number of cases where individual item values have been imputed
Instrument
Maximum no. of
items imputed
No. of cases in which imputation of individual items was undertaken
Baseline 3 months 6 months 9 months 12 months
BDI-II 2 0 – 1 – 5
PHQ-9 1 0 0 1 0 3
GAD-7 1 3 0 2 0 0
DAS-SF2 1 0 – 0 – 2
MAQ 1 0 – 1 – 2
METHODS
16
NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31Original sample size calculation
The expected treatment effect for the CoBalT study was based upon systematic review evidence for the
effectiveness of CBT,31 which concluded that there was a threefold increased odds of recovery for CBT
compared with treatment as usual (TAU).31 However, a reduced effect was expected given that this review
did not focus speciﬁcally on patients with TRD. Therefore, the original sample size calculation for the
CoBalT trial was based on detecting an odds ratio (OR) of 2 (or a difference of 16 percentage points
between groups). Other trials of residual depression,34 or chronic depression,38 report effect sizes that are
not dissimilar.
Thus, the original plan was to recruit 200 patients in each treatment group to yield 90% power to detect
a difference between 30% and 46% response (deﬁned as at least a 50% reduction in depressive
symptoms) or an OR of 2, at a 2-sided 5% signiﬁcance level. Allowing for 15% loss to follow-up at
6 months, the sample size was initially calculated to be 472.Revised sample size calculation
However, a slightly delayed start to recruitment, a slightly lower than anticipated recruitment rate in one
centre and difﬁculties matching recruitment rates to therapist capacity in two centres (to avoid a lengthy
delay between randomisation and the start of therapy) necessitated a request for extended funding.
This request was submitted in October 2009. A revised power calculation was presented as part of this
application (Table 4). The original power calculation was amended to reﬂect a reduced sample size of 432.
This reduced sample size would have 87% power to detect the originally speciﬁed difference of
16 percentage points, and would have 90% power to detect a 17 percentage point difference in the
binary ‘response’ outcome (between 30% and 47%).TABLE 4 Original and revised power calculations
Sample
size
calculation
N
randomised
n for
primary
analysis
Power to detect
originally speciﬁed
difference (%)a
Detectable difference with:
80% power 90% power
Original 472 400 90 14 percentage points
(30% vs. 44%=OR 1.84)
16 percentage points
(30% vs. 46%=OR 2.00)
Revised 432 367 87 15 percentage points
(30% vs. 45%=OR 1.89)
17 percentage points
(30% vs. 47%=OR 2.07)
a Originally speciﬁed difference: 16 percentage points (30% response in UC vs. 46% in CBT =OR 2.00).Statistical analysis
The analysis and reporting of this trial was undertaken in accordance with CONSORT guidelines.60,69,70
All statistical analysis was undertaken in Stata 11.2 (StataCorp LP, College Station, TX, USA), following a
pre-deﬁned analysis plan agreed with the Trial Steering Committee (TSC). The primary comparative
analyses between the randomised groups were conducted on an intention-to-treat (ITT) basis without
imputation of missing data.Preliminary analyses
Descriptive statistics of the key sociodemographic and clinical variables were used to ascertain any marked
imbalances at baseline, and to inform any additional adjustment of the primary and secondary analyses
as appropriate.Primary analysis
The primary analysis used logistic regression to compare the groups as randomised in terms of the primary
(binary) BDI-II outcome at 6 months, adjusting for stratiﬁcation and minimisation variables (the ‘design
variables’: centre, baseline BDI-II score, access to a counsellor, prior treatment with antidepressants and17
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18duration of the current depressive episode), which included adjustment for the baseline measurement of
the outcome (BDI-II score as a continuous variable). The ORs of ‘response’ in the intervention group
compared with the usual-care group is presented along with a 95% conﬁdence interval (CI) and the
p-value for the comparison.Secondary analyses
Secondary analyses of the primary outcome included additional adjustment for any prognostic variables
demonstrating marked imbalance at baseline (ascertained using descriptive statistics). The BDI-II was also
considered as a continuous outcome, with an associated increase in power. Secondary analyses were
conducted for other outcomes measured at 6 and 12 months.
Repeated measures analyses were used to incorporate the outcome data from both 6 and 12 months post
randomisation (or, in the case of the PHQ-9, from 6, 9 and 12 months) to examine whether or not any
treatment effects were sustained or emerged later. This was tested formally by the introduction of an
interaction between treatment group and time. In the absence of any time effect, repeated measures
analyses generate an average effect size over the duration of follow-up. In all analyses, ORs (or regression
coefﬁcients for continuous outcomes), with 95% CIs and p-values, are reported.Potential clustering by therapist
There is the potential for clustering by therapist within this trial, although clustering effects will operate in
only one arm of the trial. Secondary analyses therefore used generalised linear and latent mixed models to
obtain a fully speciﬁed heteroscedastic model (described in Roberts and Roberts71) to examine the
inﬂuence of clustering by therapist on the results.Subgroup analyses
Two subgroup analyses were speciﬁed a priori and were conducted by introducing an appropriate
interaction term to the regression model for the primary outcome. This permitted investigation of any
differential effects of treatment on outcome according to two predeﬁned factors: (1) patient expectation
of outcome (deﬁned as three levels: ‘CBT would deﬁnitely help me’; ‘CBT would probably help me’;
‘I don’t know if CBT would help me/would probably not help me’) and (2) degree of treatment resistance
[six levels based on duration of symptoms (< 1, 1–2, ≥ 2 years) and past treatment with antidepressant
medication (yes/no)].Sensitivity analyses to examine the impact of missing data
The pattern of missing data was investigated by identifying those variables recorded at baseline that were
associated with ‘missingness’ of the primary outcome (BDI-II score) at p < 0.20 at either the 6-month
follow-up and/or 12-month follow-up. Sensitivity analyses were conducted using the method of MICE72 to
impute missing data (Stata ice procedure, version 1.9.5, dated 15 April 2011). The imputation model
included all of those variables that were part of the substantive ITT model, together with the variables
associated with missingness (as identiﬁed above) and all available measures of depressive symptoms (BDI-II
and PHQ-9) and anxiety (GAD-7), irrespective of statistical signiﬁcance. The baseline CIS-R score was also
included in the imputation model as another marker of severity. Variables included in the imputation
model were declared as continuous, binary, categorical or ordinal variables, as appropriate. The match
procedure was used to handle non-normally distributed variables that could not be successfully
transformed. In total, 25 data sets were generated and 10 switching procedures were used.Treatment efficacy
Complier-Average Causal Effect (CACE) estimates73 for those who were viewed as ‘on track’ to receive the
full course of CBT treatment at the time of the 6-month follow-up (deﬁned as having completed nine or
more sessions) were estimated using instrumental variables regression methods. As the primary outcome
‘response’ was a binary variable, a probit transformation was used, and the primary ITT analysis repeated
on this transformed scale for comparison with the CACE estimates.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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12-months. For the latter, those who had received ≥ 12 sessions were regarded as having received CBT in
line with the treatment protocol.
The CACE methodology compares the outcomes for those who ‘complied’ with the intervention with a
similar group of ‘would-be compliers’ from those randomised to usual care, thus avoiding the biases
inherent in crude per-protocol analyses. The original deﬁnition of a ‘complier’ included those where the
therapy goals were achieved in fewer than 12 sessions, as agreed between the patient and therapist.
However, in practice, this included individuals who had an ‘agreed end’ of fewer than eight sessions, and
thus a stricter deﬁnition was adopted, as outlined above.Safety reporting and disclosureAlthough CoBalT was not a Clinical Trial of an Investigational Medicinal Product (CTIMP), it was recognised
that both psychopharmacology and psychotherapy have risks and beneﬁts for patients.74 Therefore, in
accordance with good clinical practice the CoBalT team recorded and reported any serious adverse events
to comply with the National Research Ethics Service annual safety report requirements of non-CTIMP trials.
In the case of CoBalT, GPs were responsible for the ongoing clinical care of participants. Therefore,
researchers and therapists had a duty of care to ensure that the GP was aware of any suicidal ideation
expressed by participants. Researchers were not clinically trained and therefore adhered to the study’s
safety and disclosure policy and did not engage in any assessment of risk. This policy stated that if at any
time the researcher believed that there was a signiﬁcant suicide risk with a patient who was participating
in the study (which had not been communicated to his/her GP), the researcher would ask the patient for
their consent to pass this information on to their GP. If the patient refused, the researcher would consult
the appropriate clinician (or nominated deputy) at the research site. This person would examine the
patient’s data and, if it was considered necessary, would assess the patient. If it was concluded that there
was a signiﬁcant risk, the patient’s GP would be notiﬁed without the patient’s consent. The need to break
conﬁdentiality in situations where there was signiﬁcant concern about harm to the individual (or others)
was explained in the patient information leaﬂet.
It was expected that therapists would use their clinical judgement to assess the seriousness of risk and
follow normal clinical procedures with respect to communicating disclosure to the participant’s GP.Trial monitoringThe trial was independently supervised by a TSC, chaired by an academic psychiatrist. Other members
included an independent statistician, another senior academic with trials experience, a service user, an
observer from the funder [National Institute for Health Research (NIHR) Health Technology Assessment],
the chief investigator (NW), principal investigator (GL), Trial Statistician (TP) and the trial co-ordinator.
The trial was also supervised by an independent Data Monitoring and Ethics Committee, chaired by an
academic GP and also including a statistician and an academic clinical psychologist. Members of these
committees are named in Acknowledgements.19
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DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31Chapter 3 Results: clinical effectivenessPractice detailsOne hundred and six general practices across the three centres were approached to participate in the
CoBalT study. Eighty-eight practices agreed to collaborate. Record searches were conducted and mailings
sent out from 73 general practices. A summary of the practice characteristics for the 73 participating
practices are presented in Table 5. The average number of patients invited to participate in the study per
practice was similar in all three centres, although the practices in Glasgow were smaller in size than the
other two centres (Bristol and Exeter).
Flow of participants into the trial
As it was not possible to easily identify those patients with TRD from general practice records, a screening
process was used to ﬁrstly identify those patients being treated for depression (ﬁlter 1) and then assess
their depressive symptoms and adherence to antidepressant medication (ﬁlter 2) in order to identify the
target population who was potentially eligible to participate in the CoBalT trial. Potential participants were
then invited to a baseline assessment with a researcher to establish eligibility (ﬁlter 3). The ﬂow of
participants through these three stages is described below. The screening process commenced in
November 2009, and the ﬁnal patient was randomised to the trial on 30 September 2010. All follow-up
data were collected between March 2009 and 31 October 2011.Search of general practitioner computerised records to identify patients
being treated for depression
In total, 15,379 patients, aged 18–75 years, who had received repeated prescriptions for antidepressant
medication over the previous 4 months and who were currently being prescribed antidepressants at an
adequate dose for depression were identiﬁed through searches of the practice computerised records.
A further 37 individuals were referred to the study directly by their GP. GPs excluded 4750 individuals
who were ineligible (Figure 3 – ﬁlter 1).
In all, 10,666 patients were mailed a letter of invitation to participate in the study asking for their
permission for the research team to contact them or were invited to take part by their GP during the
consultation. Of these, 4589 individuals (43.0%) responded to the letter of invitation, with the majority,
2947 (64.2%) agreeing for the research team to contact them (see Figure 3 – ﬁlter 1).
When available, information on age and gender was recorded from GP records. Older individuals were
more likely to decline to participate [analysis of variance (ANOVA), p < 0.001]. Women were more likely
to respond to the invitation to participate and to give permission for the research team to contact them
(‘accepted invitation’) (chi-squared test: p = 0.001) (Table 6).Assessment of depressive symptoms and adherence to
antidepressant medication
A screening questionnaire was mailed to 2947 potential participants (see Figure 3 – ﬁlter 2). In total,
631 individuals did not complete the assessment screen, either not responding to the postal questionnaire
or declining to complete this questionnaire or the additional questions to assess eligibility asked over the
telephone (see Figure 3 – ﬁlter 2). Older individuals were more likely to complete the assessment screening
process (t-test: p = 0.007) (Table 7). There was no evidence of a difference in gender between those who
did or did not complete the assessment screen (chi-squared test: p = 0.13).21
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Patients on antidepressants identified through search of
GP’s computerised records or referred by GP
(n = 15,416)
Patients excluded by GP
(n = 4750)
Total number of letters of invitations/referrals
(n = 10,666)
Responders to invitation
(n = 4589)
Non-responders to invitation
(n = 6077)
Declined further contact
(n = 1642)
Agreed to further contact and screening questionnaire sent
(n = 2947)
Did not complete assessment screen
(n = 631)
• Non-response to postal
   questionnaire
• Declined questionnaire
   or telephone screen
 n = 187
n = 444
Eligible for baseline assessment
(n = 912)
Declined to take part in baseline assessment
(n = 163)
Agreed to eligibility screen
(n = 749)
Ineligible to participate in trial
(includes one person randomised in error)
(n = 276)
Eligible but declined further participation
(n = 4)
Eligible and informed consent obtained (randomised)
(n = 469)
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FIGURE 3 Case CONSORT flow chart illustrating flow of participants into the CoBalT trial.
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TABLE 7 Comparison of age and gender of those who did or did not complete the assessment screen
N
Age Female
na Mean SD na n %
Did not complete screen 631 599 46.8 13.3 615 455 74.0
Completed assessment screen 2316 2185 48.5 13.6 2244 1590 70.9
a Number with available data using age and gender from record search.
TABLE 6 Comparison of age and gender of those who did or did not respond to the invitation to participate
N
Age Female
na Mean SD na n %
Non-responders 6077 5809 46.0 13.2 5967 4040 67.7
Declined invitation 1642 1565 54.2 12.9 1612 1125 69.8
Accepted invitation 2947 2784 48.1 13.5 2859 2045 71.5
a Number with available data.
RESULTS: CLINICAL EFFECTIVENESS
24The primary aim of ﬁlter 2 was to identify those with TRD. A large number of respondents (n = 1214) were
not eligible as their depression was below the threshold on the BDI-II (score of < 14) or they were not
adhering to their antidepressant medication or did not meet the criteria for an adequate dose/duration of
treatment (see Figure 3 – ﬁlter 2). In total, 912 participants were eligible to attend a baseline appointment
with a researcher to establish an ICD-10 diagnosis of depression but 18% declined (see Figure 3 – ﬁlter 2).
There were no differences in age or gender between those who did or did not agree to attend a baseline
appointment (Table 8) (t-test age: p = 0.48; chi-squared test gender: p = 0.37).TABLE 8 Comparison of age and gender of those who did or did not agree to attend a baseline assessment
Agreed to attend a
baseline appointment
with a researcher? N
Age Female
na Mean SD na n %
No (declined) 163 154 50.7 13.3 155 113 72.9
Yes (agreed) 749 711 49.9 12.5 749 519 69.3
a Number with available data using age and gender from record search.However, those who agreed to attend a baseline assessment were more highly educated than those who
declined (Table 9) (chi-squared test: p = 0.009).Baseline assessment of eligibility to participate in the randomised
controlled trial
A total of 749 participants agreed to attend a face-to-face appointment with a researcher to
discuss participating in the CoBalT trial, establish eligibility and obtain written informed consent
(see Figure 3 – ﬁlter 3). The baseline assessment took place, on average (median), 34 days [interquartile
range (IQR) 21–55] following completion of the screening questionnaire. Two hundred and seventy-six
individuals were ineligible to participate (including one person who was randomised in error). The majority
(n = 233) were ineligible because they did not meet ICD-10 criteria for depression. In total, 469 individuals
were eligible to participate, gave written informed consent and were randomised (see Figure 3 – ﬁlter 3).NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 9 Comparison of educational qualiﬁcations of those who did or did not agree to attend a
baseline assessment
Agreed to attend a
baseline appointment
with a researcher? N na
A-levels/
Higher Grade
or above
Other
qualiﬁcations
No formal
qualiﬁcations
n % n % n %
No (declined) 163 160 58 36.3 53 33.1 49 30.6
Yes (agreed) 749 739 366 49.5 199 26.9 174 23.6
a Number with available data using educational qualiﬁcations from screening questionnaire.
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31There were no differences between those who were and were not eligible to participate in the CoBalT trial
in terms of age (Table 10) (t-test: p = 0.20), although women were more likely to be eligible (chi-squared
test: p = 0.02).TABLE 10 Comparison of age and gender of those who were or were not eligible for the CoBalT trial
Eligibility status N
Age Female
na Mean SD na n %
Eligible (including declined
to participate)
473 473 49.6 11.7 473 342 72.3
Ineligible at baseline 276 274 50.8 13.3 274 176 64.2
a Number with available data using age and gender recorded at time of baseline assessment.There were no differences in educational qualiﬁcations among those who were or were not eligible to
participate in the trial (Table 11) (chi-squared test: p = 0.12).TABLE 11 Comparison of educational qualiﬁcations of those who were or were not eligible to participate in the trial
Eligibility status N na
A-levels/
Higher Grade
or above
Other
qualiﬁcations
No formal
qualiﬁcations
n % n % n %
Eligible (including
declined to participate)
473 467 218 46.7 131 28.1 118 25.3
Ineligible at baseline 276 272 148 54.4 68 25.0 56 20.6
a Number with available data using educational qualiﬁcations from screening questionnaire.Summary of recruitment by centre
A summary of the key recruitment statistics by centre is provided in Table 12. Between 3000 and 4000
invitations were mailed out from each of the three centres. The percentage of patients who agreed for the
research team to contact them was around 30% in both Bristol and Exeter. The percentage agreeing to be
contacted was lower in Glasgow but, otherwise, the percentage completing the assessment screen, who
were eligible to attend a baseline assessment and who were randomised, was similar in all three centres.25
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TABLE 12 Recruitment statistics by centre
Characteristic Bristol Exeter Glasgow Total
No. of practices 26 22 25 73
Invitations/GP referrals
GP referrals 13 19 5 37
Total invitations 4088 3066 3512 10,666
No. returned 1793 1607 1189 4589
No. accepted 1185 984 778 2947
Percentage accepted 29.0 32.1 22.2 27.6
Assessment screen completed 915 805 596 2316
Percentage completing
assessment screen
77.2 81.8 76.6 78.6
Eligible for baseline assessment 369 313 230 912
Percentage eligible 40.3 38.9 38.6 39.4
Baseline assessments 313 251 185 749
Randomisations
No. 190 161 118 469
Percentage of baseline assessments 60.7 64.1 63.8 62.6
Average/month 9.5/month,
20 months
8.9/month,
18 months
6.6/month,
18 months
8.4/month
RESULTS: CLINICAL EFFECTIVENESS
26Follow-up of participants in the trial
Of the 469 randomised, 234 were allocated to receive CBT in addition to usual care and 235 were
allocated to continue with usual care. All participants were taking antidepressant medication at the point
of randomisation, with the expectation that this would continue as part of usual care for this patient
group. The CONSORT ﬂow diagram for the CoBalT trial is presented in Figure 4. The number of individuals
who withdrew from the study, were lost to follow-up or died is reported, as well as the number who could
not be contacted at a particular follow-up but who were contacted later (‘unable to contact’ in Figure 4).
A summary of the follow-up rates by centre is given in Table 13. Follow-up rates in Glasgow were lower
than the other two centres. Part-way through recruitment, the Glasgow research team received additional
support from the Scottish Mental Health Research Network (SMHRN), which enabled the research team to
devote more resources to maximising the number of trial participants who were successfully contacted at
the 12-month follow-up. This was prioritised over attaining a high follow-up rate at the brief 9-month
telephone follow-up, hence explaining the lower follow-up rate at this time point. [The other two centres
received additional support from the Mental Health Research Network (MHRN) from earlier in the study
due to differences in the timing of the establishment of this network in England and Scotland.]
Follow-up assessments were scheduled to take place at 3, 6, 9 and 12 months following randomisation.
These time frames were not always achieved. However, the mean time to each follow-up was close to
the target (Table 14) and the vast majority of follow-up assessments were conducted within 2 months of
the target (see Table 14).NIHR Journals Library www.journalslibrary.nihr.ac.uk
Randomised
(N = 469)
Allocation
3-month follow-up
(94%)
9-month follow-up
(81%)
CBT (+ UC)
(n = 234)
Completed CBT as planned
(≥ 12 sessions by 12 months)
Did not complete CBT as planned
*includes one patient who withdrew from
trial therapy and accessed psychological
treatment privately
n = 141
n = 93*
Usual care (UC)
(n = 235)
Received treatment as allocated
Received psychological therapy
outside the trial
(one by 6 months; two further by 12 months)
n = 232
n = 3
Followed up n = 222
n = 222
n = 4
n = 2
n = 6
Completed PHQ-9
Withdrew from study
Lost to follow-up
Unable to contact
Followed up n = 219
n = 218
n = 7
n = 3
n = 6
Completed PHQ-9
Withdrew from study
Lost to follow-up
Unable to contact
Followed up n = 209
n = 206
n = 209
n = 14
n = 6
n = 4
n = 1
Completed PHQ-9
Completed BDI-II
Withdrew from study
Lost to follow-up
Unable to contact
Died
Followed up n = 213
n = 213
n = 213
n = 13
n = 6
n = 3
Completed PHQ-9
Completed BDI-II
Withdrew from study
Lost to follow-up
Unable to contact
n = 188
n = 188
n = 17
n = 12
n = 16
n = 1
Followed up
Completed PHQ-9
Withdrew from study
Lost to follow-up
Unable to contact
Died
n = 191
n = 191
n = 14
n = 13
n = 17
Followed up
Completed PHQ-9
Withdrew from study
Lost to follow-up
Unable to contact
Followed up n = 198
n = 197
n = 197
n = 17
n = 17
n = 2
Completed PHQ-9
Completed BDI-II
Withdrew from study
Lost to follow-up
Died
Followed up n = 198
n = 198
n = 198
n = 15
n = 22
Completed PHQ-9
Completed BDI
Withdrew from study
Lost to follow-up
6-month follow-up
(primary outcome)
(90%)
12-month follow-up
(84%)
FIGURE 4 Consolidated Standards of Reporting Trials (CONSORT) flow chart.
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TABLE 14 Timing of questionnaire completion at all follow-ups
Follow-up (months) n Mean (months) SD
Within x ± 2 months
n %
3 441 3.1 0.4 437 99.1
6 422 6.4 0.7 406 96.2
9 379 9.1 0.4 376 99.2
12 396 12.6 1.2 367 92.7
TABLE 13 Follow-up rates by centre
Follow-up
(months)
Bristol (n = 190) Exeter (n = 161) Glasgow (n = 118) Total (n = 469)
n % n % n % n %
3 180 94.7 157 97.5 104 88.1 441 94.0
6 176 92.6 156 96.9 90 76.3 422 90.0
9 166 87.4 152 94.4 61 51.7 379 80.8
12 164 86.3 150 93.2 82 69.5 396 84.4
RESULTS: CLINICAL EFFECTIVENESS
28Baseline characteristics of randomised participantsSociodemographic characteristics
Of the 469 participants, 339 (72.3%) were women and the mean age was 49.6 years (SD 11.7). Forty-four
per cent (n = 206) were in paid employment (full or part time). Forty-seven per cent (n = 217/463) were
educated to A-level/Higher Grade or above, although, conversely, 25% (n = 116) had no formal
qualiﬁcations. Twenty-seven per cent (n = 128) reported ﬁnancial difﬁculty (ﬁnding it difﬁcult or very
difﬁcult to ‘make ends meet’).Severity and history of depression, and symptoms of anxiety
The mean BDI-II score at baseline was 31.8 (SD 10.7) denoting, on average, severe symptoms (deﬁned as
BDI-II score ≥ 29). This ﬁgure was very similar to the mean BDI-II score for the same individuals from the
earlier screening questionnaire [mean 31.9 (SD 10.1)]. Fifty-eight per cent of participants met ICD-10
criteria for a moderate depressive episode and 28% (n = 129) met ICD-10 criteria for a severe depressive
episode. The duration of the current episode of depression was 2 years or longer for 59% (n = 276) of
participants. Seventy per cent (n = 327) of participants had been on their current course of antidepressant
medication for > 12 months. Eighty per cent (n = 377) of participants had taken antidepressants prior to
their current course.
The majority of participants (n = 415, 88%) had suffered from depression in the past and 52% (n = 245)
reported having experienced ﬁve or more prior episodes of depression. Forty per cent of participants
(n = 188) had previously been referred to a psychiatrist for their depression and 65% (n = 307) reported a
family history of depression.
At baseline, the mean PHQ-9 score was 16.6 (SD 5.7) and the mean GAD-7 score was 11.7 (SD 5.1).
Eighty-nine per cent of patients (n = 416) had a PHQ-9 score of ≥ 10 at baseline and 33% (n = 155) had a
PHQ-9 score of ≥ 20, which is regarded as severe depression. Seventy-six per cent (n = 356) had a score of
≥ 8 on the GAD-7. Ninety-four per cent (n = 439) were a ‘case’ (based on the deﬁnitions used in IAPT32,33)
on either the PHQ-9 or GAD-7 at baseline.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Although all participants fulﬁlled ICD-10 criteria for a depressive episode, most (n = 463, 99%) also had a
secondary psychiatric diagnosis according to the CIS-R. Of these secondary diagnoses, generalised anxiety,
mixed anxiety and depression and panic disorder were the most common (Table 15).TABLE 15 Secondary psychiatric diagnoses according to the CIS-R
Diagnosis n %
Generalised anxiety disorder 245 52.9
Mixed anxiety and depression 116 25.1
Panic disorder 67 14.5
Speciﬁc (isolated) phobia 17 3.7
Agoraphobia 10 2.2
Social phobia 8 1.7
Total 463Antidepressant medication at baseline and in the year prior
to randomisation
Sixty-one per cent of participants were taking the selective serotonin reuptake inhibitor (SSRI) citalopram or
ﬂuoxetine at doses of 20–80mg daily at baseline (Table 16). Other commonly prescribed antidepressants
were venlafaxine, mirtazapine and paroxetine. A range of other medications were prescribed from all
classes of antidepressants [SSRIs, serotonin–norepinephrine reuptake inhibitors (SNRIs), tricyclic
antidepressants (TCAs) and noradrenaline reuptake inhibitors (NARIs)]. In total, 35 participants (7.5%)
were taking two antidepressants at baseline (see Table 16).
In total, 453 participants (96.6%) gave their consent for the research team to access their medical records.
Data on antidepressant prescriptions in the year prior to randomisation were available for 413 individuals.
On average (median), participants received eight prescriptions for antidepressant medication over the
previous year (IQR 6–12). In total, 339 individuals (82.1% of 413) were prescribed only one type of
antidepressant in the year prior to randomisation.Self-reported long-standing illness, disability or infirmity
Seventy-ﬁve per cent of participants (n = 351) reported that they had a long-standing illness, disability or
inﬁrmity, based on a list of six closed responses (Table 17). This cannot be taken to indicate just physical
illness, as this was not clear from the question. Therefore, some of who indicated ‘another illness’ may
have included depression in their response.Patient preferences and expectations of the effectiveness of
cognitive behavioural therapy
Prior to randomisation, participants were asked whether or not they had a preference for treatment.
Sixty per cent of participants (n = 281) indicated that they would prefer to receive CBT in addition to usual
care, 39% (n = 183) had no preference and a small number (n = 5; 1%) indicated that they would prefer
to continue with usual care. Participants were also asked to indicate whether they thought that CBT
(in addition to antidepressant medication) would be an effective treatment for them. Almost half of
participants were unsure whether or not CBT would help them, although 50% thought that the
intervention would ‘probably or deﬁnitely’ help them (Table 18).29
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TABLE 16 Antidepressant medication at baseline
Antidepressant medication Dose (mg)
CBT
(n = 234)
Usual care
(n = 235)
Total
(n = 469)
n % n % n %
Class, name
SSRI, citalopram 20–80 82 35.0 71 30.2 153 32.6
SSRI, ﬂuoxetine 20–60 63 26.9 70 29.8 133 28.4
SNRI, venlafaxine 75–300 17 7.3 18 7.7 35 7.5
OTHER, mirtazapine 30–60 18 7.7 15 6.4 33 7.0
SSRI, paroxetine 20–40 15 6.4 12 5.1 27 5.8
SSRI, sertraline 100–400 9 3.8 6 2.6 15 3.2
TCA, lofepramine 140–210 8 3.4 5 2.1 13 2.8
TCA, dosulepin 150–175 2 0.9 6 2.6 8 1.7
SSRI, escitalopram 10–40 3 1.3 3 1.3 6 1.3
NARI, reboxetine 8–12 2 0.9 1 0.4 3 0.6
TCA, amitriptyline 150–180 0 0 3 1.3 3 0.6
SNRI, duloxetine 60–90 0 0 2 0.9 2 0.4
TCA, trazodone 150–300 0 0 2 0.9 2 0.4
TCA, clomipramine 250 1 0.4 0 0 1 0.2
Combination treatment
Citalopram and amitriptyline 20–50/10–150 2 0.9 5 2.1 7 1.5
Citalopram and mirtazapine 20–40/15–22.5 3 1.3 2 0.9 5 1.1
Citalopram and trazodone 40/50 1 0.4 0 0 1 0.2
Fluoxetine and amitriptyline 20–40/20–120 3 1.3 9 3.8 12 2.6
Mirtazapine and amitriptyline 30/50 2 0.9 0 0 2 0.4
Paroxetine and bupropion 30/300 1 0.4 0 0 1 0.2
Fluoxetine and citalopram 80/20 0 0 1 0.4 1 0.2
Nortriptyline and sertraline 100/100 0 0 1 0.4 1 0.2
Paroxetine and amitriptyline 40/20 0 0 1 0.4 1 0.2
Sertraline and mirtazapine 50–300/15–45 2 0.9 0 0 2 0.4
Venlafaxine and amitriptyline 150/225 0 0 1 0.4 1 0.2
Venlafaxine and citalopram 75/10 0 0 1 0.4 1 0.2
RESULTS: CLINICAL EFFECTIVENESS
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TABLE 17 Long-standing illnesses reported at baseline
Chronic illness n (%)
Diabetes 16 4.6
Asthma 28 8.0
Arthritis 38 10.8
Heart disease 9 2.6
High blood pressure 27 7.7
Lung disease 5 1.4
More than one of the above 79 22.5
Another illness (not listed above) 149 42.5
TABLE 18 Patient expectations about the effectiveness of the intervention prior to randomisation
Response option n (%)
CBT would deﬁnitely help me 98 20.9
CBT would probably help me 138 29.4
I don’t know if CBT would help me 228 48.6
CBT would probably not help me 5 1.1
CBT would deﬁnitely not help me 0
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31Baseline comparability of randomised groups
Table 19 provides a summary of the key descriptive statistics used to assess the baseline comparability of
the randomised groups. Data on a large number of variables including sociodemographic factors, severity
of depression, history of depression and treatment, and comorbidity were collected at baseline. A number
of imbalances were observed. The intervention group comprised more men, a greater proportion in paid
employment, more who reported ﬁnancial difﬁculty, fewer individuals with caring responsibilities, fewer
individuals with long-standing illness/disability and better physical function (on the SF-12). A smaller
proportion of those in the intervention group reported ﬁve or more prior episodes of depression but a
greater proportion had a family history of depression. A smaller proportion of the intervention group
reported taking their current course of antidepressant for > 12 months.
Losses to follow-up
Follow-up rates were similar in both arms at all time points (3, 6, 9 and 12 months). At 6 months,
the time of the measurement of the primary outcome, 90% of participants were followed up.
Eighty-four per cent of participants were followed up at 12 months (see Follow-up of participants in the
trial and Figure 4, above).Missing dataThe pattern of missing data was investigated by identifying those variables recorded at baseline that were
associated with ‘missingness’ of the primary outcome (BDI-II score) at the 6- and 12-month follow-ups. For
brevity, Table 20 presents a summary of the baseline variables associated with missingness at p < 0.20 at
either 6-month follow-up (see Table 20a) or 12-month follow-up (see Table 20b).31
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TABLE 19 Baseline comparability of randomised groups
Characteristic Intervention (n = 234) Usual care (n = 235)
Stratification variable: centre n (%)
Bristol 95 (40.6) 95 (40.4)
Exeter 79 (33.8) 82 (34.9)
Glasgow 60 (25.6) 58 (24.7)
Minimisation variables: n (%)
Previously prescribed antidepressants 187 (79.9) 190 (80.9)
BDI-II score:
14–19 24 (10.3) 28 (11.9)
20–28 78 (33.3) 75 (31.9)
≥ 29 132 (56.4) 132 (56.2)
GP practice has a counsellor 112 (47.9) 116 (49.4)
Duration of current episode of depression (years)
< 1 58 (24.8) 52 (22.1)
1–2 40 (17.1) 43 (18.3)
> 2 136 (58.1) 140 (59.6)
Sociodemographic variables
Age (years): mean (SD) 49.2 (11.9) 50.0 (11.5)
Female: n (%) 161 (68.8) 178 (75.7)
Ethnic group, white: n (%) 231 (98.7) 228 (97.0)
Marital status: n (%)
Married/living as married 120 (51.3) 128 (54.5)
Single 44 (18.8) 45 (19.2)
Separated/divorced/widowed 70 (29.9) 62 (26.4)
Employment status: n (%)
In paid employment (full/part-time) 109 (46.6) 97 (41.3)
Not in employment 58 (24.8) 75 (31.9)
Unemployed owing to ill health 67 (28.6) 63 (26.8)
Highest educational qualiﬁcation: n (%)a
A-level, Higher Grade or above 112 (48.3) 105 (45.5)
GCSE, Standard Grade or other 63 (27.2) 67 (29.0)
No formal qualiﬁcations 57 (24.6) 59 (25.5)
Financial difﬁculty: n (%)
Living comfortably/doing all right 74 (31.6) 93 (39.6)
Just about getting by 91 (38.9) 83 (35.3)
Finding it difﬁcult/very difﬁcult to make ends meet 69 (29.5) 59 (25.1)
RESULTS: CLINICAL EFFECTIVENESS
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TABLE 19 Baseline comparability of randomised groups (continued )
Characteristic Intervention (n = 234) Usual care (n = 235)
Caring responsibilities: n (%) 29 (12.4) 35 (14.9)
Long-standing illness or disability: n (%) 170 (72.7) 181 (77.0)
No. of life events in past 6 months: mean (SD) 1.3 (1.2) 1.2 (1.1)
Social support score: mean (SD) 11.8 (3.9) 12.2 (3.7)
History of depression
Suffered from depression in past: n (%) 206 (88.0) 209 (88.9)
No. of prior episodes of depression: n (%)
0–1 46 (19.7) 45 (19.2)
2–4 72 (30.8) 61 (26.0)
≥ 5 116 (49.6) 129 (54.9)
Previous referral to a psychiatrist for depression: n (%) 95 (40.6) 93 (39.6)
Family history of depression: n (%) 159 (68.0) 148 (63.0)
Length of current course of antidepressants (months): n (%)
< 6 26 (11.1) 23 (9.8)
6–12 51 (21.8) 42 (17.9)
> 12 157 (67.1) 170 (72.3)
CIS-R score: mean (SD) 30.1 (9.1) 30.0 (8.8)
ICD-10 primary diagnosis: n (%)
Mild 35 (15.0) 31 (13.2)
Moderate 135 (57.7) 139 (59.2)
Severe 64 (27.4) 65 (27.7)
BDI-II score: mean (SD) 31.8 (10.5) 31.8 (10.9)
Suicidal ideation (CIS-R thoughts/plans): n (%) 73 (31.1) 75 (31.9)
PHQ-9 score: mean (SD) 16.6 (5.7) 16.6 (5.7)
GAD-7 score: mean (SD) 11.7 (5.0) 11.8 (5.1)
Panic score: median (IQR)b 3 (0 to 5) 3 (0 to 5)
SF-12 mental subscale: mean (SD)c 28.5 (9.0) 28.7 (9.3)
SF-12 physical subscale: mean (SD)c 45.3 (13.0) 41.6 (13.7)
a Cognitive behavioural therapy, n = 232; usual care, n = 231.
b Cognitive behavioural therapy, n = 233; usual care, n = 235.
c Cognitive behavioural therapy, n = 231; usual care, n = 233.
Note: Incomplete data on some items, numbers with information available as listed above.
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TABLE 20a Summary of baseline variables related to missing outcome data at 6 months
Baseline variable Missing (n = 50) Present (n = 419) p-value
Age (years): mean (SD) 47.8 (11.0) 49.8 (11.8) 0.27
Female: n (%) 31 (62.0) 308 (73.5) 0.09
Marital status: n (%)
Married/living as married 25 (50.0) 223 (53.2) 0.20
Single 14 (28.0) 75 (17.9)
Separated/divorced/widowed 11 (22.0) 121 (28.9)
Highest educational qualiﬁcation: n (%)a
A-level, Higher Grade or above 23 (46.9) 194 (46.9) 0.02
GCSE, Standard Grade or other 7 (14.3) 123 (29.7)
No formal qualiﬁcations 19 (38.8) 97 (23.4)
Financial difﬁculty: n (%)
Living comfortably/doing all right 10 (20.0) 157 (37.5) 0.03
Just about getting by 20 (40.0) 154 (36.8)
Finding it difﬁcult/very difﬁcult to make ends meet 20 (40.0) 108 (25.8)
At least one car in household: n (%) 27 (54.0) 283 (67.5) 0.06
Home ownership: n (%)
Home owner 20 (40.0) 226 (53.9) 0.10
Tenant 26 (52.0) 152 (36.3)
Other 4 (8.0) 41 (9.8)
Smoking habits: n (%)
Current smoker 29 (58) 131 (31.3) 0.001
Ex-smoker 10 (20) 147 (35.1)
Never smoked 11 (22) 141 (33.7)
Social support score: mean (SD) 11.3 (4.3) 12.1 (3.7) 0.16
History of depression: n (%)
Suffered from depression in the past 41 (82.0) 374 (89.3) 0.13
ICD-10 primary diagnosis: n (%)
Mild 5 (10.0) 61 (14.6) 0.05
Moderate 24 (48.0) 250 (59.7)
Severe 21 (42.0) 108 (25.8)
Suicidal ideation (CIS-R thoughts/plans): n (%) 17 (34.0) 131 (31.3) 0.69
Big Five neuroticism scale: mean (SD)b 4.1 (0.5) 4.1 (0.6) 0.48
PC-PTSD score: mean (SD)c 2.3 (1.6) 2.0 (1.5) 0.29
RESULTS: CLINICAL EFFECTIVENESS
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TABLE 20a Summary of baseline variables related to missing outcome data at 6 months (continued )
Baseline variable Missing (n = 50) Present (n = 419) p-value
Panic score: median (IQR)d 3.5 [0, 5] 3 [0, 5] 0.51
SF-12 physical subscale: mean (SD)e 40.7 (13.7) 43.7 (13.4) 0.14
Dysfunctional attitudes score: mean (SD) 33.8 (10.1) 37.7 (10.9) 0.08
a Missing, n = 49;, present n = 414.
b Missing, n = 50; present n = 417.
c Missing, n = 50; present n = 414.
d Missing, n = 50; present n = 418.
e Missing, n = 49; present n = 415.
Note: Incomplete baseline data on some items, as listed above.
TABLE 20b Summary of baseline variables related to missing outcome data at 12 months
Characteristic Missing (n = 74) Present (n = 395) p-value
Age (years): mean (SD) 47.4 (11.8) 50.0 (11.6) 0.08
Female: n (%) 46 (62.2) 293 (74.2) 0.03
Marital status: n (%)
Married/living as married 35 (47.3) 213 (53.9) 0.40
Single 18 (24.3) 71 (18.0)
Separated/divorced/widowed 21 (28.4) 111 (28.1)
Highest educational qualiﬁcation: n (%)a
A-level, Higher Grade or above 27 (37.0) 190 (48.7) 0.003
GCSE, Standard Grade or other 16 (21.9) 114 (29.2)
No formal qualiﬁcations 30 (41.1) 86 (22.1)
Financial difﬁculty: n (%)
Living comfortably/doing all right 12 (16.2) 155 (39.2) < 0.001
Just about getting by 30 (40.5) 144 (36.5)
Finding it difﬁcult/very difﬁcult to make ends meet 32 (43.2) 96 (24.3)
At least one car in household: n (%) 38 (51.4) 272 (68.9) 0.003
Home ownership: n (%)
Home owner 28 (37.8) 218 (55.2) 0.02
Tenant 38 (51.4) 140 (35.4)
Other 8 (10.8) 37 (9.4)
Smoking habits: n (%)
Current smoker 42 (56.8) 118 (29.9) < 0.001
Ex-smoker 17 (23.0) 140 (35.4)
Never smoked 15 (20.3) 137 (34.7)
continued
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TABLE 20b Summary of baseline variables related to missing outcome data at 12 months (continued )
Characteristic Missing (n = 74) Present (n = 395) p-value
Social support score: mean (SD) 11.6 (3.9) 12.1 (3.8) 0.28
History of depression: n (%)
Suffered from depression in the past 62 (83.8) 353 (89.4) 0.17
ICD-10 primary diagnosis: n (%)
Mild
8 (10.8)
58 (14.7) 0.16
Moderate 39 (52.7) 235 (59.5)
Severe 27 (36.5) 102 (25.8)
Suicidal ideation (CIS-R thoughts/plans): n (%) 30 (40.5) 118 (29.9) 0.07
Big Five neuroticism scale: mean (SD)b 4.2 (0.6) 4.0 (0.6) 0.17
PC-PTSD score: mean (SD)c 2.4 (1.5) 2.0 (1.5) 0.05
Panic score: median (IQR)d 4 (0 to 5) 1 (0 to 5) 0.04
SF-12 physical subscale: mean (SD)e 41.3 (13.5) 43.8 (13.5) 0.15
Dysfunctional attitudes score: mean (SD) 36.0 (10.9) 36.4 (10.8) 0.75
a Missing, n = 73; present, n = 390.
b Missing, n = 74; present, n = 393.
c Missing, n = 74; present, n = 390.
d Missing, n = 74; present, n = 394.
e Missing, n = 73; present, n = 391.
Note: Incomplete baseline data on some items, as listed above.
RESULTS: CLINICAL EFFECTIVENESS
36There was evidence that older participants, women and those from higher socioeconomic backgrounds
(as indicated by educational qualiﬁcations, ﬁnancial difﬁculty, car ownership, smoking status and home
ownership) were less likely to have missing outcome data, as were those with greater social support. In
contrast, those who were single were more likely to have missing outcome data. There was some evidence
that those with more severe depression at baseline (based on ICD-10 diagnosis and suicidal ideation) were
more likely to have missing outcome data. Those who scored more highly on a brief measure of symptoms
of PTSD were more likely to have missing outcome data, as were those who scored more highly on
measures of panic or neuroticism. Those with better physical function at baseline (SF-12 physical subscale
score) were less likely to have missing outcome data. Similarly, those with higher scores on the DAS were
also less likely to have missing outcome data.
Excluded from this table are the stratiﬁcation/minimisation variables that would be included by default in
the imputation model as they as part of the ITT model. In addition to the variables described above, all
available measures of depressive symptoms (BDI-II and PHQ-9) were included in the imputation model.
Measures of symptoms of anxiety (GAD-7) that are likely to be closely correlated with depressive symptoms
were also included in the imputation irrespective of statistical signiﬁcance, as was the baseline CIS-R score,
another marker of severity.
Comparison of the imputed values with the observed outcomes, in terms of BDI-II scores, at 6 and
12 months suggested that those who were missing outcome data had a worse outcome than those
who were followed up (Table 21).NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 21 Comparison of observed and imputed BDI-II outcomes at 6 and 12 months
Data
Follow-up
6-month 12-month
n Mean BDI-II score n Mean BDI-II score
Observed 419 21.8 395 19.3
Imputeda 50 25.6 74 22.6
a Values for imputed data are the mean BDI-II score averaged across the 25 data sets.
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The average (median) time elapsed from randomisation to the ﬁrst session of CBT was 29 days
(IQR 17–46) (range 3–126 days). In 10% of participants (n = 23), the time from randomisation to the
ﬁrst CBT session was > 66 days. The longer intervals between randomisation and start of CBT reﬂected a
number of factors. Some participants asked to postpone the start of therapy because of other
commitments, and others proved hard to contact following randomisation to arrange a date for their
ﬁrst CBT session. Therapists in Bristol and Exeter reached capacity part-way through recruitment. This also
contributed to a lengthier interval between randomisation and the start of CBT for a short period until
additional therapists were employed to work on the trial.
On average, the total time in therapy (from randomisation) was 6.3 months (SD 3.0 months). The range
was from 0 months (for those who declined to take up CBT following randomisation) to 16.5 months. The
total time in therapy reﬂected the wait from randomisation, the number of sessions attended and the time
elapsed through any sessions that were cancelled or not attended.
Nine out of the eleven CoBalT therapists delivered 97% of the intervention sessions. Among these nine
therapists, the number of patients assigned to them ranged from 13 (5.6% of the total) to 41 (17.5%),
reﬂecting the range in the FTE basis on which the therapists were employed and their duration of
employment (Table 22).
In total, the therapists delivered 2630 sessions of CBT primarily at the patients’ GP surgery or other NHS
premises (Table 23). There were differences in where the sessions took place between the three centres,
which reﬂected differences in how existing psychological services were provided. In Bristol, most patients
were seen at their GP surgery. In Exeter, most sessions were held at the centrally located Mood Disorders
Centre, as would be the case for patients referred for psychological therapy on the NHS. In Glasgow,
patients were mostly seen at the NHS Clinical Research Facility.
Twenty participants (8.5%) did not attend any sessions of CBT (Table 24). By 6 months, on average
(median), those randomised to the intervention had received 11 sessions of CBT (IQR 5–13). One hundred
and forty-four participants (61.5%) had received at least nine sessions of CBT by the 6-month follow-up.
By 12 months, the median number of sessions received was 12 (IQR 6 to 17) and a total of
141 participants (60.3%) had received at least 12 sessions of CBT (see Table 24).
Twenty-seven participants (11.5%) were discharged for non-adherence to the intervention (repeatedly
having failed to attend appointments) (Table 25) [median number of sessions attended 4 (IQR 1–10);
range 0–16], and 47 (20.1%) withdrew from CBT [median number of sessions attended 2 (IQR 0–4);
range 0–11]. Twenty-three participants reached an ‘agreed end’ in less than 12 sessions.
Although patients in Glasgow appeared to be more likely to be discharged for non-adherence to the
intervention (see Table 25), such differences were no greater than would be expected by chance
(chi-squared test: p = 0.18).37
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TABLE 22 Therapist caseload
Centre Therapist ID n %
Bristol 101 26 11.1
102 29 12.4
103 20 8.6
104 13 5.6
105 4 1.7
106 3 1.3
Exeter 201 41 17.5
202 15 6.4
203 23 9.8
Glasgow 301 39 16.7
302 21 9.0
TABLE 24 Number of CBT sessions attended
No. of sessions attended n %
0 20 8.5
1–2 16 6.8
3–5 22 9.4
6–7 9 3.8
8–9 11 4.7
10–11 15 6.4
12–13 35 15.0
14–15 26 11.1
16–17 23 9.8
18–19a 57 24.4
a Three individuals received an additional session because of
change in therapist or logistical issues.
TABLE 23 Location of delivery of CBT sessions by centre: n (%)
Location Bristol Exeter Glasgow Total
GP surgery 1079 (95.8) 311 (31.2) 80 (15.8) 1470 (55.9)
Mood disorders centre 0 682 (68.4) 0 682 (25.9)
Clinical research facility 0 0 384 (75.7) 384 (14.6)
Home 12 (1.7) 0 0 12 (0.5)
Other 35 (3.1) 4 (0.4) 43 (8.5) 82 (3.1)
Total 1126 997 507 2630
RESULTS: CLINICAL EFFECTIVENESS
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TABLE 25 Completion rates for therapy across all centres: n (%)
Therapy outcome Bristol Exeter Glasgow Total
Discharged for non-adherence to the intervention 11 (11.6) 5 (6.3) 11 (18.3) 27 (11.5)
Withdrew from therapy 19 (20.0) 14 (17.7) 14 (23.3) 47 (20.1)
‘Agreed end’ 65 (68.4) 60 (76.0) 35 (58.3) 160 (68.4)
a‘Agreed end’ excluding those who reached an ‘agreed end’
in < 12 sessions
60 49 28 137
a This describes a subset of participants described in the previous row.
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31Fidelity of the cognitive behavioural therapy interventionBased on a sample of nine recordings (one for each of the nine main therapists working on the trial),
inter-rater reliability for the three raters evaluating ﬁdelity to the CBT model was high (ICC 0.81),
indicating very good agreement between the raters. Using a sample of a further 54 sessions selected at
random, the mean CTS-R rating (adjusted for caseload) was 38.8 (95% CI 36.7 to 40.8), exceeding the
cut-point of 36 that equates to a mean item score of 3.0 or ‘competent’.Primary outcome
Depressive symptoms considered in terms of ‘response’ at 6 months
The primary outcome at 6 months was ‘response’, which was deﬁned as at least a 50% reduction in
depressive symptoms measured using the BDI-II compared with baseline. Forty-six per cent of those
randomised to the intervention ‘responded’ compared with 22% of those in usual care (Table 26). The
results are presented in Table 26 as an OR of ‘response’ in the intervention group compared with the
usual-care group. An OR of > 1 indicates that ‘response’ was more likely in the intervention group at
6 months.
In the primary ITT analysis, those in the intervention group had a threefold increased odds of ‘response’
compared with those in the usual-care group, with the 95% CI excluding the possibility that there was no
difference between the groups (column ‘ORb’ in Table 26). Additional adjustment for the time (in days)
from randomisation to completion of the 6-month follow-up did not change the effect estimate [OR 3.25
(95% CI 2.09 to 5.05) p < 0.001]. Adjustment for the variables that were imbalanced between treatmentTABLE 26 Percentage and OR of ‘response’ at 6-month follow-up
N n (%)a ORb 95% CI p-value ORc 95% CI p-value
Intervention 206 95 (46.1) 3.26 2.10 to 5.06 < 0.001 3.48 2.17 to 5.57 < 0.001
Usual care 213 46 (21.6)
Total N 419 419 415
a Number responding (n) as a percentage of the total number (N) in the group.
b ITT analysis adjusted for baseline BDI-II score and the stratiﬁcation (centre) and other minimisation (previously prescribed
antidepressants, whether or not the GP practice has a counsellor and duration of current episode of depression)
variables.
c ITT analysis additionally adjusted for additional variables that show an imbalance between treatment groups at
baseline (gender, employment status, ﬁnancial difﬁculty, caring responsibilities, long-standing illness/disability, number
of prior episodes of depression, family history of depression, length of current course of antidepressants, SF-12 physical
subscale score.
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40groups (see Baseline comparability of randomised groups, above) slightly increased the magnitude of
the treatment effect (column ‘ORc’ in Table 26).Subgroup analyses
For the two a priori subgroup analyses, there was no evidence that patient expectation of outcome or
degree of treatment resistance had any effect on the difference between intervention and usual-care
groups (p-values for interaction with treatment group: 0.16 and 0.88, respectively).
In a post hoc subgroup analysis there was no evidence that study centre had any effect on the difference
between the intervention and usual-care groups (p-value for interaction between treatment allocation and
centre: 0.61).Clustering effects by therapist
The ICC across therapists was calculated using a random-effects logistic regression model. There was little
evidence of clustering of outcomes: ICC before adjustment for baseline BDI-II score 0.00058, attenuated
substantially to 0.000009 following adjustment for baseline BDI-II score. Considering the BDI-II score as a
continuous outcome, the ICC was also very small (0.051 and 0.0027, respectively, before and after
adjustment for baseline BDI-II score).
In a fully heteroscedastic model that accounted for the possibility of clustering by therapist, the OR for the
primary outcome of ‘response’ was 3.26 (95% CI 2.10 to 5.06). This is identical to that obtained from the
primary ITT analysis (see Table 26), demonstrating that there was no evidence that clustering by therapist
had any inﬂuence on the ﬁndings.Sensitivity analyses to examine the impact of missing data
Table 27 presents the results of the ITT analysis for the 419 ‘complete cases’, with BDI-II outcome data at
6 months and the results from an ITT analysis for which the missing data had been imputed using the
method of MICE. The results imputing missing data were consistent with the results of the primary ITT
‘complete-case’ analysis, although the OR had decreased very slightly using the imputed data set.TABLE 27 Comparison of results of ITT analysis of complete cases with ITT analysis where missing data were
imputed using the method of MICE for primary outcome of ‘response’ at 6 months
‘Response’ n ORa 95% CI p-value
ITT adjusted for design variables 419 3.26 2.10 to 5.06 < 0.001
MICE estimates 469 3.10 2.00 to 4.80 < 0.001
a Adjusted for stratiﬁcation and minimisation variables (including baseline BDI-II score).Secondary outcomesDepressive symptoms on the Beck Depression Inventory (second version) at
6-month follow-up
Beck Depression Inventory (second version) as a continuous score
Table 28 summarises the means and differences in mean BDI-II scores at 6 months. Those in the
intervention group had a BDI-II score at 6 months that was, on average, 5.7 points lower (less depressed)
than those in the usual-care group, with a 95% CI ranging from a three- to eight-point reduction in BDI-II
score see (see Table 28). The mean difference between groups equated to an effect size of 0.53 SD
[baseline SD for BDI-II (pooled): 10.7]. Additional adjustment for the variables that were imbalanced at
baseline did not make any difference to the observed effect.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 28 Means and differences in mean BDI-II score at 6-month follow-up
n Mean SD
Difference
in meansa 95% CI p-value
Difference
in meansb 95% CI p-value
Intervention 206 18.9 14.2 −5.7 −7.9 to −3.4 < 0.001 −5.5 −7.8 to −3.2 < 0.001
Usual care 213 24.5 13.1
Total N 419 419 415
a ITT analysis adjusted for baseline BDI-II score and the stratiﬁcation (centre) and other minimisation (previously prescribed
antidepressants, whether or not the GP practice has a counsellor and duration of current episode of depression)
variables.
b ITT analysis additionally adjusted for additional variables that show an imbalance between treatment groups at baseline.
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31The results imputing missing data were consistent with the results of the ITT ‘complete-case’ analysis
[MICE estimates: –5.5 (95% CI –7.8 to –3.3), p < 0.001].‘Remission’ at 6-month follow-up
Table 29 summarises the percentages and ORs of ‘remission’ (deﬁned as having a BDI-II score of < 10) at
6 months. Those in the intervention group had a twofold increased odds of ‘remission’ at 6 months
compared with those in the usual-care group (see Table 29). Adjustment for those variables that were
imbalanced between treatment groups at baseline had very little effect, if anything resulting in a slight
increase in the estimated effect.
The results imputing missing data were again very consistent with the results of the ITT ‘complete-case’
analysis [MICE estimates: OR 2.34 (95% CI 1.43 to 3.85), p = 0.001].TABLE 29 Percentage and OR of ‘remission’ at 6-month follow-up
N n %a ORb 95% CI p-value ORc 95% CI p-value
Intervention 206 57 27.7 2.30 1.39 to 3.81 0.001 2.35 1.37 to 4.02 0.002
Usual care 213 32 15.0
Total N 419 419 415
a Number in ‘remission’ (n) as a percentage of the total number (N) in the group.
b ITT analysis adjusted for baseline BDI-II score and the stratiﬁcation (centre) and other minimisation (previously prescribed
antidepressants, whether or not the GP practice has a counsellor and duration of current episode of depression)
variables.
c ITT analysis additionally adjusted for additional variables that show an imbalance between treatment groups at baseline.
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42Depressive symptoms on the Beck Depression Inventory (second version)
over the duration of the study
‘Response’
Table 30 summarises the percentages and ORs of ‘response’ (deﬁned as a reduction in depressive
symptoms on the BDI-II of at least 50% relative to baseline) at 6 and 12 months. Based on a repeated
measures logistic regression analysis using data from both 6 and 12 months, the intervention group had
overall a threefold increased odds of ‘response’ over the 12 months compared with those in the usual-care
group, with the 95% CI surrounding this estimate ranging from a two- to fourfold increased odds (see
Table 30). There was no evidence that the difference between the intervention and usual-care groups
varied over time (interaction between treatment and time: p = 0.49).TABLE 30 Percentage and OR of ‘response’ based on BDI-II scores at 6- and 12-month follow-ups
Follow-up
6 months (n = 419) 12 months (n = 395)
N n %a N n %a
Intervention 206 95 46.1 197 109 55.3
Usual care 213 46 21.6 198 62 31.3
N ORb 95% CI p-value
6-month follow-up 419 3.26 2.10 to 5.06
12-month follow-up 395 2.79 1.84 to 4.24
Repeated measures 814 2.89 2.03 to 4.10 < 0.001
a Number responding (n) as a percentage of the total number (N) in the group.
b OR adjusted for stratiﬁcation and minimisation variables (including baseline BDI-II score).Beck Depression Inventory (version 2) as a continuous score
Table 31 summarises the means and differences in mean BDI-II scores at 6 and 12 months. Based on a
repeated measures linear regression analysis using data from both 6 and 12 months, the intervention
group had a BDI-II score that was, on average, 5 points lower (less depressed) than those in the usual-care
group over the 12 months (see Table 31). There was no evidence that the difference between the
intervention and usual-care groups varied over time (interaction between treatment and time: p = 0.36).TABLE 31 Means and difference in mean BDI-II scores at 6- and 12-month follow-ups
6 months (n = 419) 12 months (n = 395)
n Mean SD n Mean SD
Intervention 206 18.9 14.2 197 17.0 14.0
Usual care 213 24.5 13.1 198 21.7 12.9
N
Difference
in meansa 95% CI p-value
6-month follow-up 419 −5.7 −7.9 to −3.4
12-month follow-up 395 −5.0 −7.3 to −2.6
Repeated measures 814 −5.1 −7.1 to −3.1 < 0.001
a Adjusted for stratiﬁcation and minimisation variables (including baseline BDI-II score).
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Table 32 summarises the percentages and ORs of ‘remission’ (deﬁned as a BDI-II score of < 10) at 6
and 12 months. Based on a repeated measures logistic regression analysis using data from both 6 and
12 months, overall the intervention group had a threefold increased odds of ‘remission’ over the
12 months compared with those in the usual-care group (see Table 32). There was no evidence that the
difference between the intervention and usual-care groups varied over time (interaction between
treatment and time: p = 0.20).TABLE 32 Percentage and OR of ‘remission’ at 6- and 12-month follow-up
6 months (n = 419) 12 months (n = 395)
N n %a N n (%)a
Intervention 206 57 27.7 197 78 (39.6)
Usual care 213 32 15.0 198 36 (18.2)
N ORb 95% CI p-value
6-month follow-up 419 2.30 1.39 to 3.81
12-month follow-up 395 3.30 2.04 to 5.34
Repeated measures 814 2.74 1.82 to 4.13 < 0.001
a Number in ‘remission’ (n) as a percentage of the total number (N) in the group.
b Adjusted for stratiﬁcation and minimisation variables (including baseline BDI-II score).Depressive symptoms on the Patient Health Questionnaire-9 items at
6 months and over the duration of the study
A beneﬁcial effect of the intervention in terms of depressive symptoms was conﬁrmed when PHQ-9 scores
were compared for the intervention and control groups (Table 33). Those in the intervention group had a
PHQ-9 score that was, on average, 3 points lower than those in the usual-care group at 6 months.
The difference in means between groups equated to an effect size of 0.53 SD [baseline SD for PHQ-9
(pooled): 5.7]. There was very little effect when additional adjustment for those variables that were
imbalanced between groups at baseline was made.TABLE 33 Means and differences in mean PHQ-9 score at 6-month follow-up
Group n Mean SD
Difference
in meansa 95% CI p-value
Difference
in meansb 95% CI p-value
Intervention 209 9.5 6.7 −3.0 −4.2 to −1.8 < 0.001 −2.8 −4.0 to −1.7 < 0.001
Usual care 213 12.5 6.6
Total N 422 422 417
a ITT analysis adjusted for baseline PHQ-9 score and the stratiﬁcation (centre) and minimisation (baseline BDI-II score,
previously prescribed antidepressants, whether or not the GP practice has a counsellor and duration of current episode
of depression) variables.
b ITT analysis additionally adjusted for additional variables that show an imbalance between treatment groups at baseline.
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44The means and differences in mean PHQ-9 scores at 3, 6, 9 and 12 months are summarised in Table 34.
Based on a repeated measures linear regression analysis using data from 6, 9 and 12 months, the
intervention group had a PHQ-9 score that was, on average, just under 3 points lower (less depressed)
than those in the usual-care group over the 12 months (see Table 34). There was weak evidence that the
difference between the intervention and usual-care groups varied over time (interaction between
treatment and time: p = 0.059), reﬂecting the smaller difference in means between treatment groups at
12 months. Data from the 3-month follow-up was not included in the repeated measures analysis because
the purpose of this follow-up was to maintain contact with trial participants and provide data that could
be useful in imputing later missing outcomes. Moreover, it was not expected that there would be any
difference between the treatment groups at 3 months because those in the intervention group would only
have attended a small number of CBT sessions at this point.Anxiety on the Generalised Anxiety Disorder Assessment-7 items
at 6 months and over the duration of the study
Those in the intervention group had a GAD-7 score that was, on average, 2.5 points lower than those in
the usual-care group at 6 months (Table 35). There was, therefore, a beneﬁt in terms of a greater
reduction in symptoms of anxiety for those who received the intervention. The difference in means
between groups equated to an effect size of 0.49 SD [baseline SD for GAD-7 (pooled): 5.1]. As for the
other outcomes, adjustment for those variables that were imbalanced at baseline had very little effect.
The means and differences in mean GAD-7 scores at 6 and 12 months are summarised in Table 36. Based
on a repeated measures linear regression analysis using data from 6 and 12 months, the intervention
group had a GAD-7 score that was, on average, 2 points lower (less anxious) than those in the usual-care
group over the 12 months (see Table 36). There was no evidence that the difference between the
intervention and usual-care groups varied over time (interaction between treatment and time: p = 0.19).
Panic symptoms at 6 months and over the duration of the study
Those in the intervention group scored, on average, 0.6 points lower on the panic symptom scale than
those in the usual-care group at 6 months (Table 37), and this did not change following adjustment for
baseline imbalances. In terms of an effect size, the difference between groups was relatively small at
0.26 SD [baseline SD for panic (pooled): 2.3].
The means and differences in mean panic scores at 6 and 12 months are summarised in Table 38. Based
on a repeated measures linear regression analysis using data from 6 and 12 months, the intervention
group had a panic score that was, on average, 0.5 points lower than those in the usual-care group over
the 12 months (see Table 38). There was no evidence that the difference between the intervention and
usual-care groups varied over time (interaction between treatment and time: p = 0.16).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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TABLE 37 Means and differences in mean panic score at 6-month follow-up
Group n Mean SD
Difference
in meansa 95% CI p-value
Difference
in means 95% CI p-value
Intervention 205 1.6 2.1 −0.6 −1.0 to −0.3 0.001 −0.6 −1.0 to −0.3 0.001
Usual care 213 2.1 2.2
Total N 418 418 414
a ITT analysis adjusted for baseline panic score and the stratiﬁcation (centre) and minimisation (baseline BDI-II score,
previously prescribed antidepressants, whether or not the GP practice has a counsellor and duration of current episode
of depression) variables.
b ITT analysis additionally adjusted for additional variables that show an imbalance between treatment groups at baseline.
TABLE 35 Means and differences in mean GAD-7 score at 6-month follow-up
Group n Mean SD
Difference
in meansa 95% CI p-value
Difference
in meansb 95% CI p-value
Intervention 207 7.0 5.9 −2.5 −3.4 to −1.5 < 0.001 −2.4 −3.4 to −1.5 < 0.001
Usual care 213 9.5 5.6
Total N 420 420 416
a ITT analysis adjusted for baseline GAD-7 score and the stratiﬁcation (centre) and minimisation (baseline BDI-II score,
previously prescribed antidepressants, whether or not the GP practice has a counsellor and duration of current episode
of depression) variables.
b ITT analysis additionally adjusted for additional variables that show an imbalance between treatment groups at baseline.
TABLE 36 Means and difference in mean GAD-7 scores at 6- and 12-month follow-ups
Follow-up
6 months (n = 420) 12 months (n = 395)
n Mean SD n Mean SD
Intervention 207 7.0 5.9 197 6.7 6.2
Usual care 213 9.5 5.6 198 8.5 5.8
N
Difference
in meansa 95% CI p-value
6-month follow-up 420 −2.5 −3.4 to −1.5
12-month follow-up 395 −1.9 −3.0 to −0.9
Repeated measures 815 −2.2 −3.0 to −1.3 < 0.001
a Adjusted for stratiﬁcation and minimisation variables and baseline GAD-7 score.
RESULTS: CLINICAL EFFECTIVENESS
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TABLE 38 Means and difference in mean panic symptoms at 6- and 12-month follow-ups
Follow-up
6 months (n = 418) 12 months (n = 393)
N Mean SD N Mean SD
Intervention 205 1.6 2.1 195 1.5 2.1
Usual care 213 2.1 2.2 198 1.7 2.2
N
Difference
in meansa 95% CI p-value
6-month follow-up 418 −0.6 −1.0 to −0.3
12-month follow-up 393 −0.3 −0.7 to 0.05
Repeated measures 811 −0.5 −0.8 to −0.2 0.001
a Adjusted for stratiﬁcation and minimisation variables and baseline panic symptom score.
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31Quality of lifeShort-Form questionnaire-12 items mental subscale scores at 6 months and
over the duration of the study
Table 39 presents the means and difference in mean SF-12 mental subscale scores for both treatment
groups at the 6-month follow-up. A positive difference indicates a better outcome among those in the
intervention group. On average, those in the intervention group experienced an improvement of 6 points
on the SF-12 mental subscale more than the usual-care group. There was very little effect of adjustment
for those variables that were imbalanced at baseline. In terms of an effect size, the difference between
groups equated to 0.63 SD [baseline SD for SF-12 mental subscale (pooled): 9.2].
The means and differences in mean SF-12 mental subscale scores at 6 and 12 months are summarised in
Table 40. Based on a repeated measures linear regression analysis using data from 6 and 12 months, the
intervention group had a SF-12 mental subscale score that was, on average, 5 points higher than those in
the usual-care group (see Table 40). There was no evidence that the difference between the intervention
and usual-care groups varied over time (interaction between treatment and time: p = 0.11).TABLE 39 Means and differences in mean SF-12 mental subscale score at 6-month follow-up
Group n Mean SD
Difference
in meansa 95% CI p-value
Difference
in meansb 95% CI p-value
Intervention 201 39.1 14.1 5.8 3.5 to 8.2 < 0.001 6.0 3.6 to 8.5 < 0.001
Usual care 209 33.7 12.6
Total N 410 410 410
a ITT analysis adjusted for baseline SF-12 mental subscale score and the stratiﬁcation (centre) and minimisation (baseline
BDI-II score, previously prescribed antidepressants, whether or not the GP practice has a counsellor and duration of
current episode of depression) variables.
b ITT analysis additionally adjusted for additional variables that show an imbalance between treatment groups at baseline.
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TABLE 40 Means and difference in mean SF-12 mental subscale scores at 6- and 12-month follow-ups
Follow-up
6 months (n = 410) 12 months (n = 389)
n Mean SD N Mean SD
Intervention 201 39.1 14.1 194 39.1 14.6
Usual care 209 33.7 12.6 195 35.4 12.8
N
Difference
in meansa 95% CI p-value
6-month follow-up 410 5.8 3.5 to 8.2
12-month follow-up 389 4.1 1.6 to 6.7
Repeated measures 799 4.8 2.7 to 6.9 < 0.001
a Adjusted for stratiﬁcation and minimisation variables and baseline SF-12 mental subscale score.
RESULTS: CLINICAL EFFECTIVENESS
48SF-12 physical subscale scores at 6 months and over the duration of
the study
Table 41 presents the means and difference in mean SF-12 physical subscale scores for both treatment
groups at the 6-month follow-up. Based on a comparison of the absolute mean values at 6 months, it
would appear that those in the intervention group had a better outcome in terms of a higher mean SF-12
physical subscale score at 6-month follow-up. There was, however, a substantial imbalance in baseline
SF-12 physical subscale scores (mean scores: intervention 45.3; usual care 41.6) such that the adjusted
difference in means indicates that those in the intervention group had a slightly worse outcome
(negative difference) compared with those in the usual-care group. In any case, the 95% CI surrounding
this estimate just included the possibility of no difference between the groups and in terms of an effect
size, the difference between groups was small at 0.12 SD [baseline SD for SF-12 physical subscale
(pooled): 13.5].
The means and differences in mean SF-12 physical subscale scores at 6 and 12 months are summarised in
Table 42. Based on a repeated measures linear regression analysis using data from 6 and 12 months, the
intervention group had a SF-12 physical subscale score that was, on average, 0.7 points lower than those
in the usual-care group (see Table 42). There was weak evidence that the difference between the
intervention and usual-care groups varied over time (interaction between treatment and time: p = 0.047).
The interaction appeared to be driven by the small difference in SF-12 physical subscale scores between
the treatment groups observed at 6 months. There was no evidence of a difference in SF-12 physical
subscale scores between the treatment groups at 12 months (see Table 42).TABLE 41 Means and differences in mean SF-12 physical subscale score at 6-month follow-up
Group n Mean SD
Difference
in meansa 95% CI p-value
Difference
in meansb 95% CI p-value
Intervention 201 44.1 14.2 −1.6 −3.3 to 0.05 0.057 −1.7 −3.4 to 0.02 0.052
Usual care 209 42.1 14.0
Total N 410 410 410
a ITT analysis adjusted for baseline SF-12 physical subscale score and the stratiﬁcation (centre) and minimisation (baseline
BDI-II score, previously prescribed antidepressants, whether or not the GP practice has a counsellor and duration of
current episode of depression) variables.
b ITT analysis additionally adjusted for additional variables that show an imbalance between treatment groups at baseline.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 42 Means and difference in mean SF-12 physical subscale scores at 6- and 12-month follow-ups
Follow-up
6 months (n = 410) 12 months (n = 389)
n Mean SD n Mean SD
Intervention 201 44.1 14.2 194 44.6 13.2
Usual care 209 42.1 14.0 195 41.1 13.5
N Difference in meansa 95% CI p-value
6-month follow-up 410 −1.6 −3.3 to 0.05
12-month follow-up 389 0.3 −1.4 to 2.0
Repeated measures 799 −0.7 −2.1 to 0.8 0.35
a Adjusted for stratiﬁcation and minimisation variables and baseline SF-12 physical subscale score.
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31Treatment efﬁcacy
Complier average causal effect analyses were performed to estimate the efﬁcacy of the intervention in
improving depressive symptoms among those in the intervention group compared with those in usual care
using instrumental variable regression methods. The results of these analyses are shown in Table 43. As
the primary outcome ‘response’ was a binary variable, a probit transformation has been used and the
primary ITT analysis repeated for comparison on this transformed scale. The CACE analysis at 6 months
showed that there was a larger effect of the intervention among those who were ‘on track’ to complete
the intervention (at least 9 sessions by 6 months; n = 144) compared with the standard ‘ITT’ estimate of
the ‘offer’ of treatment.
Using the secondary outcome of BDI-II score as a continuous variable, the CACE analysis demonstrated
that, on average, those who were ‘on track’ to complete the intervention improved by 8 points on the
BDI-II, compared with a 6-point difference in a standard ITT analysis (Table 44).TABLE 43 Binary ‘response’ outcome at 6 months comparing results of ITT and CACE analyses
Analysis n Probit regression coefﬁcienta 95% CI p-value
ITT 419 0.71 0.45 to 0.97 < 0.001
CACE 419 0.99 0.65 to 1.34 < 0.001
a Adjusted for stratiﬁcation and minimisation variables (including baseline BDI-II score).
TABLE 44 Continuous BDI-II outcome at 6 months comparing results of ITT and CACE analyses
Analysis n
Difference
in meansa 95% CI p-value
ITT 419 −5.7 −7.9 to −3.4 < 0.001
CACE 419 −8.2 −11.4 to −5.0 < 0.001
a Adjusted for stratiﬁcation and minimisation variables (including baseline BDI-II score).
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RESULTS: CLINICAL EFFECTIVENESS
50Extending the CACE analysis for the continuous BDI-II outcome at 12 months and deﬁning ‘compliers’ as
those who received at least 12 sessions of CBT (n = 141) conﬁrmed the beneﬁcial effect of adhering to the
intervention (Table 45).TABLE 45 Continuous BDI-II outcome at 12 months comparing results of ITT and CACE analyses
Analysis n Difference in meansa 95% CI p-value
ITT 395 −5.0 −7.3 to −2.6 < 0.001
CACE 395 −7.1 −10.4 to −3.8 < 0.001
a Adjusted for stratiﬁcation and minimisation variables (including baseline BDI-II score).Contamination: receipt of non-CoBalT psychological therapy
Participants were asked about non-CoBalT psychological therapy that they had received over the duration
of the study. For the 388 participants who provided data at 6 and 12 months, only 66 participants (17%)
reported having had any counselling or other ‘talking therapy’ during the 12 months [usual care: n = 41
(21.0%); intervention: n = 25 (13.0%)]. For the majority (n = 50), this comprised sessions lasting at least
50 minutes (usual care, n = 32; intervention, n = 25).
In response to a series of closed questions, those who indicated that they had had individual face-to-face
‘talking therapy’ in sessions lasting ≥ 50 minutes, and who had completed homework and thought diaries
as part of this therapy, were regarded as having received CBT outwith the trial (non-CoBalT CBT).
Only a very small minority received such treatment.
By the 6-month follow-up, two participants had attended at least nine sessions of individual face-to-face
non-CoBalT CBT with a private therapist. One of these participants had been randomised to receive the
intervention but had withdrawn from CBT (not attending any sessions). The other individual had been
randomised to usual care.
By the 12-month follow-up, a total of three participants in the usual-care group and two participants in
the intervention group had attended at least 12 sessions of non-CoBalT CBT. The second intervention
participant had received 12 sessions of CBT in the NHS following completion of the trial intervention
(n = 14 sessions). Those in the usual-care group had accessed CBT through a private provider, voluntary
organisation or the NHS.
Estimates of treatment efﬁcacy at 6 and 12 months were recalculated for the continuous BDI-II outcome
incorporating the contamination through the receipt of non-CoBalT CBT; not unexpectedly, given the small
numbers involved, the CACE estimates did not change (data not shown).NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31Use of antidepressant medication over the studyAt the point of randomisation, all participants were taking antidepressant medication and they were asked
to report whether or not they were still taking antidepressants (and whether or not there had been any
change in their medication) at each follow-up. The vast majority of participants continued to take
antidepressant medication over the 12 months of the study (Table 46). At 12 months, a smaller percentage
of those randomised to the intervention were still taking antidepressants compared with those randomised
to continue with usual care. In a repeated measures analyses, there was some evidence that the difference
in antidepressant use varied over time (interaction between treatment and time: p = 0.034) and hence it
was not appropriate to generate a summary OR for the difference.
Adherence to antidepressant medication over the previous 6 weeks was assessed as part of the screening
questionnaire and the same questions were included as part of the baseline and follow-up questionnaires.
Table 47 shows the number and percentage of participants in each group who met criteria for ‘adherence’
as applied at the initial screening stage. The majority of participants continued to adhere to their
antidepressants over the 12 months. In a repeated measures analysis there was only very weak evidence
that those in the intervention group were more likely to adhere to their medication [summary OR for
n = 1516 observations: 1.41 (95% CI 0.92 to 2.16), p = 0.12] and no evidence that the difference between
groups varied over time (interaction between treatment and time: p = 0.83).TABLE 47 Numbers and percentage of participants who had adhered to their antidepressant medication in the
6 weeks prior to each assessment from baseline to 12-month follow-up
Follow-up
Intervention Usual care
Difference 95% CIN n % N n %
Baseline 234 223 95.3 235 219 93.2 2.1 −2.1 to 6.3
3 months 217 202 93.1 210 187 89.1 4.0 −1.4 to 9.4
6 months 193 178 92.2 198 174 87.9 4.3 −1.6 to 10.3
9 months 166 159 95.8 179 166 92.7 3.0 −1.8 to 7.9
12 months 173 160 92.5 180 168 93.3 −0.8 −6.2 to 4.5
TABLE 46 Numbers and percentage of participants who are taking antidepressants during the study
Follow-up
Intervention Usual care
Difference 95% CIN n % N n %
3 months 222 218 98.2 219 211 96.4 1.9 −1.2 to 4.9
6 months 209 194 92.8 213 199 93.4 −0.6 −5.4 to 4.2
9 months 186 166 89.3 191 180 94.2 −5.0 −10.5 to 0.6
12 months 198 174 87.9 198 183 92.4 −4.5 −10.4 to 1.3
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52Outcomes that can be compared with the Improving Access
to Psychological Therapies data setIn the IAPT project,32,33 outcomes are considered in terms of whether an individual is a ‘case’ on the PHQ-9
(deﬁned as a score of ≥ 10) and/or GAD-7 (deﬁned as a score of ≥ 8).
Of the 416 participants who were a ‘case’ on the PHQ-9 at baseline, 374 were followed up and completed
the PHQ-9 at 6 months. In total, 51.3% (n = 96) of those randomised to CBT and 32.1% (n = 60) of those
randomised to usual care had a PHQ-9 score of < 10 (‘non-case’) at 6 months.
Of the 356 who were a ‘case’ on the GAD-7 at baseline, 320 were followed up and completed the GAD-7
at 6 months. In total, 59.4% (n = 94) of those randomised to CBT and 33.5% (n = 54) of those
randomised to usual care had a GAD-7 score of < 8 (‘non-case’) at 6 months.
In total, 439 patients were a ‘case’ on the PHQ-9 or GAD-7 at baseline, 393 were followed up and
completed both the PHQ-9 and GAD-7 at 6 months. Of these, 47.6% (n = 91 of 191) randomised to CBT
were a ‘non-case’ on both the PHQ-9 and GAD-7 at 6 months compared with 28.7% (n = 58 of 202) of
those randomised to usual care.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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and resultsIntroduction
Aim
The aim of the economic evaluation was to assess the cost-effectiveness of individual face-to-face
CBT as an adjunct to usual care compared with usual care alone, for primary care patients with TRD.
The economic evaluation was carried out alongside the RCT, where patients recruited to the study
were randomly allocated to CBT plus usual care or usual care alone.The interventions
Control: Patients allocated to the control group received TAU. There were no restrictions imposed on GPs,
and treatment could include any combination of pharmacotherapy, counselling, CBT and secondary care if
considered to be clinically appropriate.
Intervention: Patients allocated to the intervention group were offered between 12 and 18 sessions of
face-to-face CBT in addition to TAU. The intervention was delivered by qualiﬁed therapists who received at
least one day of training speciﬁc to the trial and who all used the same CBT manuals for depression; these
were informed by the Moore and Garland manual on chronic depression.64 Therapy took place at the
patients’ GP surgeries or at nearby NHS or University premises.Methods
Form of analysis
The economic evaluation was based on all costs incurred during the 12 months following randomisation.
The main perspective was that of the health and social care provider, although personal costs incurred by
patients and productivity costs due to time off work were also considered. These are presented separately.
A cost–consequences approach was used to compare cost from all three perspectives (health and social
care, patients, and lost productivity) with a range of outcomes.
A cost-effectiveness (utility) analysis was carried out in line with the recommendations of NICE75 to
compare health and social care costs with quality-adjusted life-years (QALYs).Outcomes
The primary outcome for the trial was a reduction of at least 50% in the BDI-II score46 at 6 months
compared with baseline. In addition, several outcomes were measured at 12 months, including the BDI-II
score as a continuous variable; remission deﬁned as BDI-II score of < 10, the SF-12 mental and physical
subscales56 and the EQ-5D-3L.76 All outcomes were measured at baseline, 6 months and 12 months.
Quality-adjusted life-years over the 12-month period were estimated from responses to the EQ-5D-3L at
baseline, 6 months and 12 months. Utility values – representing health-related quality of life on a scale
between 0 (death) and 1 (best imaginable health) – were derived using the valuation tariff obtained from a
UK general population survey.77 QALYs were computed from these values using the area under the curve
approach and adjusted for any difference between the groups at baseline.7853
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54Identification of relevant costs
The analysis included the cost of caring for all patients during the 12 months between randomisation and
ﬁnal follow-up. This included the following.Direct costs to the health service provider (the NHS)l The cost of delivering the CBT intervention.
l Primary and community care: all primary and community care was included, irrespective of the reason
for the encounter because the nature of primary care makes it difﬁcult to identify consultations that
are for underlying mental ill health. This included:
¢ face-to-face consultations with GP, practice nurse, nurse practitioner, specialist nurse,
health-care assistant
¢ telephone consultations with GP, practice nurse, nurse practitioner
¢ home visits by a GP
¢ out-of-hours consultations with GP, nurse
¢ other primary and community care: district nurse, community health workers, referral to alternative
therapists, referral to exercise on prescription, use of NHS Direct
¢ prescribed medication
l Hospital care, restricted to care relating to mental health, which was identiﬁed according to the
specialist involved and/or the reason for the encounter:
¢ visits to accident and emergency (A&E)
¢ outpatient appointments
¢ inpatient stays.Direct costs of Personal Social Services
This included:
l social worker
l home help
l self-help groups run by social services
l day centre use.Costs to patients and their carersl Travel to trial CBT sessions.
l Travel to appointments at GP surgery, exercise on prescription.
l Over-the-counter medication and remedies.
l Private and alternative therapies and associated travel.
l Self-help groups and associated travel.
l Prescription costs.
l Loss of earnings owing to time off work.
l Disability payments received.Productivity costsl Time off work.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Trial cognitive behavioural therapy
During the trial, the CBT therapists recorded details of all sessions booked and attended by participants.
These records were used to measure – for each patient in the intervention group – how many sessions
each attended, how many were booked but were not attended and how many were booked but cancelled
in time to allow the therapist to make alternative arrangements.
No extra equipment or other capital was required by the therapists.Health and social care
Information about all primary care encounters over the 12-month period was extracted from GP records
for participants who gave consent. Information extracted included type of professional seen (e.g. GP,
practice nurse), where the encounter took place (e.g. face-to-face, over the telephone) and number of
encounters. Details of prescribed medication were extracted in the same way; the information recorded
included name of drug, method of delivery (e.g. capsules, liquid), strength and amount prescribed.
A questionnaire was administered to participants at 6 months and 12 months to obtain resource-use data
(about use of health and social care) that were not available from GP records. The 6-month questionnaire
asked about resource use for the period between randomisation and 6 months, and the 12-month
questionnaire asked about the time period between 6 months and 12 months.
The questionnaires were designed in two parts. Part 1, which was largely self-completed with a researcher
present, contained ‘yes/no’ questions about each item of resource use to ﬁnd out which categories each
participant had used at all. Those who answered ‘yes’ to any category were then asked detailed questions,
contained in part 2, by the researcher to gain more information. In the case of NHS hospital use, for
example, part 2 of the questionnaire asked participants about the reason for the encounter, the name of
the clinic attended or the ward in which they stayed, and information about treatment received. The
design of the questionnaire allowed for free text to be entered as comments, to facilitate accurate costing.
Detailed information about the use of social services was obtained in the same way, covering use of a
social worker, any home help, self-help groups run by social services and use of day centres.Personal expenditure and time off work
Data on personal out-of-pocket expenditure was obtained using the questionnaires administered at
6 months and 12 months, as described above. Part 1 of the questionnaire asked if each category of
resource was used at all and if a participant responded ‘yes’ to any category, part 2 of the questionnaire,
administered by a researcher, was used to obtain detailed information about distances travelled to
appointments, the estimated cost of over-the-counter medication and remedies, and use and cost of
private and alternative therapies and self-help groups. Participants were also asked if they normally pay for
prescriptions and whether or not a prescription payment certiﬁcate (PPC) was used.Disability payments
Data on disability payments received was obtained using the questionnaires administered at 6 months and
12 months, as described above. Part 1 of the questionnaire asked whether or not any payments were
received, and if the participant responded ‘yes’ then part 2 of the questionnaire, administered by a
researcher, was used to obtain detailed information about the type of beneﬁt and the amount received.Productivity losses owing to time off work
Information about time off work was obtained using the questionnaires administered at 6 months and
12 months, as described above. Part 1 of the questionnaire asked whether or not the participant took
any time off work because of their illness and if they responded ‘yes’ then part 2 of the questionnaire,
administered by a researcher, was used to obtain detailed information about frequency and length
of absences.55
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56Valuation of resource use
The principle of opportunity cost was applied to the valuation of resources; however, in most cases market
prices were used as a proxy for opportunity cost. All costs were valued in pound sterling at 2010 prices,
adjusted for inﬂation where necessary.79Trial cognitive behavioural therapy
Methods used by Curtis in the Unit Costs for Health and Social Care79 were used to estimate a unit cost
for the trial CBT sessions (Table 48). Most of the therapists in the trial were Band 8a on the NHS Agenda
for Change scale,80 and this was used in the base-case analysis. After allowance for National Insurance,
superannuation, overheads and non-contact time of 50%, this equated to £73 per hour of face-to-face
contact. The ﬁrst CBT session was 90 minutes in length with subsequent sessions lasting 60 minutes.
Appointments that were cancelled were not included in the costing but when a patient did not cancel but
failed to attend we included an amount equal to half the usual rate, reﬂecting the fact that therapists
would make some use of the time but would not be fully productive. Supervision was generally carried out
in groups of two or three. Therapist time for this was subsumed in the non-contact time but we included
an estimate of £2.50 per hour of therapy delivered to cover the cost of the supervisors’ time. This was
based on the salary of a consultant psychiatrist/consultant clinical psychologist.TABLE 48 Unit cost of trial CBT therapy sessions
Costs and unit estimation Value (£)
Basic annual salary (Band 8a) 41,000
Oncosts: National Insurance and superannuation 10,065
Capital and overheads 6422
Total cost per annum 57,487
Hours worked per year 1575
Cost per hour 36.50
Cost per hour face to face allowing for 50% non-contact time 73
Supervision per hour of therapy 2.50
Cost of ﬁrst session (90 minutes): attended 113.25
Cost of follow-up sessions (60 minutes): attended 75.50
Cost of ﬁrst session (90 minutes): did not attend 54.74
Cost of follow-up sessions (60 minutes): did not attend 36.50Direct costs to the health service provider (the NHS)Primary and community health and social services
The majority of unit costs for primary and community health, and social services, were taken from Curtis.79
These are shown in Table 49.
The cost of out-of-hours care was based on estimates obtained from a local provider (BrisDoc), of walk-in
centres81 and NHS Direct82 from published evaluations, adjusted to 2010 values using the pay and prices
index.79 These are shown in Table 50.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 49 Unit costs for primary and community health and social services
Type of consultation Cost per consultation (£)
Primary and community health care
GP
Surgery 28.00
Telephone 17.00
Home visit 94.00
Practice nurse
Surgery 10.00
Telephone consultation 5.00
Nurse practitioner
Surgery 14.00
Telephone consultation 7.00
Diabetic nurse 11.92
District nurse 16.33
Health visitor 24.67
Midwife 24.67
Phlebotomist 6.92
Podiatrist 11.00
Occupational therapist 75.00
Exercise on prescription 8.00
Alternative therapy 30.00
PSS
Home help 21.40
Self-help groups 15.00
Day centre use 21.00
PSS, Personal Social Services.
Source: Curtis.79
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TABLE 50 Unit costs for out-of-hours care, walk-in centres and NHS Direct
Type of consultation Cost per consultation (£)
Out of hoursa
GP
Face to face 75.00
Telephone consultation 50.00
Home visit 150.00
Nurse
Face to face 56.25
Other primary care
Walk-in centre (Salisbury et al.81) 39.00
NHS Direct (Munro et al.82) 20.20
a Estimates supplied by BrisDoc.
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58Prescribed medication
The values of prescriptions issued in general practice were based on costs published in the BNF,83 by item
name, strength and amount prescribed. These were adjusted to allow for:
l the discount allowed to the NHS, which depends on volume; an average deduction of 8.56% was
applied to all basic drug prices
l the professional fee of 90p per prescription,84 and
l a container allowance of 3.24p per prescription.84Hospital care
Unit costs for hospital use were taken from the NHS National Schedule of Reference Costs for 2010–11.85
Costs used in the analysis are shown in Table 51.
Patients and their carersTravel costs
Travel costs were reported directly by the participants in their questionnaire responses, with the exception
of travel by car, which was reported as mileage. Information about mileage costs was obtained from the
Automobile Association schedule of motoring costs86 and a value of 60.5p per mile was used.Personal expenditure
Information on personal expenditure on over-the-counter medication and remedies, private and alternative
therapies, and attendance at self-help groups was obtained from the participants’ questionnaire responses.Prescription costs
The cost of individual prescriptions and PPCs was obtained from the Department of Health.87Loss of earnings due to time off work
Information on loss of earnings owing to time off work was obtained from the participants’
questionnaire responses.Disability payments received
Information on disability payments received was obtained from the participants’ questionnaire responses.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 51 Unit costs for hospital use
Type of consultation Cost per consultation/visit (£)
A&E
Investigation and minor treatment followed by discharge 112.33
Observation followed by admission 150.00
Outpatient appointments and clinic visits
Clinical psychology 71.00
Community psychiatric nursing 71.00
Neurology: ﬁrst attendance 206
Neurology: follow-up visits 146
Psychiatry: ﬁrst attendance 284
Psychiatry: follow-up visits 165
Mental Wellbeing Clinic 58.50
Hospital-based support group 71.00
Inpatient stays
Observation only, for overdose, panic attack 291.00
Treated by occupational therapist 354.00
Source: NHS National Schedule of Reference Costs.85
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The human capital approach was used to value time off work. Median hourly earnings by age and sex
were obtained from the Ofﬁce for National Statistics 2010 Annual Survey of Hours and Earnings.88
These are shown in Table 52.
Data analysis
Resource use by patients in the intervention and usual-care groups were compared using frequencies,
means and medians of the number of encounters. The level of uncertainty around the point estimate was
determined using SDs and IQRs as appropriate.
Resource use was combined with unit costs to obtain mean cost per participant for each category of cost.TABLE 52 Median gross weekly earnings (£) by age and sex
Age (years) Men Women
18–21 285.9 268.3
22–29 421.2 401.3
30–39 573.7 507.9
40–49 613.7 472.2
50–59 582.7 440.9
60+ 483.0 389.0
Source: Annual Survey of Hours and Earnings, Ofﬁce for National Statistics.88
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60Missing data
The MICE procedure was used to address the issue of missing cost and QALY data.72 The ice command
(version 1.9.5 PR/IW 15apr2011) in Stata version 12 was used to generate ﬁve data sets using 10
switching procedures, in addition to a range of cost and EQ-5D-3L variables, the model also included
randomisation group, age and sex.Uncertainty resulting from patient variation
Uncertainty in the estimates of cost and QALYs was captured using SDs around the point estimates and
CIs around incremental differences.
Uncertainty around the incremental cost-effectiveness ratio (ICER) was captured using the bootstrapping
technique. A total of 5000 replicates of the ICER were generated and these were used to estimate
(1) CIs around the net beneﬁt statistic and (2) a cost-effectiveness acceptability curve.Sensitivity analyses
Sensitivity analyses were used to investigate the effect of uncertainty on the results. Four separate one-way
analyses were undertaken as follows:
1. Grade of therapist In the trial the therapists were mainly Band 8a, although in practice they are often
appointed at a lower grade. Sensitivity analysis was used to estimate the effect on cost per QALY if all
therapists were costed at Band 7.
2. Hospital costs Patients in this trial were all recruited from (and largely cared for by) primary care.
Secondary care is relatively uncommon but expensive and can affect results disproportionately.
The potential effect of this was assessed by removing hospital costs from the analysis.
3. QALY weights The base-case analysis used the EQ-5D-3L to derive QALY weights; sensitivity analysis
tested the robustness of these weights by applying the Short Form questionnaire-6 Dimensions (SF-6D)
algorithm89 to responses to the SF-12 plus four questions from the SF-36.
4. Missing data The effect of imputing missing data was assessed by comparing the imputed results with
those restricted to complete cases, i.e. including only those participants for whom complete cost and
QALY data were available at both 6 and 12 months.Discounting
Costs and outcomes were not discounted, as the study was limited to a period of 12 months.Results
Data completeness
Nearly all participants (97%) gave permission for the research team to access their GP notes to obtain data
about primary care encounters and prescribed medication. Data obtained from the questionnaire were
slightly less complete: 83% of participants returned the questionnaire at both 6 and 12 months, although
not all completed all sections at both time points. Complete cost and QALY data were available for
368 (78%) participants and complete personal cost data were available for 274 (58%) participants.Resource use
Trial cognitive behavioural therapy sessions
The number of CBT sessions attended by participants is shown in Table 53, which includes the number
of sessions arranged but not attended. Sessions cancelled ahead were not costed and are not included.
Most participants received between 12 and 18 sessions as per protocol, although a small number (8.5%)
received no therapy.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 53 Number of CBT sessions attended, and number of
sessions arranged but not attended
Frequency No.
First session
Attended 214
Did not attend
1 11
2–4 8
Follow-up sessions
Attended
1–4 30
5–11 62
12–18a 114
Did not attend
1 42
2 15
3 8
4–9 4
a Three participants had one session more than the 18 permitted
under the protocol because of a change in therapist.
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Results of primary care resource use are presented in Table 54 using frequency of use for all participants
who provided data. Frequencies, means and median number of encounters are presented, along with SDs
and IQRs, to indicate the level of uncertainty around the point estimates.
Most participants (89%) saw their GP at least once during the year and, on average, they had about eight
consultations. There was very little evidence of a marked difference in primary care resource use between
participants in the intervention group and those in the usual-care group. The usual-care group appear to
be consistently higher users of services but the difference is small and the level of variation is high. One in
eight participants in the usual-care group accessed (non-trial) CBT or cCBT at least once during the
12 months compared with one in 14 of those offered trial CBT.Prescribed medication
Information about the amount of prescribed medication is given in Table 55.
Over 90% of participants had at least one prescription for an antidepressant, and at least 10% had more
than 15. There was little evidence of a difference between the two groups.
More participants in the usual-care group had more non-antidepressant medication than those in the
intervention group, although variation was high, with the number of prescriptions ranging from 0 to > 150
in both groups.61
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TABLE 54 Primary care resource use by category and allocation group
Frequency of consultations
Intervention Usual care
No. Percentage No. Percentage
GP consultations
0 25 11 24 11
1–5 74 32 59 26
6–10 64 28 74 33
11–15 42 18 45 20
16+ 24 10 22 10
229 100 224 100
Mean (SD) 7.62 (7) 8.26 (6.2)
Median (IQR) 7 (3 to 11) 7 (4 to 12)
Nurse consultations
0 100 44 99 44
1–5 109 48 107 48
6–9 14 6 13 6
10+ 6 3 5 2
229 100 224 100
Mean (SD) 2.03 (4.10) 1.95 (2.81)
Median (IQR) 1 (0 to 3) 1 (0 to 3)
Other surgery-based consultations
0 146 64 136 61
1–5 76 33 80 36
6–9 4 2 3 1
10+ 3 1 5 2
229 100 224 100
Mean (SD) 0.88 (2.16) 1.23 (2.56)
Median (IQR) 0 (0 to 1) 0 (0 to 2)
Out of hours, walk-in centres and NHS Direct
0 164 87 163 89
1 13 7 13 8
2+ 11 6 6 3
188 100 182 100
Mean (SD) 0.23 (0.73) 0.20 (0.83)
Median (IQR) 0 (0) 0 (0)
Other primary and community care therapies and interventions: no. using the service
Intervention
Intervention Usual care
n No. (%) n No. (%)
Exercise on prescription 191 11 (6) 194 10 (5)
Alternative therapies 191 21 (11) 194 21 (11)
cCBT and CBT 195 14 (7) 195 23 (12)
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TABLE 55 Use of prescribed antidepressant and other medication by allocation group
Frequency
Intervention Usual care
No. Percentage No. Percentage
Medication: no. of antidepressant prescriptions
0 24 10 19 8
1–5 40 17 39 17
6–10 84 37 94 42
11–15a 56 24 50 22
16+ 25 11 22 10
229 100 224 100
Mean (SD) 8.95 (6.84) 8.71 (5.92)
Median (IQR) 7 (5 to 12) 7 (5 to 12)
Medication: no. of non-antidepressant prescriptions
0 39 17 25 11
1–10 67 29 63 28
11–20 25 11 36 16
21–30 25 11 17 8
31–40 14 6 16 7
41–50 11 5 14 6
51+ 48 21 53 24
229 100 224 100
Mean (SD) 28.4 (36.8) 34.0 (43.3)
Median (IQR) 13 (3 to 41) 19 (4 to 47)
a Represents monthly prescriptions. Fewer than 11 implies either prescriptions of 2 months’ supply or reduction in use.
More than 15 is likely to imply more than one antidepressant being prescribed concurrently.
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Results of hospital resource use are presented in Table 56 using frequency of use for all participants who
provided data. Frequencies, means and median number of encounters are presented, along with SDs and
IQRs, to indicate the level of uncertainty around the point estimates.
Few participants accessed hospital care: 15 (4%) visited A&E, 24 (6%) attended at least one outpatient
clinic and ﬁve (1%) were admitted overnight. The difference in mean number of outpatient appointments
between the two groups is due to three patients in the intervention group having three appointments,
whereas none in the usual-care group had more than two.Personal Social Services
Reported use of social services because of mental health was low, with no evidence of a difference
between the two groups (Table 57).63
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TABLE 56 Hospital care resource use by category and allocation group
Frequency
Intervention Usual care
No. Percentage No. Percentage
A&E visits
0 185 96 184 96
1 4 2 8 4
2 2 1 0 0
3 1 1 0 0
192 100 192 100
Mean (SD) 0.06 (0.33) 0.04 (0.20)
Median (IQR) 0 (0) 0 (0)
Outpatient attendances
0 179 93 183 94
1 8 4 9 5
2 2 1 2 1
3 3 2 0 0
192 100 194 100
Mean (SD) 0.11 (0.46) 0.07 (0.29)
Median (IQR) 0 (0) 0 (0)
Inpatient attendances
0 189 98 190 99
1 1 1 1 1
2 2 1 1 1
192 100 192 100
Mean SD 0.03 (0.22) 0.02 (0.16)
Median (IQR) 0 (0) 0 (0)
TABLE 57 Number of participants using Personal Social Services (PSS), by category and allocation group
Intervention
Intervention Usual care
n No. (%) n No. (%)
PSS: no. using services
Social work 191 3 (2) 195 5 (3)
Home help 192 3 (2) 194 4 (2)
Self-help groups 192 3 (2) 194 4 (2)
Day centre use 192 6 (3) 194 3 (2)
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The amount of time off work by taken participants because of their condition is shown in Table 58.TABLE 58 Number of days off work owing to depression, by allocation group
Frequency
Intervention Usual care
No. Percentage No. Percentage
Time off work: no. of days reported
0 142 78 143 77
1–14 20 11 16 9
15–30 4 2 5 3
31–60 5 3 8 4
61–180 7 4 10 5
181+ 4 2 3 2
182 100 185 100
Mean (SD) 12.0 (44.8) 12.1 (38.4)
Median (IQR) 0 (0) 0 (0)Just under one-quarter (22%) of participants reported having some time off work because of their illness,
and for these the mean number of days off work was 54. Seven participants (2%) reported that they were
unable to work at all during the 12 months. There was no evidence of a difference between the
two groups.Cost analysis
Trial cognitive behavioural therapy
Table 59 details the costing of the intervention CBT. The total cost of 18 sessions was £1400 but allowing
for those who had < 18, the mean cost per participant in the intervention group was £910. The overall
mean cost of one session was £81.TABLE 59 Intervention costs by type of appointment: unit cost and mean cost per participant
Type of appointment No. Unit cost (£) Mean cost (£) per participant (n = 234)
First session: attended 214 113.25 103.57
Follow-up sessions: attended 2416 75.50 779.52
First session: DNA 36 54.75 8.42
Follow-up sessions: DNA 120 36.50 18.72
Overall mean cost of therapy 910.23
DNA, did not attend.
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66Direct costs to the health service provider (the NHS) and Personal Social Services
Mean cost per participant, by category and allocation group, is given for all available data; Table 60 gives
NHS and PSS costs.
The mean cost, per patient, of caring for those in the usual-care group was slightly higher than for the
intervention group, due mainly to more visits to the GP and more non-antidepressant medication.
However, the wide CIs around all the categories of cost reﬂect considerable variation and there is no
conclusive evidence of a meaningful difference between the two groups.TABLE 60 Mean (SD) NHS and PSS cost per participant, by category and allocation group: all available data
Cost category
Intervention Usual care
Difference (95% CI), £n
Mean (SD) cost,
£ n
Mean (SD) cost,
£
GP consultations 229 198.50 (183.85) 224 217.69 (163.87) −19.20 (−51.38 to 12.99)
Nurse consultations 229 19.88 (41.54) 224 19.33 (28.56) 0.55 (−6.04 to 7.15)
Other primary care
consultations
229 7.69 (23.29) 224 10.27 (23.00) −2.59 (−6.86 to 1.69)
Out-of-hours care, walk-in
centres and NHS Direct
188 14.35 (42.44) 184 9.96 (32.22) 4.38 (−3.31 to 12.08)
Other community-based
interventions
188 57.52 (199.43) 183 73.38 (282.60) −15.86 (−65.69 to 33.97)
All primary and
community care services
188 319.92 (354.17) 183 344.67 (366.12) −24.75 (−98.29 to 48.79)
Antidepressant medication 229 51.58 (63.42) 224 69.42 (130.95) −17.84 (−36.78 to 1.09)
Other prescribed
medication
229 304.62 (602.35) 224 351.05 (557.76) −46.42 (−153.67 to 60.83)
All primary care
prescribed medication
229 356.20 (619.49) 224 420.47 (565.99) −64.27 (−173.90 to 45.37)
All primary and
community health care
188 700.28 (830.90) 183 755.04 (707.33) −54.76 (−212.49 to 102.97)
A&E visits 192 8.80 (48.66) 192 7.02 (37.78) 1.78 (−6.96 to 10.52)
Outpatient visits 192 47.38 (296.56) 194 21.96 (113.74) 25.42 (−19.45 to 70.28)
Inpatient stays 192 8.23 (69.09) 192 4.55 (46.86) 3.69 (−8.16 to 15.53)
All hospital costs 192 64.41 (355.01) 192 33.76 (137.09) 30.65 (−23.35 to 84.66)
All NHS services 188 766.07 (967.03) 182 786.32 (718.03) −20.25 (−194.82 to 154.31)
Social worker visits 191 10.04 (82.60) 195 9.83 (65.93) 0.21 (−14.74 to 15.15)
Home help 192 6.24 (80.51) 194 1.10 (15.36) 5.14 (−6.43 to 16.71)
Self-help groups 192 0.47 (4.83) 194 1.01 (12.96) −0.54 (−2.50 to 1.43)
Day centre attendance 192 1.75 (24.25) 194 0.32 (4.52) 1.43 (−2.06 to 4.91)
All PSS 191 18.54 (117.27) 194 12.31 (73.01) 6.23 (−13.32 to 25.77)
All NHS and PSS 188 784.91 (1015.20) 182 799.45 (725.10) −14.54 (−195.41 to 166.32)
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Mean cost per participant, by category and allocation group, is given for all available data; Table 61 gives
personal out-of-pocket expenditure.
Out-of-pocket personal expenses were higher in the usual-care group than in the intervention group
because of greater expenditure on alternative therapies. However, the wide CIs around all the categories
of cost reﬂect considerable variation and there is no conclusive evidence of a meaningful difference
between the two groups.TABLE 61 Mean (SD) personal cost per participant, by category and allocation group: all available data
Cost category
Intervention Usual care
Difference (95% CI), £n
Mean (SD) cost,
£ n
Mean (SD) cost,
£
Travel to intervention 214 12.94 (1.60) – – –
All other travel 190 1.74 (2.64) 195 2.02 (3.19) −0.27 (−0.86 to 0.31)
Cost of non-trial CBT 190 4.50 (40.94) 186 28.81 (215.30) −24.31 (−55.58 to 6.97)
Alternative therapy cost 190 19.46 (116.82) 193 32.32 (150.78) −12.86 (−39.99 to 14.27)
Exercise on prescription 188 8.48 (105.28) 193 20.44 (264.43) −11.95 (−52.70 to 28.79)
Self-help groups 194 0.00 (0.00) 194 0.00 (0.07) 0.00 (−0.01 to 0.00)
Voluntary services 194 0.05 (0.65) 195 0.00 (0.00) 0.05 (−0.04 to 0.14)
Day centres 194 0.05 (0.61) 194 0.00 (0.00) 0.05 (−0.04 to 0.14)
Home help services 192 2.03 (28.15) 192 0.00 (0.00) 2.03 (−1.96 to 6.03)
Cost of prescriptions 221 29.41 (43.51) 220 29.40 (43.58) 0.00 (−8.15 to 8.15)
Over-the-counter
medication costs
193 3.83 (22.36) 192 1.78 (9.98) 2.05 (−1.42 to 5.53)
Loss of earnings 161 693.68 (4823.87) 162 517.46 (2464.35) 176.22 (−661.62 to 1014.05)
All personal costs
(excluding DLA)
141 852.61 (5151.27) 133 516.51 (1952.22) 336.09 (−601.03 to 1273.22)
Amount of DLA received
(negative valuea)
158 −220.24 (985.74) 154 −171.39 (684.54) −48.85 (−238.36 to 140.65)
All personal costs
(including DLA)
111 478.98 (5253.48) 103 422.29 (2331.14) 56.69 (−1053.13 to 1166.51)
DLA, Disability Living Allowance.
a DLA received is effectively a negative personal cost. The amount received can be deducted from the total personal
out-of-pocket expenditure to arrive at a net ﬁgure for personal costs.
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68Lost productivity
Table 62 gives the cost to society of lost productivity due to time off work. This is shown by age for
intervention and control participants separately. Despite marked differences between the groups, by age,
the mean value of time off work (lost productivity) was similar between the two groups and there is no
evidence of a meaningful difference.TABLE 62 Mean (SD) cost of lost productivity due to time off work, by age and allocation group: all available data
Age group (years)
Intervention Usual care
Difference (95% CI), £n
Mean (SD) cost,
£ n
Mean (SD) cost,
£
18–21 3 125 (217) 1 751 (–) −626 (–)
22–29 12 2301 (3595) 9 2069 (4762) 232 (−3577 to 4041)
30–39 21 334 (927) 20 462 (1013) −128 (−7414 to 484)
40–49 49 973 (2519) 50 1673 (4948) −700 (−2271 to 871)
50–59 56 1353 (5302) 54 1182 (3031) 170 (−1470 to 1811)
60+ 41 871 (4138) 51 546 (2663) 325 (−1091 to 1742)
All ages 182 1067 (3887) 185 1102 (3529) −36 (−797 to 726)Cost consequences
The cost–consequences matrix in Table 63 presents disaggregated cost, by perspective and broad category,
along with primary and secondary outcomes. These results are for all available data, by category.TABLE 63 Cost consequences: all available data, by category
Cost category
Intervention Usual care
Difference in mean
cost (95% CI), £n
Mean (SD) cost,
£ n
Mean (SD) cost,
£
Trial CBT 234 910 (467) – – –
Total NHS cost 188 766 (967) 182 786 (718) –20 (–154 to 194)
PSS 191 19 (117) 194 12 (73) 6 (–13 to 26)
Personal expenditure 165 80 (12) 159 127 (35) –47 (–120 to 25)
Out-of-pocket loss of earnings 161 694 (4824) 162 517 (2464) 176 (–662 to 1014)
Lost productivity 182 1067 (3887) 185 1102 (3529) –36 (–797 to 726)
Outcome
Intervention Usual care
OR or adjusted difference
in means (95% CI)N
n or mean
(% or SD) N
n or mean
(% or SD)
Response (50% reduction in BDI-II)a 197 109 (55.3) 198 62 (31.3) 2.89 (2.03 to 4.10)
BDI-II score (mean)a 197 17.0 (14.0) 198 21.7 (12.9) –5.1 (–7.1 to –3.1)
Remission (BDI-II < 10)a 197 78 (39.6) 198 36 (18.2) 2.74 (1.82 to 4.13)
SF-12 mental subscale (mean)a 194 39.1 (14.6) 195 35.4 (12.8) 4.8 (2.7 to 6.9)
SF-12 physical subscale (mean)a 194 44.6 (13.2) 195 41.1 (13.5) –0.7 (–2.1 to 0.8)
QALYs 192 0.62 (0.22) 195 0.56 (0.25) 0.053 (0.019 to 0.087)
a ITT repeated measures analyses of outcomes at 12-month follow-up.
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group improved more than those receiving usual care alone. The mean score at 12 months was 5.1 points
lower for these patients and twice as many in this group recorded a 50% reduction in BDI-II score
compared with those receiving usual care. This clinical difference was reﬂected in the QALY estimates;
patients in the intervention group experienced a better health-related quality of life as measured by QALYs
(0.615 vs. 0.562) giving a gain of 0.053, a value that equates to 19 extra days of good health.
Excluding the cost of the intervention, the mean cost per patient was similar between the two groups from
all three perspectives (NHS and PSS, personal expenditure, lost productivity).Cost–utility analysis
The cost–utility analysis in Table 64 uses imputed data to allow summary cost totals to be calculated. This
analysis is restricted to costs to the NHS and PSS, in line with NICE recommendations.75 Cost is combined
with QALYs to produce an ICER, and the uncertainty around this statistic is indicated by the results of the
bootstrapping and the probability that there is a positive NMB.TABLE 64 Cost–utility analysis: NHS and PSS perspective
Intervention, n = 234:
mean (SD) cost, £
Usual care, n = 235:
mean (SD) cost, £
All primary care 267 (285) 294 (241)
Prescribed medication 352 (614) 418 (558)
Hospital care 64 (323) 38 (128)
PSS 20 (107) 14 (67)
NHS and PSS services 704 (938) 763 (697)
Cost of CBT 910 (467) –
Total cost NHS and PSS perspective 1614 (1100) 763 (697)
QALYs: Mean (SD) 0.608 (0.22) 0.551 (0.24)
Incremental cost (95% CI) £850 (683 to 1017)
Incremental beneﬁt: QALY gain (95% CI) 0.057 (0.015 to 0.099)
ICER: cost per QALY gain £14,911
Median NMB and (probability that NMB > 0):
Willingness to pay (λ) = £20,000 per QALY £289 (0.74)
Willingness to pay (λ) = £30,000 per QALY £859 (0.91)
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70The cost of the intervention (£910) is slightly offset by the higher cost of health and social care in the
usual-care group (£59), giving an incremental cost of £850. Combining this with the estimated QALY gain
of 0.057 gives an ICER of £14,911.
If society is willing to pay £20,000 per QALY, as suggested by NICE,75 the NMB per patient per year is
£289 (95% CI –£603 to £1182) and the probability that the intervention is cost-effective is 0.74 (Figure 5).
These rise to £859 (95% CI –£455 to £2179) and 0.91 at a threshold of £30,000 per QALY.Pr
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FIGURE 5 Cost-effectiveness acceptability curve showing the probability that the intervention is cost-effective at
different levels of willingness-to-pay.
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The results of the four sensitivity analyses are presented in Table 65.
The sensitivity analyses showed that:
1. If therapists were employed at Band 7, the ICER would be lower at £13,006.
2. As hospital costs were similar in the two groups, excluding these made very little difference to the cost
per QALY.
3. Using data from the SF-12 to estimate QALYs, gave slightly higher estimates for both groups than using
the EQ-5D-3L and the difference between them was narrowed, which resulted in a higher ICER of
£29,626.
4. Participants for whom we had complete data on NHS and PSS cost and QALYs at both 6 and 12 months
had more therapy sessions on average than those with missing data (12.8 vs. 11.2). Other costs and
QALYs were similar but the greater cost of therapy (£1020 vs. £910) produced an estimated ICER of
£18,361 for this subset of participants, somewhat higher than the base-case estimate of £14,911.TABLE 65 Sensitivity analyses testing the robustness of results against assumptions of grade of therapist,
importance of hospital use, QALY valuation method and imputation of missing data
Sensitivity analysis Intervention Usual care Difference (95% CI)
Base case Mean and SD cost (£) 1614 (1100) 763 (697) 850 (683 to 1017)
QALYs 0.608 (0.22) 0.551 (0.24) 0.057 (0.015 to 0.099)
ICER (£) 14,911
Median NMB (£) and p
(NMB > 0) at λ = £20,000
289 (0.74)
(1) Grade of therapist Mean and SD cost (£) 1505 (1071) 763 (697) 742 (578 to 905)
ICER (£) 13,006
Median NMB (£) and p
(NMB > 0) at λ = £20,000
391 (0.80)
(2) Excluding hospital costs Mean and SD cost (£) 1550 (1003) 726 (681) 824 (669 to 980)
ICER (£) 14,453
Median NMB (£) and p
(NMB > 0) at λ = £20,000
326 (0.76)
(3) QALYs using the SF-6D Mean and SD QALYs 0.613 (0.09) 0.584 (0.09) 0.029 (0.014 to 0.043)
ICER (£) 29,626
Median NMB (£) and p
(NMB > 0) at λ = £20,000
−274 (0.08)
(4) Complete cases Mean and SD cost (£) 1810 (1119) 799 (725) 1011 (817 to 12,304)
QALYs 0.614 (0.24) 0.559 (0.24) 0.055 (0.202 to 0.090)
ICER (£) 18,361
Median NMB (£) and p
(NMB > 0) at λ = £20,000
82 (0.57)
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DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31Chapter 5 Qualitative ﬁndingsIntroductionQualitative methods are increasingly being used within RCTs to explore the views and experiences of trial
participants. Data gathered can be an essential part of a trial’s evaluation and can highlight possible
reasons for quantitative ﬁndings. As stated in earlier (see Chapter 1, Research objectives), the qualitative
study nested within the CoBalT trial had three main aims: to (1) explore patients’ views and experiences of
CBT; (2) identify patients’ reasons for completing or not completing therapy; and (3) describe what usual
care entails for this patient group. This chapter details the ﬁndings from this study.Methods
Sampling and recruitment to the qualitative study
At the baseline assessment for the trial, patients were informed about the nested qualitative study and
invited to consent to the possibility of being contacted by the qualitative researcher with regards to
participating in a face-to-face interview.
Patients were contacted about taking part in the qualitative study after they had completed their primary
outcome measures for the trial at 6 months post randomisation, in case the experience of being
interviewed affected their views of CBT, of usual care, or of the trial in general.
A purposeful sampling strategy was used to ensure interviews were held with individuals in both arms of
the trial. Conducting interviews with patients in both trial arms would enable us to fully address the aims
of the qualitative study and to illuminate possible reasons for the main trial ﬁnding, i.e. why CBT in
addition to usual care was or was not found to be as effective as usual care alone. Within this sampling
approach we aimed for maximum variation in relation to study centre (Bristol, Exeter, Glasgow),
participants’ age, gender, socioeconomic background, and whether or not their BDI-II score indicated at
least a 50% reduction in depressive symptoms 6 months post randomisation. When sampling participants
from the intervention arm, we also aimed to sample individuals who varied in their levels of treatment
adherence, i.e. those who had or had not completed therapy.
Patients were deﬁned as having completed therapy if they had stopped receiving CBT having reached
an ‘agreed end’ with their therapist, regardless of how many sessions they had received, or had received
the maximum number of sessions permitted within the trial (‘completers’). ‘Non-completers’ were deﬁned
as patients who had never started CBT having been randomised to receive this treatment, had requested
to end treatment or had been discharged by their therapist having cancelled or not attended three
sessions without giving a reason.
We aimed to interview all of those sampled within 2 months of the 6-month follow-up assessment to give
people maximal chance of remembering their experiences of treatment. However, this was not always
possible for some of the completers, as some of these patients were still receiving CBT 2 months after the
6-month follow-up. Thus, a decision was made that for these individuals, we would interview them after
they had completed their 6-month outcome measures and their treatment. Furthermore, because we could
not interview patients before they had completed their primary outcome measures, this meant that for
some of the non-completers, for example patients who had not started CBT or withdrawn from treatment
shortly after being randomised, it was several months between making the decision to withdraw from
treatment and being interviewed.73
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74Two researchers conducted the qualitative interviews (SS, then MB). The researcher made contact with the
patient to discuss the qualitative component of the trial. This contact was usually by telephone and
occasionally by email if the patient had indicated a preference for this form of contact. Having made
contact, the researcher asked the individual if he/she would be willing to take part in an interview about
their views and experiences of depression and any treatments they had received during or prior to
participating in the trial. If the patient agreed to be interviewed, a conﬁrmation letter and information
leaﬂet was then posted to him/her.Interviews and analysis
A topic guide was used to ensure consistency across the interviews. The same guide was used for
completers, non-completers and participants from the usual care arm, with questions tailored to suit
certain areas (Table 66). The guide was developed in light of the aims of the qualitative study, the design
of the trial and relevant literature.
The interviews were conducted on a face-to-face basis and patients could choose to be interviewed at
home or in their own GP surgery. Each interview was audiotaped and fully transcribed. Data collection and
analysis proceeded in parallel. Recruitment ended when data saturation had been reached.
The interviews were analysed thematically, as this allowed comparisons to be made within and across the
interviews, and for the views expressed in relation to a particular issue to be highlighted, for example
patients’ experiences of CBT. This analytical approach entailed individual members of the research team
(KT, SS, MB and AOS) reading and re-reading transcripts in order to gain an overall understanding of
the participants’ views and experiences, and to identify emerging themes. A coding frame was then
developed, based on the themes identiﬁed, and the same members of the research team independently
coded transcripts and then met to discuss areas of consensus and discrepancy. This led to further codes
being developed and to existing codes being deﬁned more clearly. Transcripts were then imported into the
software package ATLAS.ti to allow electronic coding and retrieval of data. Once all the transcripts had
been coded, data were systematically analysed using a framework approach.90 Using this method, what
participants had said in relation to speciﬁc issues were summarised in tables and comparisons then made
across and within the interviews to identify thematic patterns and deviant cases, and to determine if, for
example, there appeared to be any differences between the views expressed by men and women or
individuals of different ages.TABLE 66 Key topic areas explored during interviews with participants from the intervention and usual-care arms
Type of interview Topic area
Usual care Health prior to starting CoBalT
Current health and health status
Experiences of depression
Experiences of any treatment/support for depression before study
Views and use of antidepressants
Views of CBT
Any other care received during study
Views on CBT plus antidepressant medication
Intervention arm (completer and non-completer) As above, plus:
l views and experiences of CBT including expectations
l views and experiences of therapist
l reasons for completing or not completing CBT
l overall views of CBT including ongoing beneﬁt
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DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31ResultsForty interviews were conducted in total between April 2010 and February 2011 (Table 67). Nineteen were
held in Bristol, 10 in Exeter and 11 in Glasgow. The ﬁrst seven interviews were conducted by SS. The
remainder were undertaken by MB. The interviews lasted between 24 minutes and 1 hour 43 minutes, the
average being around 1 hour. Half of the interviews took place in patients’ homes and half in their local
GP surgeries. The average (median) time from end of therapy to the qualitative interview was 96 days, and
for those interviewed who did not complete therapy it was 168 days.
Bristol patients were slightly over-represented in the non-completers (six of the nine non-completers
interviewed were Bristol patients). This group was particularly difﬁcult to recruit and would often cancel
appointments. Thus, for pragmatic reasons, non-completers tended to be recruited from the interviewer’s
home city.TABLE 67 Sociodemographic characteristics of the patients interviewed (based on data collected at baseline)
Characteristic
Intervention
(completers),
n = 17
Intervention
(non-completers),
n = 9
Usual care,
n = 14
Total,
n = 40
Centre Bristol 7 6 6 19
Exeter 5 1 4 10
Glasgow 5 2 4 11
Age at baseline (years) 20–36 2 2 3 7
37–52 10 3 7 20
53–67 5 3 4 12
Sex Women 11 5 10 26
Men 6 4 4 14
Highest educational
qualiﬁcation
None 2 0 4 6
GCSE 5 4 2 11
A-level/Higher
Grade
6 4 5 16
Degree 4 0 3 7
Employment Student 0 1 0 1
Housewife 1 0 3 4
Ill health 2 2 3 7
Jobseeker 2 0 0 2
Part time 5 2 4 11
Full time 4 3 2 9
Retired 3 1 2 6
Housing Homeowner 14 6 8 28
Tenant 2 3 5 10
Living with
relative
1 0 1 2
No. of sessions of CBT
attended (median)
14 2 – –
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76All of the patients interviewed were white British. More women than men agreed to be interviewed and
over half of the participants had an A-level/Scottish Higher or university degree, and owned their own
home. Many of the interviewees had other health problems, such as multiple sclerosis, emphysema,
ankylosing spondylitis, diabetes or osteoporosis. Some of these conditions disabled the individuals and/or
resulted in physical pain.
Within this chapter, ﬁndings have been presented within three main sections that reﬂect the aims of the
research: patients’ views and experiences of CBT (including the impact of therapy on their symptoms);
reasons for completing and not completing therapy; and what usual care entailed for this patient group.
All quotes reproduced have been tagged according to whether the patient was a completer,
non-completer or in the usual care arm, and according to the patient’s gender, age and study site.
Quotes from individuals in the intervention arm have also been tagged with information on whether their
symptoms had improved by 50% (+) or not (–) between baseline and the 6 month outcome assessment,
according to the BDI-II.Patients’ views and experiences of cognitive behavioural therapy
Few patients talked about having any previous knowledge or experience of CBT prior to their involvement
with CoBalT, and in terms of expectations, most patients said they did not expect to be ‘cured’. The
majority of patients interviewed who had received CBT during the trial, having been allocated to the trial’s
intervention arm, stated that they had found CBT beneﬁcial, particularly in terms of learning techniques to
help them manage their symptoms. This included individuals who described how they had struggled with
CBT, and both completers and non-completers.
On analysing the data, it was apparent that patients’ views and experiences of the CBT related to the
therapy sessions they had received, the homework that they had been asked to complete between
sessions and the impact of CBT. When talking about the therapy sessions, patients detailed their
experiences ‘in session’ and their relationship with their therapist.Therapy sessions
Cognitive behavioural therapy in sessions
For many patients, the initial sessions could make them feel uncomfortable because the session’s content
and format were outside their previous experience and they were not sure how to respond to the therapy/
therapist. However, in most cases patients described working through this preliminary discomfort to
gaining from the sessions:NIHR[I felt] panic at the first one because I’d never been in this situation before and it was outside of my
comfort zone. [After that] It was great because I actually looked forward to them . . . They just want
to talk to you about how you’re feeling about things and how it affects you and all this. And you
could open up to [therapist’s name] and it was good.
Completer, male, 65 years, Glasgow +Some patients described how they felt that CBT did not address the cause of their depression; they talked
about feeling that there was not enough exploration of their early lives and the root of their problems or
about getting enough insight into why they felt the way they did:I would maybe have liked to talk, have talked about my earlier life a wee bit more because I feel a lot
of the foundations of this all kind of started back then.
Completer, female, 39 years, Glasgow –Journals Library www.journalslibrary.nihr.ac.uk
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something fundamental to the model of CBT itself:© Que
This is
suitab
Journa
SO16So CBT . . . I think it touches the surface without going in too deep . . . I do think it would be nice just
to go a little bit further to understand a bit more.
Completer, female, 37 years, Exeter –This desire for more understanding about their depression than CBT provided was expressed mainly
among interviewed patients who were educated to A-level and above and who were in their late thirties
and forties.
Other comments made about CBT indicated how an individual’s comorbidity could complicate the
therapeutic process. Despite the fact that therapists are trained to work with patients who experience
chronic physical pain, it was apparent that such patients could struggle to see how CBT could help
them personally:The only thing that really gets me low is when it’s hurting, the MS is hurting a lot and I found it
difficult to often put the model on to dealing with pain, really . . . I did find it difficult just to apply the
logic to something which is not an emotional thing, it’s a physical thing. I think that’s probably why I
don’t think I was really a 100% right for the study . . . with pain, it doesn’t matter which way you
look at it, it’s still the same.
Completer, male, 46 years, Bristol +For other patients, the learning and insights gained as part of the therapy process could be distressing.
CBT was often described as painful owing to discovering aspects of themselves or revisiting difﬁcult
periods of their lives, for example realising that one has social anxiety:I learned things about myself that I never knew and social anxiety came up. I always just thought I
was antisocial, a loner, but when I read about it and everything and it exactly fit me and some of it
was really upsetting . . .
Completer, female, 43 years, Bristol –Although patients may have felt challenged by the ‘discovery’ element of therapy – and would consider
halting therapy because of it – they would often talk about the insights and beneﬁts to be gained from
going through this process:I’ve found it quite painful at times because you sort of go back to your childhood almost and err yeah
it was, it was quite difficult. And first of all when I started I didn’t think I would carry on with it but
I persevered and um I think it has done me good actually.
Completer, female, 64 years, Bristol –Each week, during therapy, patients were asked to complete a short questionnaire (BDI-II) to measure their
depressive symptoms. Some patients talked about using the BDI-II score to measure their progress or as a
starting point for discussion within the therapy session. BDI-II scores were also talked about as a way of
calibrating their experience of depression, for example as evidence that their depression was improving,
even if the patient felt the same.77
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78Views and experiences of the therapist
Patients described their therapist’s personal qualities, role and skills, the therapist–patient relationship, and
how these impacted on their experience of treatment.
Most patients described their therapist as calm, friendly, trustworthy and caring, all of which encouraged
patients to feel comfortable and talk freely during the therapy sessions:NIHR. . . it probably matters a great deal that you get on with your therapist and I suspect that, it’s like
most talking therapies, if you don’t get on with your therapist you’re buggered . . . I think [it’s]
something about somebody making you feel safe to discuss these things but you know it’s not a
friend, it’s a therapist. You are safe to cry and you don’t feel that you can’t come in next week.
Completer, female, 57 years, Exeter +Most patients considered the role of their therapist was to aid them in coping with and managing their
symptoms of depression through giving them ‘tools’ to change their thinking, particularly in separating
their thoughts from their emotions:[The therapist] would draw diagrams and say ‘so OK this happened and then from there what were
your thoughts? From there what did you then feel? From there what were you then thinking?’ and
then you can see how it turns up a circle and then you can discuss how you stop it from becoming a
circle . . . what could you counter that thought with?
Completer, female, 41 years, Exeter +The therapist skills that were identiﬁed and appreciated were largely to do with getting patients to talk
and non-judgemental listening. These skills were appreciated by all patients regardless of gender, age
and education:I can’t praise her enough, she was helpful, I suppose she just seemed to see all the things. Like the
time when I wanted to storm off sort of thing, I think a month before she would have changed the
subject but she almost knew to push and perhaps she could see that I needed it out.
Completer, male, 49 years, Exeter +[Her role] was for me to sound off to . . . and she done it very nicely. She was very very pleasant and
it was just . . . I’ve never thought about this before but it was just that it was pleasant to have
someone like that to sit and talk to you know? Because it’s never happened to me before.
Completer, male, 65 years, Glasgow +The therapists’ ability to steer and guide patients through the structure and agenda of the session was also
appreciated, although not necessarily at the time:The therapist was very good at making sure we stuck to an agenda . . . skilled in leading me in
the right direction, skilled at picking out things from what I was saying and bringing about
more discussion.
Completer, female, 41 years, Exeter +If the therapist felt that I needed to go back over something then she wouldn’t lose that, she would
make me do it next time, much to my begrudgement.
Completer, female, 46 years, Exeter +Other skills mentioned were the therapists’ valued knowledge and advice, which enabled patients to gain
insight into their thought processes. Patients, particularly women, also talked about how they had gained
in self-conﬁdence having worked with their therapist.Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31Most patients had a ‘good’ relationship with their therapist and could not praise them enough. An
important aspect of this relationship was the feeling it was ‘genuine’, that the therapist cared, was
trustworthy and collaborative:© Que
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SO16After a wee while it was fine. Um, because I genuinely felt that [the therapist] wanted to help.
Non-completer, male, 44 years, Glasgow +I would always leave there feeling fantastic, like really excited because of the discoveries we had
made and it really did feel like ‘we’ . . . you sort of uncover them together.
Completer, female, 41 years, Exeter +Some female patients also described the relationship they had with their therapist as similar to a
teacher–pupil relationship. It was these patients who were most likely to speak about how committed they
were to CBT and how fulﬁlling they had found the process:[The therapist] was almost like my teacher [laughs] but not in a bad way or anything . . . was there for
me to talk to and to tell me – not how stupid I was being, but to help me to get my head around
what I was thinking.
Completer, female, 42 years, Glasgow +[The therapist] was quite formal but I quite liked that because it was almost like the teacher and pupil
and we never got pally and so everything was my decision . . . suddenly I had to do everything for
myself, not ask somebody else to lean on, so I found that really really helpful.
Completer, female, 59 years, Bristol +Conversely one non-completer actively refuted the teacher role while going on to describe the therapist
role in similar terms to the above women:[The therapist was] a sounding board, sometimes just giving you ideas really. You know . . . it’s not a
teaching one it is literally just kind of wiser or giving a number of options and letting you choose
which one is more personally appropriate.
Non-completer, male, 50 years, Bristol –Although most patients detailed how they had felt comfortable with their therapist, some patients talked
about feeling uncomfortable with their therapist and/or under pressure to come up with the ‘right’
answer. The feeling that they were being guided to answer did not, in these cases, feel like a positive
aspect of the therapy relationship and is similar to patients’ feelings that the therapy itself was too
inﬂexible for their needs:I felt a little bit like I was having to run through the maze and . . . take the lefts and rights when I was
told to . . . it was easier because I didn’t have to make the decisions so much but you did feel you
kept being nudged back on the path . . . the therapist I had basically didn’t really want to know about
my MS at all, really. But that was the reason for the depression, and yet . . . I felt like I had to try and
disregard that . . . and felt a little bit like I was a square peg trying to be pushed into a round hole
[laughs]. I felt a little bit uncomfortable with the fact that . . . [the therapist] was trying to push, put
another reason behind why I was having the depression.
Completer, male, 46 years, Bristol +79
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80In addition, a couple of patients commented on the age or perceived experience of their therapist in
comparison to their own knowledge and experience, having lived with depression for years. This might
also have been a barrier in the therapeutic process:NIHRShe was quite young. So I suppose I wouldn’t have thought, well, you know, not saying that she’s not
knowledgeable of it or anything but, I was more, in some respects, I was more knowledgeable really
because I’ve dealt with it [depression] for so many years . . . I’ve done a lot of research on it . . . and
I’ve done a lot of different things. I think if I’d seen, I don’t know, someone who was like, 40 . . . you
know, I might have thought, well you know, you may have been doing this for quite a few years now.
Non-completer, female, 28 years, Bristol +Overall, non-completers talked less about their relationship with their therapist than completers. This could
be an artefact of having had less therapy, although three of the non-completers had attended eight or
more sessions and their therapist had not featured heavily in their accounts. These patients may have felt
less engaged with their therapist – thus dropping out of therapy early – alternatively their individual coping
mechanism may have been one of avoidance of difﬁcult situations or ‘facing up’ to problems.Cognitive behavioural therapy homework
Patients described homework as the most challenging aspect of CBT, in particular the thought and activity
diaries. The accounts given indicated that individuals had struggled with homework tasks for both
emotional and practical reasons.
Emotional reasons given by patients for why they struggled with homework were often linked to fear of
failure, which they, in turn, associated with their school homework experiences and being judged for what
they had or had not done. This lack of conﬁdence in patients was also manifested in the concern about
‘not doing it [homework] right’:Homework never liked it anyway, never liked homework at all but forcing yourself at the start to start
writing these down and writing out how you feel. It’s a very difficult thing to write out how you feel
it’s difficult to put it into words and you don’t feel you’re doing it right and for me if I don’t feel I’m
doing something right then that’s it! So you know it was a double edged sword I couldn’t write it
down and then I thought, ‘Och well you can’t write it down because you’re rotten at it anyway’.
Completer, female, 39 years, Glasgow –Doing homework could also be distressing because it required having to think either about the causes of
their depression and/or situations that could not be changed:Erm [long pause] I think the majority of the time I didn’t particularly want to do it. I didn’t want to
dwell on it because well obviously thinking about situations and that you’re dwelling on perhaps
certain things you, you can’t deal with . . . that seemed depressing having to think about the
depression [yeah] and think of things that perhaps I would normally block out.
Completer, male, 42 years, Bristol –Homework could be a painful process if it conﬂicted with individual coping mechanisms of denial. A
couple of patients even referred to making things up to complete their thought diaries because they felt
they did not have anything to put in it and/or they did not want to have to think about the cause of
their depression.Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31In terms of practical difﬁculties, some patients felt their depression did not lend itself to separating out
thoughts and feelings and then writing them down. One patient detailed how he felt the CBT homework
model was too structured for his depression:© Que
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SO16I would think ‘oh I’ve got to record something every five minutes, I’ve got to record and make a note
of everything’ and it’s just my gosh! What a tall order, because she wants to analyse it, why isn’t it
saying enough? I started to get frustrated because I am not being listened to . . . because the
homework was set at these, I had times to write something down or whatever and I was looking at it
thinking, well 6 hours I don’t feel nothing, 12 hours I didn’t think nothing, oh and then I have
3 hours of all this and I’ve got to try and cram in. And I thought… do they think that your depression
is a structured, standard thing that can comply and can conform into their models? Cos it isn’t, not
for me it isn’t anyway.
Non-completer, male, 34 years, Bristol +Some patients spoke about writing at work or at home as a public act and one, therefore, which came
with the risk of getting ‘caught’. The riskiness of the endeavour was related to stigma associated with
depression, or with the risk of family members reading their private thoughts:I did struggle first of all you know.. um trying to get my mind into the frame that putting something
on paper about how I felt and all that sort of thing you know. I used to say ‘I don’t want anyone to
see this and you know I’d hate my family to see what I’ve written down’. I did cope with it in the end
but I found it difficult at first.
Completer, female, 64 years, Bristol –To address the practicalities (and risk) of writing during work time, patients would often report leaving
their homework until the end of the day. However, this delay brought its own set of problems in not being
able to remember or re-live thoughts and emotions from earlier. Sometimes, simply ﬁnding the time at all
was the most difﬁcult part of completing homework. Lack of time could threaten completing the course:The only problem I found was trying to commit the time to doing them [homework sheets]. That was
the difficult bit . . . at one stage I did have a discussion with the therapist to say ‘look I don’t feel I’m
committing enough time to the homework tasks, you know I want to commit more time but I just
cannot find more time.. I might drop out of the study’.
Completer, female, 43 years, Bristol +Accounts of time/practical pressures could also contain emotional reasons for not doing homework:I was finding because of the pressures of work and the pressures of everything and the fact that I
wasn’t coping, I couldn’t even go sometimes to work and so the homework became an issue for me.
And trying to give it the level of time - it fell apart after about five or six weeks. We kind of reviewed
it and you know there were times when I said ‘look I haven’t done it’ and there were times where I
was trying to do it and so even the fact of not doing it became an issue for me as well.. And part of
my problems are my avoidance issues.
Non-completer, male, 50 years, Bristol –Motivation was also a factor for some in committing to the homework, when a lack of motivation was a
large part of their depressive symptoms. This could be interpreted as an emotional, as well as a practical
reason for ﬁnding homework difﬁcult:It was just having the motivation really, that’s something that I was really struggling with at that time
and have done in my life struggled with motivation, especially in periods of bad depression and the
worse the depression is at any time, it sort of can be measurable by my motivation.
Non-completer, male, 34 years, Bristol +81
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82Overall, reports of practical or avoidance issues with the homework tended to be given by male rather
than female patients interviewed.
Whilst most patients found the homework difﬁcult, there was a group who associated it (and its
associated difﬁculties) directly with the level of beneﬁt gained through CBT. The only patients who spoke
about homework in this positive way were completers and all bar one were women whose BDI-II scores
had improved by more than 50%. Direct gains were described from actually ‘seeing’ patterns of thoughts,
emotions and behaviours written down:NIHRJust having the actual writing and seeing it. So it’s a visual thing. I mean you can think as much as
you like about your routine and how you’re going wrong with it and how it’s damaging you but until
you see it on paper, that’s almost a slap in the face . . . which is good for me.
Completer, female, 46 years, Exeter +I found it was really good and I actually, you know if only I’d been as good as that at school, but I
kind of liked it all written down . . . and it all became so much clearer to me.
Completer, female, 36 years, Glasgow +Patients talked about homework making them engage with the process and work between sessions; the
effort invested was equal to the improvement felt:I did struggle with the homework definitely and I often felt gosh if there hadn’t been any homework
you could become very lazy and just keep expecting your therapist to keep bringing something up to
talk about or not think at all about anything during the week . . . I guess homework is one of the
ways of helping you to continue with things learned in the sessions and at the end of the day of you
want to improve how you’re feeling, it’s not going to just happen without any hard work or effort.
Completer, female, 41 years, Exeter +Patients’ views and experiences of CBT also included accounts of the impact of therapy on their condition.Impact of cognitive behavioural therapy: fewer bad days
The majority of patients interviewed, who had received CBT during the trial, said they would recommend
CBT to others. In addition, even those who did not complete a full course of CBT felt that they had
beneﬁted from receiving this treatment:It’s [CBT] made me more aware of the fact that it’s just feeling an emotion really. It doesn’t really
govern your life. And it’s given me the tools to recognise when I’m becoming more depressed . . . and
to try to implement things to change that.
Non-completer, male, 44 years, Glasgow +Random negative thoughts in depressed people tend to be turned up like a volume so that’s
something that I’ll always have. And when I started thinking about that and became conscious and
aware of it, I was able myself to turn them [negative thoughts] down and think of a positive
alternative which is a skill I’m supposed to have been taught.
Non-completer, male, 34 years, Bristol –When talking more speciﬁcally in terms of what they had gained from having CBT, patients talked about
learned techniques and tools, a changed understanding of self and behaviours, better communication with
their family, and the trigger to healthy lifestyle changes.Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31Patients most commonly praised the techniques or tools they had learned in CBT that had helped them to
manage their depression. Patients especially valued the skill of questioning their negative thoughts to
change their behaviour:© Que
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SO16It just made me look at the way I look at myself, and other people look at me and it’s just made me
feel more positive and question things that I do. ‘Why are you doing that cause if you do X and Y,
then Z will happen and you’ll feel miserable’. Whereas if you do something else it could be A, B and
C that happen and you feel totally more positive.
Completer, female, 44 years, Bristol +Patients often talked about gaining a better understanding of themselves and how this had helped them
manage their condition. Understanding was usually couched in terms of what had been learned through
CBT and how this translated into their thinking and behaving differently:[The therapist] talked me through why did I feel bad about asking for help and it wasn’t a sign of
failure – because I always thought that if I asked for help it was a sign of failure . . . I don’t do those
things anymore. I don’t feel bad asking for help and I do get the kids to help and I don’t feel it’s a
failure to ask for help now.
Completer, female, 42 years, Glasgow +Patients also described the gains to be made from learning how to manage their situation. Making small
changes to their usual routine could have very beneﬁcial effects, for example putting tasks to one side
until one is having a ‘better’ day or changing a routine chore:It’s dealing with problems, I have learnt now to sort of say, bad letter comes in or something, ‘look I
don’t feel right today, let’s deal with it tomorrow’. I have learnt to do that, whereas before I would do
it and just get more and more frustrated and lashing out verbally sort of thing. So I have learnt to do
that, because before I have always been, what’s the point of putting things off, I have always,
whatever has needed doing I have done it straight off.
Completer, male, 49 years, Exeter +My routine was actually causing me to be depressed as well. I’d actually got myself in this rut, almost
like self-harming that is difficult to get out of and you know is not good for you. And then we
changed the routine, even if it was something simple like changing your shopping day . . . we started
off very small.
Completer, female, 46 years, Exeter +Some patients felt that CBT had been effective in teaching them better communication techniques and
that this had produced a positive effect on family life in particular:The daughter and I, as the wife says, are two of a kind. You know? We argue like buggery. We used
to . . . now . . . I say ‘right, okay’ and walk away, and then come back maybe and say, ‘well, if we do
it this way and do it that way, I’ll do it your way’ and that’ll get things done. Before, I would have
stood there arguing with her about it. Now, I’ll just say, ‘ah well, fair enough, right’. And walk away.
Completer, male, 65 years, Glasgow+83
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84Cognitive behavioural therapy could also encourage or act as a trigger to wider, healthy lifestyle changes:NIHRI don’t feel cured, I feel that I’ve got some pieces of equipment in my head and my gut that I can use
and have to remind myself to use sometimes . . . I’ve done a bit better at saying ‘no’ if I don’t want to
do something without feeling that means I’ll never be invited again. I’m better at making myself
achieve something in the day however little, even bad days when walking hurts, I know I’ll feel better
at the end if I achieve something. l walk the dog more and I’ve lost about a stone and a half. It
actually gave me the kick up the bum to do something cos I’d got into a rut and when you get into a
rut or a deep hole it’s very hard to get yourself out of it, so it give me the incentive to do some things
I’d talked about.
Non-completer, female, 57 years, Exeter –However, some patients talked about ﬁnding it difﬁcult to put what they had learned from the CBT into
action, and these tended to be male patients whose symptoms had not generally improved:I don’t think it’s [CBT] ever been unhelpful but sometimes difficult to actually put into practice. I mean
if you’ve got a depressive thought that may block out thoughts of ‘Oh CBT, I must use that’. So you
may not automatically think of the thought cycle you should be using to help you.
Completer, male, 42 years, Bristol –It was also possible for patients to put in the hard work and not feel better or have met the criteria for
‘response’ based on their BDI-II score:I worked pretty hard, I got the books, I did everything that I could and I did really find a benefit from
it yes at the time. I can’t say I enjoyed it because you wouldn’t enjoy it really would you? It did make
me feel a lot better and at the time I was really optimistic that I was going to get a lot better and I
suppose that was why it was quite bad afterwards to be quite ill again.
Completer, female, 43 years, Bristol –Both completers and non-completers described having ‘less bad days’ and ‘more good days’ than before
their involvement in CoBalT, owing to the therapy. Patients also talked about their symptoms being
less intense:My bad days aren’t half as bad as what they were.
Completer, female, 46 years, Exeter +Overall, patients gave a very rational and careful account of their current symptoms following CBT. No-one
claimed to be cured or that they would not get depressed again. They hoped that they now had the
techniques to cope with and better manage their symptoms:Well I am coping with things better. I can’t say it’s going to be like that next week, but you know I
said this money thing was quite a big issue and I am not saying it did not annoy and frustrate me and
make me depressed again, because it did. But I got over it or I dealt with it so much better than I
would have 4 months ago.
Completer, male, 49 years, Exeter +I feel at times slightly better, though I have to say there is times when you feel . . . oh, God I wish I’d
never got up this morning you know? But it doesnae seem to last as long as it did before.
Completer, male, 65 years, Glasgow +Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31For those that felt they still had more bad days than good – most of whom had symptoms which had not
improved by 50% on the BDI-II – the barriers to alleviation of their symptoms tended to be related to a
comorbidity and/or to a feeling of hopelessness:© Que
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SO16Sometimes it like you don’t notice it [the depression]. You think you’re alright, going on quite happily
. . . But things do run through your head sometimes you know, with this health thing, and I think to
myself ‘what’s the point in being here? Can’t do anything. Can’t hold a pen for more than 5 minutes
because of my hand . . . I drop things and then I start thinking stupid things, although I wouldn’t do
it. But I do start thinking about it. Couldn’t do it to my son to be honest. Tried it before and I don’t
want him to think his mother killed herself you know.
Non-completer, female, 57 years, Bristol –Sometimes I get these waves of hopelessness. You know like I feel I have just got no future
sometimes. That is what I feel like all the time, I feel like there is no point to me basically. I feel like it
all the time really but when I am really depressed it is a lot worse.
Completer, female, 43 years, Bristol –There was little cause for optimism among this group of patients when thinking about their future health:I don’t see an end to it. I don’t see anything that is actually going to turn a light on and I
will be different.
Non-completer, male, 50 years, Bristol –Those patients who had completed CBT and felt positive about the experience were, unsurprisingly,
positive about the future and their condition. Patients would often marry the hope of continued lessening
of symptoms with being able to reduce or stop their antidepressant medication:Well, I’m hoping that I can keep up using CBT myself to the extent that I can at least reduce the
antidepressants – I mean at the moment my goal would be how to reduce or stop them for the
summer and winter with minimum pills and to keep using CBT.
Completer, female, 57 years, Exeter +I’m hoping that I’ll be able to cut down on antidepressants . . . whether it’ll be in 6 months I don’t
know but (laughs) the plan ahead is that. And just to keep going the way I am and keep questioning
everything that I think and do and say and not be too hard on myself. It’s as simple as that (laughs).
Completer, female, 42 years, Glasgow +Many of the elements of the impact of CBT described by patients are summarised in the following quote
from a Glasgow patient who, despite her BDI-II score not improving by at least 50%, had committed to
CBT and felt it had changed her life:Well I’m not saying that there’s not going to be times where I maybe fall off the wagon and end up
depressed or low again, but it won’t be for the want of trying to keep myself on an even keel. Now
that I know there are ways to avoid that. So I’m hoping it’s just going to go from strength to strength
and given that it is the end of November and I’m usually in the pits of depression at this time of the
year I am really feeling quite good about everything. I know it’s not just medication I know it’s
because I’m feeling better about myself as a person as well.
Completer, female, 39 years, Glasgow –85
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86Reasons for completing and not completing therapy
Patients tended to give more than one reason for completing or not completing their course of CBT. These
reasons were often interwoven with their accounts of their views and experiences of CBT. Overall, patients
talked about whether or not they were able to ﬁt CBT into their existing life in terms of practicalities and
other commitments. For completers this was a relatively easy process. For non-completers, CBT could prove
difﬁcult owing to work factors and associated stigma, caring responsibilities, emotional responses to the
process or the complications of their own ill health. These ﬁndings are discussed further below.Reasons for completing therapy
For the majority of patients who completed their CBT course, the practicalities involved with attending
sessions were largely unproblematic. The workplace was described as being ‘good’ and ‘ﬂexible’ and/or
the location and timing of the appointment was acceptable:NIHRMy work’s really good. Any time I’ve ever had . . . they just gave me the day off or somebody would
swap shifts with me or whatever.
Completer, female, 36 years, Glasgow +It was just at my local surgery, which I still attend, so I felt it was home from home almost . . .
Completer, female, 59 years, Bristol +For others, not working owing to retirement, ill health or job-seeking meant that attending therapy was
quite straightforward:I didn’t have a lot going on my life at the time except parents . . . so that was OK.
Completer, female, 57 years, Exeter +When work proved less ﬂexible for one patient, leading her to almost dropping out of therapy, it was the
therapist who was accommodating:I went through a tricky phase where I couldn’t make the appointments at a certain time because of
work and things but the therapist was really good and changed, changed the times and we managed
to get through it cause at one stage I was really close to just dropping out of the study because
everything was just getting too much just to get there but we worked through that and got out the
other side.
Completer, female, 43 years, Bristol+The location of sessions could be regarded as tricky by some patients owing to their condition (e.g.
agoraphobia alongside depression) or when therapy sessions took place at a location other than the
patient’s own GP surgery. For most of these patients it was a surmountable obstacle, either by being able
to change location or making the journey part of their exercise regime:[the] hospital was where I was asked to go originally and at that time, the way I felt, navigating two
or three buses – I just couldn’t have done it. It just wasn’t feasible. Whereas the routine of coming
down here [GP surgery] it’s fine for me.
Completer, female, 39 years, Glasgow –For the completers, ending therapy was broadly described as a decision taken between themselves and
their therapist at a point where they deﬁned themselves as being ready to end therapy, feeling better or
feeling that there was no more to be gained from continuing therapy. Patients went on to describe the
ending as being suggested by the therapist and agreed by themselves.Journals Library www.journalslibrary.nihr.ac.uk
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the maximum number of sessions allowed in the trial. Some patients described their anxiety about
stopping CBT:© Que
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SO16I was quite looking forward to it really [ending] and it is mixed feelings. You are apprehensive because
there is someone there for you every week, someone who listens to you and goes through things
with you and I knew I was going to really miss that. But then it is quite nice not to have to do it
you know.
Completer, female, 43 years, Bristol –Anxieties about ending therapy could be alleviated by feeling there were processes in place to support the
patient after sessions had ﬁnished:I did panic at [the end of therapy] because in a way the therapist is like that crutch when you are
offered it. But we discussed that because she said. ‘you know this will come to an end and we need
to look at how you are going to carry on and cope and have little things in place.’
Completer, female, 59 years, Bristol +For some patients their change in BDI-II score recorded in therapy sessions was considered as part of the
decision to end CBT as it was tangible evidence of their progress:Well I suppose the scores you know I was up in the 20s a few times and then I was like 5 or 6 so I
think it was the scores I probably outtalked myself I suppose . . . we could both see progress there
and it was a good cutting off point.
Completer, male, 49 years, Exeter +For one man, the stress involved in attending sessions outweighed any beneﬁts:I started toward the end thinking, I don’t really want to do any more of these sessions. I’m starting to
get stressed about going to them [laughs]. The last three sessions I didn’t really feel I was gaining a
lot more because I’d taken time off work and I didn’t feel I was getting enough benefit against what I
was having to [put in].
Completer, male, 46 years, Bristol+Reasons for not completing therapy
Explicit reasons given by participants for not completing therapy grouped around the themes of work
issues and stigma, practical reasons (such as other commitments), feeling CBT was not for them,
and ill health.
It was apparent that some of the non-completers had found it hard to commit to CBT because they felt
they needed to prioritise other commitments in their lives, such as work or caring for others, over
completing therapy. If they worked, the possible censure of work colleagues could also inﬂuence patients’
ability to commit to CBT. For those in employment, the perceived cost–beneﬁt of attending sessions
compared with attending work could lead to early dropout from CBT. For some, the threat of work
colleagues ﬁnding out about their depression, linked with the imagined moral judgement about taking
time off work, became an insurmountable obstacle to ﬁnishing the course of therapy:You know I was skint, I hadn’t had work for a whole year I think and I’d started working. And it just
became more and more difficult, you know, I could do a few Fridays, a few Tuesdays but then after
that it was just like ‘Oh bloody hell he’s off again on Tuesday ‘. . . It conveys the wrong message.
People think ‘Oh where’s he going? Is he still signing on?’ So I tried to schedule them [appointments]
so as I could keep seeing her for as long as I could and then it just got to a point where it was like,
‘No I don’t’ think I can make it any more’.
Non-completer, male, 44 years, Glasgow +87
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88As indicated in the above quote, ﬁnancial priorities were also taken into account when weighing up the
costs and beneﬁts of continuing therapy.
The fear of being potentially judged by work colleagues was a theme more common in the accounts given
by male than female patients. Similarly, a female patient did not want her work colleagues to know about
her appointments as the workplace was very ‘male’ and she feared would consequently be less
understanding of mental, as opposed to physical, health problems:NIHR[The therapist] that I was seeing, had to change to a Wednesday which would have meant having to
leave work early and I really didn’t want to do that . . . especially where I work as well it’s very male
orientated . . . I don’t think it would have gone well as I didn’t really want to go into my business with
them anyway about that. And also I don’t think they would have been so understanding about
something like that you know . . . and I didn’t really want anyone saying ‘oh why’s [interviewee’s
name] leaving early?’ And you know, the office thing.
Non-completer, female, 47 years, Exeter –One patient who was randomised to CBT felt unable to start therapy due to work commitments, and it
was apparent that several participants who were parents or carers had not started or completed therapy
because they had prioritised their caring duties over their own health needs:I was to go ahead with it [therapy] but then because my husband’s health had deteriorated . . . I just
felt that to focus on both things and trying to take part in that when a lot of my time was spent
going back – some weeks we were at the hospital every single day you know for six and seven weeks
at a time . . . I just prioritised and at that point in time his health was more important to me.
Non-completer, female, 53 years, Glasgow –One patient who attended only three sessions, being reminded of distressing events was a reason to stop
CBT. For another patient, her emotional response to the homework diaries, with its intimations of school
(‘I rebelled’) was a large part of her reasoning for not continuing with CBT:I had to fill in this . . . these papers about how I felt every day and I didn’t want to do it. I think that
was what put me off as well, filling in these things every day of how I felt . . . I looked at it and I
thought, ‘How can you do that?’ And yet I’m not stupid, but I just felt like I was . . . I kind of rebelled.
I didn’t want to do it.
Non-completer, female, 57 years, Bristol –Ill-health could also be a barrier to completion of CBT, for example a woman spoke about her mental
health as getting worse during the time of the study and of taking an overdose:I was very disappointed actually that I had to come out of the CBT bit of this study and that was due
to my ill health and things that I did feel that the therapist I was actually working with, I think she
[the therapist] probably would have ended up breaking the cycle [of my condition], I think just
because of the questions that she’d actually asked. So therefore you know I did feel disappointed that
I had to come out . . . But unfortunately I think I only made about three sessions, because once again
my health took a real dip and I got myself really down and I ended up taking extra tablets [overdose].
Non-completer, female, 57 years, Bristol –For another individual, physical comorbidity was a factor:In my head like it’s [the depression is] ongoing for me because a lot of it is tied in with the health.
And that ain’t getting any better and I don’t know how to get it better. Like it’s the pain is there all
the time.
Non-completer, female, 57 years, Bristol –Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31The above quote was part of a patient’s account of why she dropped out of therapy after one session and
included the disabling nature of her conditions (osteoporosis, emphysema, diverticulitis) and associated
feelings of unease outside the comfort of her own home.
Attendance could be an issue due to the symptoms of depression, for example a patient struggled with
attendance due to his lack of motivation/inability to speak when he was having a bad day.Usual care for this patient group
The accounts of patients in both arms of the trial, detailing their experiences of usual care, indicated that
this mainly entailed them taking antidepressants. These accounts also highlighted that the extent to which
patients received support from their GP varied greatly between patients. In terms of other sources of
support, it was apparent that some patients had received invaluable support from family and friends, and
had developed their own personal strategies to help them cope.Patients’ views and experiences of taking antidepressants
Most patients talked about how they had been on antidepressants for years. Patients described being on a
‘maintenance’ dose, which kept them ‘ticking over’, and detailed how the dose they were on had changed
over time, in response to their needs:© Que
This is
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Journa
SO16I’ve been on them [antidepressants] for years. I know when I’m sort of having a bad episode and I
need to increase the dose. So I can go to the GP and say ‘Look you know something’s not quite right
here . . . I think the dose needs to be increased’ and then when I’m feeling better again, it can
be decreased.
Completer, female, 44 years, Bristol +It was apparent that whilst some patients had been on the same type of antidepressant for some time,
others had been on several different types over the years. Reasons given for changing the type of
antidepressant were experiencing side effects, and restarting on a different type of antidepressant having
been off medication for a while and/or now being under the supervision of a different GP. Comments
made by one individual, however, suggested that no explicit reason may be given by the GP for changing
medication type. His comments also suggested that, although some patients described going back on the
same type of antidepressant, this had not been his experience:Patient: I’ve been through a large number of them [antidepressants] now, I think.Interviewer: Why is that, they keep changing?Patient: Changing yeah, sometimes you go with a problem and they say, ‘Oh just change it, just stop,
change it.’ They say, ‘We’ll try you on this one’ and they don’t say, ‘Well you’re better on that one, so
we’ll put you back on that one until’, you never go back again. I don’t know whether that’s part of the
protocols or whatever but you never go back.
Usual care, male, 60 years, Glasgow –A few patients described how when they ﬁrst started taking antidepressants, they had experienced side
effects, such as headaches and feeling dizzy. In addition, one individual recounted how initially she had
felt suicidal. Other side effects described, which stayed beyond the initial period of starting them, were
feeling more tired, feeling numb and less aware of what is going on around them, weight gain and
experiencing a lack of libido.89
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90Only a few patients stated antidepressants had improved their mood. Most patients described the effect of
medication as keeping their mood stable or at a certain level:NIHRI had erm lots of different antidepressants . . . Although I’ve not been happy, I’ve not been depressed,
I’ve just been even sort of like flat, which has been easier to contend with than having depression.
Non-completer, female, 57 years, Bristol –I think they [antidepressants] help me, they sort of give me a sort of baseline to work from . . . as if
I’m not going to drop too far down . . . it gives me a sort of baseline to work from, em even a buffer.
I don’t know quite how to explain it, but it makes me feel safe.
Usual care, female, 53 years, Bristol +A few patients described still feeling low or experiencing low periods despite taking antidepressants. In
addition, several patients commented that they were unsure whether or not being on antidepressants was
having any effect on their mood, and/or described not knowing if they were feeling better because they
were better or because their medication was working. These patients argued that the only way they could
establish what impact antidepressants were having, would be to stop taking them; something which some
of them had attempted to do and which had left them feeling worse:The thing is you only know with these things that they’re doing some sort of good when you try to
give them up and then suddenly you feel twice as bad.
Usual care, male, 60 years, Exeter –Within the accounts given by those who had received CBT during the trial, there was the suggestion that
antidepressants could help an individual to feel less tearful and therefore more able to work on the source
of their depression:If used correctly it [antidepressants] can be a really good platform as a starting point for people . . .
I think generally speaking that they are a necessary thing sometimes. You know just to get you to a
point where you can think clearly to resolve some issues you know and stop the crying.
Completer, female, 41 years, Exeter +Most patients in both arms of the trial described how they wanted to come off medication. A range of
reasons were given for this view: experiencing side effects, feeling that antidepressants only addressed the
symptoms and not the cause of their depression, concerns about becoming dependent on medication,
wanting to be ‘normal’, viewing antidepressants as ‘unnatural’ and having concerns about what they were
doing to their bodies, wondering if the antidepressants themselves were causing the individual to be more
depressed and feeling that they should be able to cope with life without the support of medication.
These patients remained on medication because they had attempted to come off them before and then
experienced nightmares or a signiﬁcant drop in mood; they feared a relapse in mood; their GP had not
suggested they came off them; they became agitated when they forgot to take them; or because they felt
they should wait until life was less stressful before doing so, for example when they retire. It was also
apparent that, being on medication for years could mean taking antidepressants became a habit:Before you know it I think you are on them 5 years and they are not really doing you any good you
know? But you are so used to taking them; it just becomes a habit I think to take them.
Completer, female, 43 years, Bristol –Only a few patients appeared to be comfortable with taking medication. Interestingly, all were female.
Their accounts implied that this was a pragmatic view rather than one based on viewing antidepressants in
a positive light:If it’s a choice between taking two tablets a day and feeling okay or not taking two tablets a day and
feeling absolutely crap, then I know which I would rather do.
Completer, female, 44 years, Bristol +Journals Library www.journalslibrary.nihr.ac.uk
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SO16I don’t have a problem [with taking antidepressants] if it’s making me feel better I don’t
have a problem.
Usual care, female, 41 years, Bristol –Never particularly bothered me being on them because it’s always made the difference between
staying in bed and being up.
Completer, female, 57 years, Exeter +Patients in both arms of the trial talked about feeling ready to come off mediation because they felt their
mood or situation had improved enough to enable them to do this. There was no clear evidence that this
feeling was more common among those who had received CBT during the trial. However, a few patients
who had been randomised to receive CBT did talk about feeling differently about being on antidepressants
because they now felt they had other ways of coping.Contact with the general practitioner
Only a few patients described regularly seeing their GP and their medication being actively monitored.
Most patients detailed how they simply got their antidepressants via repeat prescriptions and if they did
see their GP, this was because of other health issues. This lack of direct contact, and the limited amount of
time patients had with their GPs, may have meant some patients were on antidepressants longer than they
needed to be:I think maybe I have been on them slightly longer than I could have . . . because the doctor just sees
you for two minutes, says ‘how are you doing?’ and that is the way it goes.
Completer, female, 59 years, Bristol +Patients may also have been on medication longer than they needed to be because they did not feel GPs
were well placed to help them, not only in terms of lacking in time but also in terms of knowledge about
depression:People keep telling me I should actually go to see the doctor again [and talk about coming off
antidepressants], but I haven’t got a lot of faith in GPs because I know they’re GPs, they’re general
practitioners, they don’t know about these things. I mean a lot try more than others but they haven’t
got much time, you know they’re, it doesn’t do a lot of good seeing your GP really.
Usual care, male, 60 years, Exeter –There was no evidence to suggest that patients who had been allocated to usual care saw their GP more
frequently than patients who had been randomised to CBT plus usual care, or sought additional GP
appointments or alternative sources of support in order to ‘compensate’ for not being allocated to the
intervention arm. Financial constraints may have been one reason for this latter point, as usual-care
patients talked about wanting counselling but not being able to afford it. Also, there was little evidence to
suggest that GPs had offered extra support or referred patients for counselling, having established that the
patient was in the usual-care arm; only one patient in the usual-care arm mentioned that his GP had
referred him for counselling.
When talking about their GPs, some patients described them in a negative light. GPs were described as
individuals who were focused on making money and reaching targets, and who had little understanding
of depression. There was also evidence to suggest that some GPs had not treated their patients with much
sympathy or respect:I went to see him erm back in November . . . because he’d halved my antidepressants before that,
and I said I want them doubled up because I feel quite low. He said, ‘You feel low because you’re
fat.’ . . . I walked out that doctor’s surgery and I wanted to dig a hole and bury myself and disappear.
Usual care, female, 38 years, Exeter –91
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92Others however, described their GP in a very positive way. Attributes mentioned included listening and
having time for their patients, providing continuity of care and believing the patient when he/she said
he/she felt down:NIHRI’m lucky here because I’ve got a doctor I can go to who understands me, who believes me when I
say I’m down, who trusts me when I say this is worse than I felt a couple of months ago.
Usual care, female, 53 years, Bristol +Various comments made throughout the interviews indicated that it was very important to this patient
group that they were not viewed as ‘time-wasters’, as individuals who exaggerated their symptoms or
were ‘crazy’, and it was apparent that the possibility of being viewed as such could deter a patient from
accessing services:In the last 6 months I haven’t had to visit him (GP) very much. I’ve felt like a proper crazy person in
the last sort of 2 years because I was constantly at the doctors and it’s horrible. And I’ll tell you
something every time I have to go and see a GP or anything like that now, all I can think about in the
back of my head is all they’re thinking of me is that she’s this crazy anxiety person and I hate that.
And it’s, it’s just horrific.
Usual care, female, 26 years, Exeter +Another theme that was evident within the accounts relating to GPs was a lack of treatment options for
this patient group. Patients often talked about their GP offering them only antidepressants. In addition,
comments made by one individual, who had received CBT within the trial, indicated that within the NHS,
there were only so many treatments for which a patient may be eligible and, that, having received them
all, no further help could be given:I had had the CBT, I had had the therapy, you know, I had had the antidepressants and that was all
like the NHS could do for me and the doctor even said that. You know like he said that there is
nothing else, he wouldn’t sort of refer me to a psychiatrist or anything and he just said that there is
nothing else that the NHS can do for me and I think I felt like I was like 44 and I was sort of like stuck
on the scrapheap and he kept saying ‘You know you are still relatively young, you know our aim is to
get you off medication into you know live your life again’ and all I could think of was well how do I
do that? Because when you are feeling down, really down, it is hard to do that on your own and I
think he just thought you know I have had what you know I am entitled to and that is it, and that
really did send me in a downward spiral because I just thought that is it for me from now on.
Completer, female, 43 years, Bristol –Other sources of support
Many patients described how they had received invaluable support from family and friends. This support
could take the form of simply listening to the individual, distracting them from their negative thoughts,
providing encouragement and advice. Friends who had knowledge of depression, either because they had
experienced it personally or knew someone who had, were described as being particularly helpful in terms
of giving the individual advice and understanding their situation:[Friend’s name] actually sat me down and explained to me what it was like [to have depression], what
it was about, actually having anxiety and depression and stuff, so every time I’d be like, ‘This is
happening, this is how I’m feeling, is that normal?’ She actually just sat there and went, ‘It’s normal
mate don’t worry.’
Usual care, female, 26 years, Exeter +Journals Library www.journalslibrary.nihr.ac.uk
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SO16My friend [name] I’ve known know for 11 years and she understands as well, her mother suffers from
depression. So she knows where I’m coming from when I’m having the low times and I’ve been
friends with a neighbour for quite a few years whose husband has depression. And again, somebody
else who knows what’s happening, understands where you’re coming from and these are people
that I can sit down and talk about anything to . . . Things that you wouldn’t bring into normal
conversation, silly things [hmm mm] irrational thoughts, stuff like that, I can throw them at them and
they can say, ‘Och now you know that’s not true’ and I start the next thing.
Completer, female, 39 years, Glasgow –Patients mentioned treatments they had tried outside the NHS. Some of these were sought in order to
help with their depression or anxiety levels (e.g. counselling, hypnotherapy), whereas others had been used
to address other illnesses the individual experienced, some of which were viewed as contributing to or
underpinning their depression, for example self-management course for chronic fatigue. Patients also
described how they had developed personal strategies to help them cope with their depression. These
included avoiding situations that they found stressful, exercising, meditating, doing t’ai chi or self-hypnosis,
wearing a hat to block out noise and listening to relaxation tapes. Patients’ descriptions of when and how
they used these strategies suggested they were experienced as helpful because they reduced the
individual’s levels of anxiety or helped them to feel removed from reality or the immediate situation:If I find I’m getting anxious at work . . . I will sit down and hopefully I don’t go to sleep but, erm,
perhaps on occasions, I will nevertheless sit down there and, I mean I don’t necessarily have to have
my eyes closed to meditate so again it will, you know, I’ll use meditation from that sort of point of
view.. I can meditate when I’m walking along . . . it doesn’t mean that I am separate from other
things that are going around . . . to me obviously it’s wonderful, but a wonderful little, big I suppose
in some sense, er, scenario that I can, when I’m really upset, I can sort of put myself into in my mind
. . . I can put myself there and wash my troubles away for want of a term, you know.
Usual care, male, 61 years, Exeter –In addition, some patients referred to counselling they had had in the past, including CBT, and it was
apparent that lessons learnt during that time were still being employed:I looked at things very much as if they were black and white [mm], you know, erm, I mean, and after
that accident . . . CBT taught me that there was an awful lot of greys in the middle of it . . . if you’re
prepared to work at it, it gradually makes you aware that life isn’t against you all the time.
Usual care, male, 61 years, Exeter –This lady used to say to me, ‘If you are feeling bad one day and somebody says to you how are you
feeling’, she said ‘Don’t say to them I feel fine’ because you don’t, she said tell them how you feel. So
now I do actually, if I am feeling bad I do say to people, obviously only people I can trust who
understand me. I don’t say to somebody, somebody in the supermarket queue [laughter]. But yeah I
usually say, I admit to how I’m feeling, I listen to myself, listen to my body, listen to my mind,
whatever . . . And I think because I do that I’m more honest with myself I suppose, I’m not trying to
keep things suppressed.
Usual care, female, 53 years, Bristol +A couple of patients talked about using the internet to ﬁnd out about treatments, or social networking
sites, such as Facebook, to ‘talk’ to other people in similar situations. One patient also described how she
had read several books on how to cope with depression, such as, ‘Mind Over Mood’, which she had
found helpful.
Although the accounts given by some of the patients suggested that they had proactively sought out and
accessed treatments and resources that could help them with their depression, it was clear that many93
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94individuals had not attempted to do this. This may have been due to a lack of motivation to seek help.
Some patients talked about a symptom of their depression being a lack of energy or motivation, and
comments by some individuals suggested that they had come to accept their depression and to feel there
was nothing which could change their situation. A lack of ﬁnancial resources could be another reason, as
patients talked about not being able to access counselling or alternative therapies because they could not
afford them. Not being located within a social network may also have been a factor, as it was clear that
not everyone had someone they felt they could turn to when they needed help:NIHRI haven’t always got the support when I want it . . . You know, there’s no one at the end of the phone
if I feel really low and I feel like I want to smack one of the kids . . . there’s no one I can ring up and
say, ‘Help’ or ‘Can I chat for five minutes?’
Usual care, female, 39 years, Exeter –Discussion
Summary of findings
Overall, patients who had CBT were appreciative of the methods used and felt that they had been given
the techniques to help them better manage their symptoms. Patients could describe components of CBT
that they struggled with, or were a barrier to them completing the therapy, and still feel they had
beneﬁted from the sessions. In particular, in learning to question negative thought patterns and
behaviours and, therefore, better managing their condition. Patients’ accounts of usual care indicated
that this consisted mainly of taking antidepressants.Views and experiences of cognitive behavioural therapy
Most patients had little or no knowledge of CBT prior to taking part in the trial. Most patients settled
down to enjoy the process of the sessions, often after some initial discomfort due to the unfamiliar
situation. For some patients, however, there were barriers to the therapy process in sessions. Patients could
feel that the CBT model did not necessarily address the cause of their depression and provide the depth of
understanding that they required to make sense of their condition.
Cognitive behavioural therapists are trained to deal with physical and/or psychological comorbidity by bringing
the focus of treatment onto the here and now and how their condition is linked to current depressive
symptoms. However, for a few individuals their comorbidities could complicate the therapeutic process; in a
few instances chronic pain caused by physical condition(s) was perceived not to ‘ﬁt’ the CBT model.
Most patients thought the role of the therapist was to aid them in learning to cope with and manage their
symptoms through giving them tools to change their thinking, for example, separating their thoughts and
emotions. Therapist skills identiﬁed and appreciated by most were to do with getting patients to talk and
non-judgemental listening. Indeed, overall, patients in the study reported their relationship with their
therapist as genuine, trustworthy and collaborative. For a few individuals the therapeutic relationship was
an uncomfortable one. They related this to feeling under pressure to come up with the ‘right’ answer.
The qualitative study highlighted the fact that patients often struggled with the homework element of
CBT. The hourly/daily thought and activity diaries were emotionally charged exercises for some patients,
who associated them with negative school homework experiences and feared being judged at a time
when they were feeling vulnerable or lacking in self-conﬁdence or motivation. Having to work through
feelings and events between therapy sessions could also be distressing if the individual’s coping
mechanism was one of avoidance. Avoiding homework could, in some cases, be a reason to stop therapy.
Some patients felt completing thought and activity diaries could be risky, as family or work colleagues
might see them writing private thoughts. As a consequence, some patients would describe leaving
completing homework until the end of the day and then experience difﬁculties in trying to rememberJournals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31thoughts and emotions. Although it is important for GPs and patients to be aware of the commitment to
(and engagement with) the homework element of CBT as part of the decision-making process about CBT
referral, it should also be noted that for some completers in our study, homework and the attendant
difﬁculties were associated directly with the level of beneﬁt experienced from CBT. For instance, in ‘seeing’
patterns of thoughts and behaviour written down that previously had not been apparent to them.Impact of cognitive behavioural therapy
Many patients expressed opinions on why they thought CBT was effective. They described a changed
understanding of self and behaviour and how this translated into thinking and behaving differently;
learning how to manage their depression through small goals and changes; better communication with
others and its positive effect on family life; and how CBT had triggered changes to a healthier lifestyle.
Barriers to the efﬁcacy of CBT were to do with feelings of failure when patients could not put what they
had learned into action or the continuing (and deteriorating) nature of their comorbidities. These ﬁndings
may inform the continued dialogue between therapist and patient during therapy.
Interestingly, there was no obvious association among the interviewed patients between not liking CBT
and not beneﬁting from it, based on their BDI-II score and their interview accounts. In fact, a substantial
number of those who said they found the process challenging and difﬁcult had improved in terms of their
BDI-II scores.Reasons for completing and not completing therapy
Patients tended to describe more than one reason for completing or not completing CBT. For most completers,
the practicalities of ﬁtting CBT into their existing life were largely unproblematic; if people were not working, or
were working but their workplace and therapist were ﬂexible and supportive during therapy, attendance was
straightforward. For non-completers, however, commitment and attendance could prove difﬁcult because of
needing to prioritise caring for a family member, work or ﬁnancial commitments over their own health. In
addition, if employed, patients feared censure from work colleagues for missing work and their depression
being ‘found out’ by others. The perceived judgement of work colleagues was a particular worry among men.Patients’ experiences of usual care
Most patients described antidepressants as stabilising rather than improving their mood. Many patients
wanted to come off medication. Reasons for continuing were linked to fears of withdrawal symptoms or
relapse, waiting for the right moment to stop taking antidepressants or for their GP’s suggestion that
they do so.
Despite being on medication, it was evident that most patients interviewed were not in regular contact
with their GP, as they usually received their medication via repeat prescription. Contact may also have
been limited because some patients had not found their GP supportive or did not feel GPs were in a
position to help them. Furthermore, it was apparent that patients may be reluctant to see their GP in case
they were viewed as wasting his/her time, and some described critical comments from GPs that reinforced
these fears. The limited contact some patients had with their GP may have meant they were on medication
longer than necessary.
Patients talked about receiving invaluable support from family and friends, and some patients described
strategies they had developed to help them cope with their depression. The internet and books were used
as sources of information. There was no evidence to suggest that patients randomised to usual care had
received or sought additional treatment or support to compensate for not receiving CBT during the trial.Strengths and limitations
We used a purposeful sampling approach to maximise the diversity of patients across the three study
centres and continued data collection until data saturation was reached (using ATLAS.ti). Having managed
to recruit patients from both arms of the trial, and interview both completers and non-completers, we95
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96were able to address the aims of the qualitative study. However, the extent to which our ﬁndings are
applicable to other patients with depression may be limited because we sampled patients who had agreed
to take part in a trial of CBT and thus may have held particular views or expectations of treatment. Also,
the patients we interviewed were primarily white British and individuals of other ethnic backgrounds may
hold different views towards CBT. In addition, most of the patients we interviewed who had not
completed therapy were based in Bristol. However, the qualitative sample was reﬂective of the CoBalT
sample in general and interviewing both completers and non-completers ensured we gathered data from a
range of perspectives. In addition, the reasons patients gave for not completing therapy were similar across
the three centres. Furthermore, patients in the CoBalT study were individuals with TRD, and it is likely that
primary care patients who are referred for CBT are those who have refused or not responded to
medication for their depressive symptoms.
The interviews were conducted by researchers who were not involved in recruitment/follow-up of the
trial participants, which may have helped elicit a high degree of openness from the participants. This
proposition is supported by the fact that patients gave negative as well as positive views of CBT. The fact
that we could not interview patients before they had completed their primary outcome measures for
the trial or had completed treatment, meant the accounts given were open to recall bias and post hoc
reconstruction of events. Patients, however, appeared able to remember their experiences of treatment
during the trial, and what beneﬁts and difﬁculties had arisen during this time period. A number of
researchers worked together on the analysis of the data, and a software package was used to aid data
management. This ensured a rigorous, systematic analysis of the material gathered.Comparison with existing literature
Cognitive behavioural therapy requires a signiﬁcant commitment from patients in terms of attending a
number of therapy sessions, engaging with a therapist and completing homework between sessions.62,63
However, engagement with CBT may be problematic and there are no studies directly exploring what
patients ﬁnd difﬁcult or dislike about CBT. Greater adherence to therapy should equal greater
effectiveness.41 Thus, there is a need to identify barriers to adherence. Patients often say they would prefer
talking therapies22,91–93 but for GPs to refer, it is necessary to explain what therapy involves. An exploration
of these issues has the potential to guide GPs in their discussion with patients at the point of possible
referral for CBT, as well as therapist’s initial and ongoing relationship with the patient.
Qualitative studies exploring patients’ perspectives of CBT have tended to focus on patient expectations
and experiences of written or cCBT40,94–96 or aspects of group CBT97,98 for a range of conditions. For
example eating disorders and alcohol dependency, not just depression. The few qualitative studies that
have explored patients’ experiences of face-to-face CBT have reported on patients with psychosis,41,96
described the techniques by which patients used CBT after leaving therapy97 or compared patient
experiences of CBT and psychodynamic therapy.98
Our study found that patients could struggle with the focus of CBT if they felt their past or current
situation – such as physical symptoms or what they felt was their primary condition – was not being
explored sufﬁciently to address the cause of their depression. Patients sometimes expressed dissatisfaction
with aspects of the relationship with their therapist. These ﬁndings have something in common with
research reporting that dissatisﬁed CBT patients (in comparison with other psychotherapy patients)
considered the therapist to be applying a rigid and predetermined therapy design, and felt steered by the
therapists’ ideas.98 However, our study highlights the particular difﬁculties of addressing the comorbidities
in patients; although CBT therapists are trained to take into account comorbidity and how it affects the
patient currently, patients do not necessarily engage with the CBT as relevant to their physical pain(s).
From a therapeutic standpoint, patients struggle with having to think about distressing aspects of their
lives and completing homework tasks can be viewed as a result of cognitive or emotional avoidance of
issues that can prolong depressive mood. Patients with depression for many years learn to avoid stressful
situations or painful thoughts and discussions.64 The process of avoidance can have major implications forNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31the conduct of CBT, which focuses on ‘emotionally charged’ thoughts and feelings. These difﬁcult issues
can be dealt with through the collaborative nature of the therapist–patient relationship, and this includes
obtaining feedback from patients regarding their understanding of the therapist’s communications and
exploring any counterproductive reactions to the therapist’s manner, technique or suggestions.62 However,
one of the themes that emerged from our data was that this level of collaboration is not always perceived
as present by patients and this can have important implications for patient engagement, particularly when
the patient perceives the therapist is not as experienced as they would like.
The literature around CBT homework tends to focus on evidence that engagement with homework is an
important mediator of outcome.99 Although it is suggested that problems with homework seem to be the
norm rather than the exception,100 there is little research into patients’ perspectives of why this may be. To
the best of our knowledge, only one other study has explored patients’ views of CBT homework and this
was among patients with psychosis,96 whose views may not generalise to those with depression. Factors
identiﬁed in this earlier study that affected completion of homework were a lack of motivation, difﬁculty in
ﬁlling in worksheets, putting off assignments, and not understanding the rationale and perceived beneﬁts.
Although some of our ﬁndings regarding motivation and avoidance overlapped with this previous study,
our nested qualitative study provided insight into the speciﬁc difﬁculties for depressed patients, for
example associations with school homework, fear of judgement and failure; issues that can then be
addressed by the GP or therapist in dialogue with the patient.
It is of note that although patients may have disliked aspects of the CBT, most felt they had gained some
insight into how to manage their depression; in particular how to challenge their negative thought
patterns. This is in contrast with previous research, which found that it was the ‘high compliance’ patients
with psychosis who felt that CBT had given them effective skills to realise their goals.96
Patients’ accounts of how antidepressants affected their mood suggested medication stabilised their
emotions, giving them a platform from which they could then function and engage with others. Similar
ﬁndings have been reported by Knudsen et al.,101 who found that women viewed antidepressants as
enabling them to lead ordinary lives. We also found patients were unsure of whether or not being on
antidepressants affected their mood. Such uncertainty has been reported by others.102
Most of our patients described wanting to come off antidepressants. Other studies have also reported that
patients view this as preferable103,104 and, like us, identiﬁed a moral dimension to this view, for example
patients feeling that they would only be ‘normal’ once off medication.104 It has been reported that patients
may stay on antidepressants because they fear relapse and withdrawal symptoms.102,104 Such fears were
also described by our patients, some of whom had been tempted to stop their medication but then
experienced withdrawal symptoms. There is increasing evidence to suggest that withdrawal symptoms are
more likely to occur if a patient discontinues his/her medication abruptly, and has been on medication
long term.104
Most patients received their medication through repeat prescription. This limited the amount of direct
contact they had with their GP and may have discouraged regular review of their medication. Johnson
et al.105 recently commented on the fact that currently there are no formal processes in primary care to
support routine review of patients on long-term antidepressants and results of a prospective observational
cohort study they conducted, suggested that reviewing patients can lead to appropriate reductions in
prescribing. As the patients we interviewed had been eligible to enter the CoBalT trial, it is likely that they
still needed to be on medication for their depression. However, the lack of contact some patients had with
their GP was of concern. Some patients described still feeling very low despite being on medication, and it
was evident that not all patients had access to support from family and friends, and that some patients
were not proactive in seeking help.
Patients may be reluctant to approach their GP about their depression and may feel people are not
sympathetic to their situation.106 We found evidence to suggest that GPs are not always supportive97
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98towards patients with depression. Patients described how they had received invaluable support from
friends and relatives, and it was apparent that patients viewed individuals who had had experienced
depression as being particularly well placed to understand their situation. Patients with depression have
described the ‘ideal’ person to conﬁde in, as being someone who can draw on their own personal
experience of depression and who has recovered.106Implications
Our qualitative ﬁndings contribute to the body of work on patient views on the acceptability of, and
adherence to, CBT. The practical implications of the ﬁndings can be applied on two levels: in the initial
discussion between the GP and patient in primary care regarding referral for CBT and in the ﬁrst therapy
session, and ongoing therapist–patient dialogue.
These accounts of patients’ experiences of therapy have the potential to help GPs in their discussions with
patients at the time of referral. A conversation with the GP that includes acknowledgement of the
difﬁculties and challenges of CBT may better prepare patients to make an informed choice about referral
for therapy. In particular, homework and its potentially negative associations, issues around feeling judged
on written work, the risky nature of writing things down, recall problems and avoidance strategies. Being
aware of these perceived or actual barriers to completion of CBT by some patients again may aid the
informed decision-making process.
It is also possible that therapists may be able to address some of these issues by using alternative media.
For example, there are now thought and activity diary ‘apps’ available for smartphones and tablets, which
can be completed in a discrete manner in the workplace or home.
By addressing possible difﬁculties between therapist and patient in the ﬁrst instance, and emphasising the
collaborative nature of the relationship, adherence may well be maintained or improved over the course of
therapy. Our ﬁndings also underline the importance of eliciting negative thoughts and feelings that may
induce the patient to leave treatment, these feelings being more likely to surface and be addressed if there
is good rapport between therapist and patient and what is known as ‘engagement with therapy’.
However, it is clear that not everyone will like CBT. Our data also suggest that physical comorbidities can
also be an important part of the experience of depressed patients, and a perception of a lack of ﬂexibility
on the part of therapists concerning these comorbidities may be a barrier to engagement with therapy.
This may be of particular relevance to therapists working with patients from primary care.
Overall, patients in our study, despite struggling with some aspects of CBT, reported that they had found
CBT beneﬁcial. The majority of patients reported gaining insight and learning skills enabled them to deal
more effectively with their depression.
If we can increase both patient and clinicians’ knowledge about what the patient is signing up for when
being referred to CBT, and continue the dialogue with therapists about possible barriers to engagement,
completion rates of therapy may be improved and the efﬁciency of the use of these resources can
be maximised.
In terms of improving patients’ experiences of usual care, GPs should aim to regularly review their patients’
medication to assess whether or not the patient needs to continue with antidepressants, and if so, to
determine whether or not they are on the correct dose. GPs should also use these consultations to identify
what other forms of support the patient is able to access and to consider whether there are resources
within the community or on the internet, such as patient support groups or websites, from which the
patient may beneﬁt. GPs need to reassure patients they will not be judgemental and should support
patients who are ready to stop medication, as this transition can be difﬁcult.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31Chapter 6 Discussion and conclusionsSummary of ﬁndingsCognitive behavioural therapy, when given as an adjunct to usual care, which included antidepressant
medication, was effective in reducing depressive symptoms in primary care patients with TRD. In order to
be eligible to take part in the trial, it was necessary for participants to have not responded to at least
6 weeks of treatment with an antidepressant at an adequate dose for depression; however, many of the
CoBalT participants presented with severe chronic depression with physical and/or psychological
comorbidity. At baseline, 29% fulﬁlled ICD-10 criteria for a severe depressive episode, and 70% had been
on their antidepressant medication for > 12 months. Although a greater proportion of the intervention
group ‘responded’ at 6 months compared with those in the usual-care group, a beneﬁcial effect of the
intervention was also observed with respect to the more stringent criteria of ‘remission’ (BDI-II score of
< 10) at this time. The difference in mean BDI-II score between groups equated to an effect size (0.5 SD),
which exceeded the target effect size of ≈0.3 SD, which has been suggested as corresponding to a
clinically important difference.12 Estimates of treatment efﬁcacy based on a CACE model found an even
larger positive effect (0.8 SD) on depressive symptoms at 6 months for those who were regarded as ‘on
track’ to receive the full course of CBT at this time. The beneﬁcial effect of the intervention was sustained
from 6 to 12 months, both in terms of the primary outcome of ‘response’ and the secondary ‘remission’
outcome. Furthermore, a reduction in symptoms of anxiety and panic was also found for those in the
intervention group compared with those in the usual-care group over the 12 months. The intervention was
also effective in improving quality of life (SF-12 mental subscale score) over the 12 months.
Cognitive behavioural therapy in addition to usual care was also shown to be cost-effective using the
methods and criteria recommended by NICE. The ICER, from the perspective of the health-care provider,
was £14,911, considerably less than the accepted threshold of £20,000–30,000. The probability of the
intervention being cost-effective was estimated to be 0.74 at the £20,000 threshold, and 0.91 at the
higher level of £30,000. This ﬁnding was shown to be robust under a range of scenarios tested in the
sensitivity analysis.
Out-of-pocket personal expenditure was dominated by loss of earnings, and the value of lost productivity
was substantial, but neither of these differed between the two groups.
Cognitive behavioural therapy requires a signiﬁcant commitment from patients in terms of regular
attendance at therapy sessions, engaging with the therapist and completing ‘homework’ between
sessions. Patients described how they had found CBT to be a challenging and difﬁcult process at times,
and had struggled to complete homework tasks for emotional and practical reasons. Understanding the
aspects of CBT that patients ﬁnd difﬁcult will aid therapists in engaging the patients with treatment.
Moreover, the ﬁndings from the qualitative interviews will enable GPs and patients with depression to
discuss the possible challenges and beneﬁts of committing to a course of CBT. This will enable patients to
make more informed decisions about whether or not to be referred for CBT. This may reduce failure to
complete therapy, which, in turn, may result in efﬁciencies in the provision of this limited resource.
Patients recruited into the CoBalT trial had depression that had not responded to antidepressant
medication alone, but most had moderate or severe depression, with symptoms that had been ongoing for
several years. The fact that this intervention both reduced depressive symptoms and was cost-effective has
important implications for the management of this patient group whose depression is difﬁcult to treat and
who would otherwise incur considerable costs to both the NHS and society.99
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Wiles et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
DISCUSSION AND CONCLUSIONS
100Strengths and limitationsThe CONSORT statement60 and the extensions for pragmatic trials70 and trials of non-pharmacological
interventions69 were followed in terms of both the conduct and reporting of the CoBalT trial. Allocation was
concealed through the use of a remote telephone randomisation system. The primary analyses were conducted
according to the principle of ITT following an analysis plan that was agreed in advance with the TSC.
Follow-up rates at 6 and 12 months were high (90% and 84%, respectively) and exceeded the target
follow-up rate at 6 months (85%). Follow-up rates in Glasgow were lower but this may have reﬂected
greater deprivation and higher mobility among this population. Importantly, there was no evidence for
a difference in completion rates of therapy between centres, and, in a post hoc subgroup analysis there
was no evidence that study centre had any effect on the difference between the intervention and
usual-care groups.
Given the high follow-up rates overall, the potential impact of missing data on the ﬁndings was minimised.
Sensitivity analyses that imputed missing outcome data were consistent with the results from the primary
ITT analysis, and hence there was no evidence that the missing data had biased ﬁndings. Moreover,
although a number of imbalances were evident when the baseline comparability of the two groups was
examined, additional adjustment for such imbalances did not substantially affect the ﬁndings.
It was not possible to blind the treatment allocation from participants, researchers or from those delivering
the intervention. Outcomes were therefore collected by means of a self-report questionnaire in order to
eliminate the possibility of observer bias.
Our primary outcome was depressive symptoms on the BDI-II. This instrument was also used by the
therapists within CBT sessions; hence, for those in the intervention group, the responses on this speciﬁc
measure may have been inﬂuenced by the process of therapy. Nevertheless, results were consistent for the
other mental health outcomes (that were not used in therapy), including for the PHQ-9, which is part of
the core outcome data set within UK psychological services.27,28
The identiﬁcation of those with TRD from primary care was challenging. There is no single accepted
deﬁnition of treatment resistance. Therefore, we used an inclusive deﬁnition of TRD, that was directly
relevant to UK primary care, given the uncertainty about what course of action to recommend to patients
who have not responded to (at least) 6 weeks of antidepressant medication.13 However, as highlighted
earlier, many of those recruited to CoBalT had severe and chronic depression. Seventy per cent had been
taking their current antidepressant medication for > 12 months, and only 10% of those recruited had
taken their current medication for < 6 months. Hence, the sample recruited was more chronic than
originally envisaged. Nonetheless, patients recruited to CoBalT were a heterogeneous group in terms of
prior treatment and duration of their current depressive episode, so this inclusive deﬁnition ensured that
trial results were as generalisable as possible.
Measurement of adherence to medication is also challenging, especially as tablet counts are difﬁcult to
interpret. Although, electronic monitoring bottles are considered as the ‘gold standard’ for assessing
adherence, using such bottles to document adherence to medication prior to trial entry was impractical
and prohibitive on the basis of cost. We therefore relied upon a self-report measure of adherence48 that
had been validated against electronic monitoring bottles.49 Although some of those recruited may not
have adhered to their medication (i.e. were false positives), the vast majority had been on their medication
for > 12 months and the long half-life of many antidepressant medications would minimise the effect of
any non-adherence.
There was no ‘attention control’ group as this was regarded of limited value in the context of a pragmatic
trial. Therefore it is not possible to exclude the possibility that this could explain the ﬁndings, but there is
little evidence that counselling is effective over the long term.107NIHR Journals Library www.journalslibrary.nihr.ac.uk
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data for the economic evaluation were examined. Nonetheless, not unexpectedly, there were some
missing data for the economic evaluation. However, the CBT intervention comprised the largest
component of cost, and complete data were available on this. The vast majority (90%) of other health and
social care costs were based on data extracted from primary care medical records (consultations in primary
care and prescribed medication) and such data were 97% complete. QALY data were 83% complete.
Hence, our base-case scenario is a cost–utility analysis, with the small amount of missing data imputed.
Sensitivity analyses, using complete cases, demonstrate the robustness of our ﬁndings. Under all scenarios,
the cost per QALY was below the upper threshold of £30,000 used by NICE, hence conﬁrming that this is
a cost-effective intervention.
There was more missing data in relation to personal costs and the cost of lost productivity. Therefore,
we presented these costs in a cost–consequences format, using all available data by category to
ensure transparency.
Cognitive behavioural therapy takes an educational approach in order to help patients incorporate
therapeutic strategies into their everyday activities, thereby enabling them to better manage their mood.
If they are successful in this then it seems reasonable to suggest that they may have better health in the
future and better work attendance. The results of this study are limited to outcomes at 12 months, so we
cannot comment on the longer-term costs and beneﬁts of this type of therapy. However, there may be
evidence from this study and others that could enable modelling of future costs and beneﬁt.Other methodological issuesThe sample size calculation was revised following a slightly delayed start to recruitment, recruitment
difﬁculties in one centre and problems matching recruitment rates to therapist capacity in two centres. The
original target of 472 was reduced to 432, with only a small reduction (87% vs. 90%) in power to detect
the pre-speciﬁed target difference of 16 percentage points. In the event, though, there was a surge in
recruitment in the ﬁnal months, and the ﬁnal number of 469 randomised participants was only three short
of the original target.
In the context of a pragmatic trial of a non-pharmacological intervention, a key methodological consideration
is the background and experience of the health-professionals delivering the intervention.69,70 In the CoBalT
trial, the aim was to recruit therapists who were representative of those working within NHS psychological
services (such as IAPT). Although it is difﬁcult to recruit a truly representative sample, the therapists working
on CoBalT came from a range of professional backgrounds, and although the majority had practised as a
therapist for a number of years, two of the trial therapists were newly qualiﬁed (≤ 18 months experience),
reﬂecting the variation seen in clinical services. In line with standards for ‘high-intensity’ IAPT practitioners
(www.iapt.nhs.uk/silo/ﬁles/national-curriculum-for-high-intensity-cognitive-behavioural-therapy-courses.pdf),
the majority of the CoBalT therapists had completed postgraduate CBT training. An independent evaluation
of the therapy delivered in CoBalT found good ﬁdelity to the CBT model, with the mean CTS-R score for the
nine therapists who delivered the majority of the intervention indicating that the therapy was delivered at a
standard that met conventional levels of ‘competence’.65
Therapists were supervised by an experienced therapist at each centre. Supervision arrangements for
therapists met the standards for clinical supervision set out by the BABCP (www.babcp.com/ﬁles/
Accreditation/CBP/Reaccreditation/CBP-Reaccreditation-CriteriaGuidelines-V2–1009.pdf) and the more
stringent requirements set out by IAPT (www.iapt.nhs.uk/silo/ﬁles/iapt-supervision-guidance-revised-march-
2011.pdf).101
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102All of the CoBalT therapists were employed on a part-time basis and hence allocation of patients to
therapists was based on matching patient availability with therapist availability. This non-random
assignment of patients to therapists meant that it was not possible to examine the effect of therapist
characteristics on outcome in an unbiased manner. The potential for clustering of outcomes by therapist
was nonetheless explored using appropriate statistical techniques72 and there was no evidence of any such
clustering effects.
Eighty-ﬁve per cent of CBT sessions took place in the patient’s GP surgery or in other local NHS premises.
Differences in the provision of NHS psychological services between the three centres were reﬂected in
variations between sites in terms of where the majority of the CoBalT CBT sessions took place. In Bristol,
96% of patients were seen at their GP surgery, reﬂecting the model used by the local IAPT services
(www.bristol.nhs.uk/your-health/mental-health-and-wellbeing/help-in-bristol.aspx). In Exeter, a partnership
between the NHS and University (www.exeter.ac.uk/mooddisorders/) meant that NHS patients in Exeter
and the surrounding area were expected to travel to the centrally located Mood Disorders Centre for
therapy, a pattern that was replicated in the trial, whereas patients registered at more remote practices
were seen by the therapists in their GP surgery. In Glasgow, patients were primarily seen at the Glasgow
Clinical Research Facility (www.glasgowcrf.org.uk/), which is located on the site of one of the main
Glasgow hospitals. If patients had been referred to psychological services on the NHS in Glasgow, they
would have been expected to travel to their local primary care mental health team (PCMHT) for therapy.
The distance travelled by CoBalT participants to the Clinical Research Facility would have, on average,
mirrored the distance travelled to their local PCMHT. Again, such variation reﬂects the pragmatic design
of the trial.
Finally, there were concerns that the roll-out of the IAPT services in England could have led to a substantial
number of those randomised to usual care receiving CBT on the NHS (outwith the trial). The potential for
such contamination was of concern because it would reduce any difference in the treatment effect
between the two groups. In the event, only a very small minority of those who participated in CoBalT
(three participants in the usual-care group and two participants in the intervention group) received a
course of ‘non-CoBalT’ CBT. This contamination had little impact on the ﬁndings.Comparison with existing studiesPrior to CoBalT there was no existing RCT evidence on the effectiveness of CBT as an adjunct to usual
care that included pharmacotherapy as a ‘next-step’ treatment option for primary care patients whose
depression had not responded to antidepressant medication. However, the effects observed are similar
to those found in an earlier RCT of combined psychological and pharmacological treatment for
chronic depression.38
Using a similar deﬁnition of response, Keller et al.38 found that 48% of those randomised to the
antidepressant nefazodone (Serzone, Bristol-Myers Squibb – now withdrawn) ‘responded’ after 12 weeks
treatment, compared with 73% of those randomised to receive both medication and psychological
treatment (16 sessions of CBASP). The difference between these two groups was similar to the difference
in response rates between treatment groups found in CoBalT (24%). The response rate among those
randomised to medication (48%) in the Keller trial38 was higher than in CoBalT (22%), and may be due to
differences in the patient populations. Those recruited by Keller et al.38 were chronically depressed (mean
duration of current episode of depression 7.8 years), but patients with TRD (deﬁned as an absence of
response to three previous trials of at least two different classes of antidepressants) were excluded.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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responders) to 12 weeks of antidepressant medication (allocated based on a medication algorithm). Of
those randomised to switch to the next step in the medication algorithm, 14.7% met criteria for ‘response’
after 12 weeks’ treatment, with a similar ﬁgure for response (15.3%) among those allocated to receive
medication and psychotherapy (either CBASP or BSP; mean number of sessions: CBASP 12.5, BSP 13.1).
The lack of a difference in outcomes between the groups was viewed as surprising18 given the earlier
ﬁndings of Keller et al.38 However, although both studies recruited patients with chronic depression, those
recruited to the REVAMP trial were, in addition, a treatment-resistant population. Importantly, those
randomised to CBASP in the REVAMP trial attended an average of 12.5 sessions, compared with
16 sessions in the earlier trial by Keller et al.,38 which may also contribute to the explaining the differing
trial ﬁndings.
There was a higher remission rate among those receiving pharmacotherapy in REVAMP (38.5% at
12 weeks)18 compared with CoBalT (15.0% for the usual-care group at 6 months) but this may be
attributed to differences in the patients recruited. In REVAMP, only one-third of participants had previously
had an adequate trial of pharmacotherapy in contrast with the CoBalT population, of whom most (80%)
had previously been prescribed antidepressants and 70% had been on their current medication for
> 12 months.
In CoBalT, the treatment protocol deﬁned the intervention as ‘a course of 12 sessions [of CBT], with
(up to) a further 6 sessions if deemed clinically appropriate by the therapist’.45 Anecdotally, the therapists
reported that the CoBalT population included a high proportion of very complex cases with signiﬁcant
comorbidity. This observation was reﬂected in the fact that, of those who completed therapy as per
protocol, the median number of sessions attended was 16. This ﬁgure was similar to that in the Keller
trial,38 which also reported a beneﬁcial effect for combined pharmacological and psychological treatment
but in those with chronic depression rather than non-responders to antidepressant medication.
Only 26% of STAR*D participants agreed to be randomised to CBT as a second-step treatment option21
but those in the CBT augmentation group (n = 65) were similar to CoBalT with most (86%) having a
history of depression, with an average of seven prior episodes.21 The percentage who fulﬁlled criteria for
response based on self-reported depressive symptoms for those in the CBT augmentation group of
STAR*D21 was slightly lower than the ﬁgure for CoBalT (35% vs. 46.1%), although remission rates were
similar. However, as highlighted earlier (see Chapter 1, Existing evidence on the management of treatment
resistant depression), STAR*D answered a different question to CoBalT. STAR*D examined alternative
treatment approaches to the management of TRD, rather than examining the effectiveness of augmenting
antidepressant medication with CBT as a ‘next-step’ treatment option.
Finally, others have shown that those with personality disorder are less likely to beneﬁt from CBT than
individuals without such comorbidity,108 and that those with more severe depression are likely to gain
greater beneﬁt from CBT than those with mild depression.109 However, there was no evidence that severity
of treatment resistance differentially affected the effectiveness of the CoBalT intervention. Similarly, in the
other a priori subgroup analysis, there was no evidence that patient expectation of outcome inﬂuenced the
magnitude of the treatment effect.Comparison with data from Improving Access to Psychological
Therapies servicesGiven the investment in the expansion of psychological services in England through the IAPT project,27,28 a
pertinent question relates to the generalisability of the ﬁndings from CoBalT. As outlined earlier, therapists
were recruited to be representative of those in NHS psychological services and the majority of CBT sessions
were delivered in GP surgeries or other NHS premises in line with the ‘standard’ provision of psychological
services in each of the three centres.103
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DISCUSSION AND CONCLUSIONS
104So how does the proﬁle of patients recruited by CoBalT relate to those being seen in IAPT services?
Reports from the two demonstration (pilot) sites32 and the review of the ﬁrst year of the IAPT roll-out33
enable comparison. Of the two pilot sites, data from the Newham site that provided more ‘high-intensity’
CBT are the most relevant. Most patients seen in Newham had a primary diagnosis of depression (46%) or
anxiety (43%) and, as in CoBalT, they had chronic symptoms, with 61% reporting that the duration of
their current problem had persisted for over 2 years.32 In Newham, 76% of patients scored ≥ 10 on the
PHQ-9 (with 28% being classiﬁed as having ‘severe’ depression deﬁned as a PHQ-9 score of ≥ 2032),
similar to the ﬁgures for CoBalT. Eighty-six per cent of patients seen in Newham were regarded as being a
‘case’ on the PHQ-9 or GAD-7 (scoring ≥ 10 or ≥ 8 respectively), again a ﬁgure similar to the CoBalT
population (94%).
Data from the ﬁrst year of the roll-out of IAPT across 32 sites33 conﬁrmed that the majority of those
referred to IAPT services (76%) present with a diagnosis of depression and/or anxiety, with the majority
(84%) being a ‘case’ on either the PHQ-9 or GAD-7 (PHQ ‘case’, 72.5%; GAD-7 ‘case’, 77.4%). In terms
of outcome, 36.8–42.4% of IAPT patients ‘recovered’ (deﬁned as not a ‘case’ on PHQ-9 or GAD-7) after
treatment, which is slightly lower than the ﬁgure for participants in the intervention group of CoBalT
(48%). However, in neither report32,33 are any data given on the proportion of patients who have not
responded to antidepressant medication.
Improving Access to Psychological Therapies services are focused on delivering ‘NICE-compliant’
treatment,110 which equates to 16–20 sessions of CBT for depression according to NICE guidelines.13
However, there are currently few robust data on the average number of sessions delivered in IAPT
services.33 Data from the ﬁrst year report suggest that < 2% of patients (with depression or generalised
anxiety disorder) received 16–20 sessions of CBT, although it is thought that there was a problem with the
recording of all treatment sessions.33 However, knowledge of the number of sessions received by patients
treated in IAPT services, together with more details about the patient proﬁle (in terms of their prior history
of treatment), are important in terms of generalising the ﬁndings of CoBalT and projecting the likely
beneﬁts (both in terms of clinical and economic outcomes) that may be obtained.Implications for health care and suggestions for
further researchIn 2006, Layard8 suggested that investing in training more therapists deployed in psychological treatment
centres across the UK would lead to signiﬁcant savings in terms of incapacity beneﬁts and NHS costs to
the UK government. The subsequent investment and expansion in psychological services in England27,28
was founded on this premise of cost-effectiveness. The results of the CoBalT trial are useful in informing
the ‘next step’ for those who do not respond to antidepressant medication. CBT, given as an adjunct to
usual care that includes antidepressant medication, is an effective treatment in reducing depressive
symptoms and improving quality of life over 12 months when compared with usual care alone.
Importantly, the intervention was cost-effective when judged against the criteria used by NICE.
Given the chronic relapsing nature of depression, it is important to examine the long-term outcome of this
intervention. It has been argued that CBT has the potential to produce a more sustainable improvement
than pharmacotherapy alone. This is because CBT adopts an educational approach that teaches patients
skills to help manage their mood and to gain an understanding of persistent unhelpful aspects of their
behaviour. In principle, this approach should lead to an improvement in longer-term outcomes that should
outlast the duration of the treatment. This is evidenced by the positive outcomes at 12 months in CoBalT
and the beneﬁcial effects observed by others in terms of relapse prevention.111 However, many RCTs of a
CBT intervention only report outcomes after 12–16 weeks,38,112 although some have included a longer-
term follow-up (at 10–16 months34,113–116). To date, there is little evidence of the effectiveness of CBT over
the long term (> 3 years); that which does exist relates to the role of CBT in relapse prevention.35,117NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31Hence, the question remains whether the beneﬁcial effects of the intervention observed at 12 months are
maintained over subsequent years or if such effects ‘wear off’. Given the educational approach that is key
to CBT, it is plausible that a smaller, albeit clinically relevant, difference might still exist 4 years later,
although this remains unproven. Furthermore, although clinical effectiveness may decline with time, the
intervention could still be cost-effective over the long term. There is an opportunity for future research to
develop a decision-analytic model to evaluate CBT for this patient group, taking a long-term societal
perspective and weighing up costs invested at the outset against future beneﬁts in term of health,
well-being and productivity.
Of those studies examining the long-term outcome of CBT in terms of relapse prevention,35,117 none
has examined the cost-effectiveness of such a strategy. Previous reports on cost-effectiveness of CBT
(e.g. Durham et al.25) are conﬁned to different patient populations and varied CBT interventions (including
low-intensity interventions with a contact time of < 3 hours) meaning that these ﬁndings cannot be
generalised to the population of patients with TRD studied in CoBalT. If the intervention was found to be
cost-effective over the long term, this would have signiﬁcant implications for recommendations as to how
depression should be managed.
Future investment in psychological services in the UK and elsewhere should take account of the needs of
this population for a ‘live’ therapist, who is able to tailor the treatment approach to the individual (the idea
of meta-competence in the CBT competencies framework: www.ucl.ac.uk/clinical-psychology/CORE/
competence_frameworks.htm). Although cCBT is often promoted as a way of improving access to
psychological therapies, such an approach is inﬂexible to the needs of many depressed patients.
As highlighted by the CoBalT population, many of those whose depression does not respond to
antidepressant medication have chronic depression, with physical and/or psychological comorbidity. A
skilled therapist will be able to deal with such comorbidity and formulate more long-lasting beliefs that,
according to cognitive theory, underpin the longer-term risk of depression. Other modes of delivering CBT
over the internet109 or by telephone118 could retain such a ﬂexible approach, but may also afford an
opportunity for greater efﬁciency in the provision of such treatment.
Finally, it is important to remember that although nearly half of those in the intervention group met criteria
for response, 54% did not. Therefore, it is a priority that the evidence base for the effectiveness of a range
of ‘next-step’ treatments for those who do not respond to medication alone is expanded. Alternative
‘next-step’ treatments may include increasing the dose of the antidepressant medication, switching to
another antidepressant or augmentation with another pharmacological treatment (either two
antidepressants or augmentation with a non-antidepressant medication, such as lithium).13,119 Combining
pharmacological agents broadens the pharmacological actions involved.120 Although many different
strategies have been evaluated, to date there is little robust evidence regarding the effectiveness of many
of these strategies,13 with reviews frequently incorporating evidence from uncontrolled studies and/or
non-randomised studies as well as RCTs.121–123 Furthermore, there is little evidence for the effectiveness
of other psychological therapies as an adjunct to pharmacotherapy. Although CBT is, at present, the
psychological treatment that is most frequently available on the NHS, it is evident that from CoBalT that
other psychological treatment approaches may be preferred by some patients. Indeed, evidence from
ongoing RCTs investigating the effectiveness of DBT (REFRAMED trial: ISRCTN85784627), ISTDP
(NCT01141426) and MBCT (NCT01021254) will be welcome. Only by obtaining robust evidence on
the effectiveness and cost-effectiveness of a range of ‘next-step’ psychological and pharmacological
interventions will it be possible to reduce the signiﬁcant burden to patients, NHS and society, which is
associated with non-response to the most common ﬁrst-line treatment for depression in primary care.105
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In addition to the main analyses reporting the clinical effectiveness and cost-effectiveness of theintervention and the results of the nested qualitative study, three additional secondary analyses using
data from the CoBalT study were conducted, the aims of which were to:
1. estimate the prevalence of TRD in UK primary care
2. examine whether or not dysfunctional attitudes and metacognitive awareness are mediators of the
effect of CBT on depression outcomes
3. examine potential moderators of response to CBT.
These additional analyses will be reported in Chapters 8–10.107
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depression in primary careIntroductionDepression is a disabling condition and the third most common reason for consulting a GP in the UK.124
As outlined earlier (see Chapter 1), antidepressants are the ﬁrst-line treatment for moderate and severe
depression in primary care, and there has been a steady rise in antidepressant prescribing in recent years,
in the UK and elsewhere.2–4 However, not all patients respond adequately to antidepressants and there is
concern about the impact on both patients and society for those whose symptoms do not respond to such
treatment. Much of the cost and disability associated with depression is accounted for by treatment
resistance.125,126 Yet, there are few estimates of the prevalence of TRD.
The large US STAR*D study found that more than half of all patients recruited through primary care and
psychiatric clinics did not achieve remission after ﬁrst-line antidepressant treatment, and one-third did not
experience remission after four courses of acute treatment.127 A multicentre European study (Group for the
Study of Resistant Depression) found that 50.7% of depressed patients recruited from specialist referral
centres were considered treatment resistant after two consecutive courses of treatment with
antidepressants.128 Although there is no single accepted deﬁnition of what constitutes ‘treatment
resistance’,129 these data suggest that non-response to medication following antidepressant treatment is a
substantial problem. However, it is unclear whether or not these data would generalise to UK primary care.
Accurate estimates of non-response to antidepressant treatment are important to determine whether or
not there is unmet need, particularly given the high prevalence of depression among patients presenting to
primary care. The CoBalT study provides an opportunity to estimate the prevalence of TRD among those
prescribed antidepressants for at least 6 weeks in UK primary care.MethodsThis was a secondary analysis of data collected during the initial screening stage of the CoBalT study
(ﬁlter 1 and ﬁlter 2), which is described in full earlier (see Chapter 2, Filter 1: Search of general practitioner
records to identify patients being treated for depression). Brief details are outlined below.Identification of participants
A search of computerised records was conducted at each of the 73 collaborating GP practices, to identify
patients aged 18–75 years who were currently receiving antidepressants and who had received repeated
prescriptions for antidepressants [at an adequate dose for depression (see Appendix 1) during the previous
4 months]. GPs excluded individuals with bipolar disorder, psychosis or major alcohol or substance use
problems, as well as those who were unable to complete the study questionnaires or for whom the study
was regarded as inappropriate. Patients who were currently receiving CBT or other psychotherapy (or who
had undertaken CBT in the last 3 years) were also excluded. The remaining patients were mailed an
invitation letter and brief information sheet about the study and asked to respond, indicating whether or
not they were willing to be contacted by the research team. Anonymised data on age and gender of those
patients who were mailed an invitation to participate but who did not respond were collected in order to
assess the generalisability of the study ﬁndings.109
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Wiles et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
THE PREVALENCE OF TREATMENT-RESISTANT DEPRESSION IN PRIMARY CARE
110Questionnaire
Patients who agreed to participate were mailed a short screening questionnaire. This questionnaire
included a self-report measure of depressive symptoms – the BDI-II46 – and asked for details of their
current antidepressant medication, including the duration of their current treatment and their adherence
to antidepressants. The latter was assessed using a modiﬁed version of the Morisky scale48,49 (see
Chapter 2, Inclusion criteria). The questionnaire also collected data on sociodemographic variables (age,
gender, marital status, educational qualiﬁcations, employment status, housing situation and
ﬁnancial situation).Defining treatment resistance
Given the lack of consensus in the deﬁnition of TRD, we proposed an inclusive deﬁnition, directly relevant
to UK primary care.13 Treatment resistance was deﬁned as those patients who scored ≥ 14 on the BDI-II
and who had been taking antidepressant medication at an adequate dose for at least 6 weeks.Data set
As well as recruiting participants via a search of electronic records, GPs were able to refer patients directly
to the research team. However, for the purpose of the present analysis, such individuals (n = 37) were
excluded. In addition, for those individuals who were rescreened to ascertain eligibility for the trial, data
from only their ﬁrst postal questionnaire were used. Thus, the estimates of prevalence are based on
questionnaire data obtained from one search of patient records from all participating practices.Statistical analysis
All analyses were conducted in Stata 11.2. The prevalence of TRD was estimated with 95% CI, adjusting
for clustering by GP practice. The impact of non-response (to the initial study invitation and screening
questionnaire) on estimates of prevalence was assessed using probability weights (inverse of the
non-response rate for each GP practice), such that data from practices with higher response rates were
given more weight. Weighted estimates of prevalence were calculated using the survey commands in Stata
(svy commands). Technical limitations meant that it was not possible to adjust the latter estimates for
clustering by GP practice; however, preliminary analyses showed that there was little evidence of clustering
by GP practice.
Descriptive data on the type of antidepressant medication taken by those fulﬁlling our deﬁnition of TRD
are reported, including the number on combined (deﬁned as two different antidepressant medications at
an adequate dose) or augmented antidepressant treatment (with a non-antidepressant medication).
Sociodemographic characteristics were compared for the TRD group, with those who were not adhering to
medication and with those who had minimal depressive symptoms. Comparisons of age and gender were
also made between those who did and did not participate in the study.Results
Response to study invitation and questionnaire completion
A total of 10,629 patients who were mailed an invitation letter, of whom 4552 (43%) responded
(Figure 6). Of these, 64% agreed to being sent a questionnaire by the research team, and subsequently,
most (n = 2439, 84%) returned a completed questionnaire (see Figure 6).
Of those who returned a questionnaire, we had complete data on dose and duration of antidepressant
treatment and depressive symptoms from 2317 participants (95%). Of these, 8.8% were not taking an
adequate dose of medication or had been taking their medication for < 6 weeks and were excluded from
further analyses. This gave a sample of 2129 patients (see Figure 6) for whom to estimate the prevalence
of TRD.NIHR Journals Library www.journalslibrary.nihr.ac.uk
Patients on antidepressants identified through search of
GP computerised records
(n = 15,379)
Total number of letters of invitations
(n = 10,629)
Patients excluded by GP
(n = 4750)
Responders to invitation
(n = 4552)
Non-responders to invitation 
(n = 6077)
Declined further contact 
 (n = 1643)
Agreed to further contact and screening
questionnaire sent
(n = 2909)
Non-responders to questionnaire
(n = 428)
Declined to complete
questionnaire
(n = 42)
Missing data (data not complete on one or
more measures)
(n = 122)
• Dose/duration
• Adherence
• BDI-II
n = 29
n = 79
n = 19
Returned the questionnaire 
(n = 2439)
Complete questionnaire data
(n = 2317)
Adequate dose/duration of medication   
(n = 2129)
 Inadequate dose/duration of
medication
(n= 188)
FIGURE 6 Flow chart of the recruitment process and number of participants with data for estimating the prevalence
of TRD.
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112Data on age and gender were available for most of those who were mailed an invitation and were
compared for participants and non-participants (those who did not respond to the invitation, n = 6077;
and those who responded but who declined to participate, n = 1643). There were no differences in age
between those who returned a completed questionnaire (participants) and those who did not (Table 68).
However, women were more likely to participate than men (see Table 68).TABLE 68 Comparison of age and gender for participants and non-participants of the CoBalT study
Characteristic
Participants, n = 2909 Non-participants, n = 7720
p-valuena Mean SD na Mean SD
Age 2746 48.2 13.5 7375 47.8 13.6
0.13
na n % na n %
Gender 2821 2020 71.6 7580 5166 68.2 < 0.001
a Data on age and gender were not available for all.Prevalence of treatment-resistant depression
Among the 2129 patients who had been prescribed an adequate dose of antidepressant medication
for at least 6 weeks, 1635 (77%, 95% CI 75% to 79%) had a BDI-II score of ≥ 14. Overall, 55% met our
deﬁnition of TRD (Table 69). Twenty-two per cent had a BDI-II score of ≥ 14 but had not adhered to
medication, and 23% had minimal symptoms of depression (BDI-II score of < 14) (see Table 69). Of
those with minimal symptoms, the majority [n = 401; 81% (95% CI 78% to 84%)] had adhered to
their medication.TABLE 69 Prevalence of TRD
Description of group n % 95% CIa
BDI ≥ 14 and adhered to medication (TRD) 1177 55.3 52.8 to 57.8
BDI ≥ 14 but had not adhered to medication 458 21.5 19.4 to 23.6
BDI < 14 (minimal symptoms) 494 23.2 20.9 to 25.5
a CIs have been adjusted for clustering by GP practice.Given the non-response to the study invitation and subsequently to the postal questionnaire, we examined
the impact on estimates of prevalence. The response rate (for the study invitation and screening
questionnaire) varied between 8% and 50% for the 73 practices. Response rate was negatively correlated
with prevalence of TRD (Figure 7) and positively correlated with prevalence of minimal depressive
symptoms (BDI-II score of < 14) (Table 70) for the 73 practices. However, estimates of prevalence weighted
for non-response differed little from the ﬁgures reported above [weighted prevalence of TRD: 54.7%
(95% CI 52.2% to 57.2%); non-adherers: 21.6% (95% CI 19.5% to 23.7%); minimal symptoms: 23.7%
(95% CI 21.4% to 26.0%)].TABLE 70 Correlation between invitation/questionnaire response rate, and prevalence of TRD, non-adherers and
those with minimal symptoms for the 73 general practices
Practice prevalence of:
Response rate
Invitation Questionnaire
TRD –0.29 –0.43
Not adhering to medication –0.04 0.19
Having minimal symptoms 0.38 0.31
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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FIGURE 7 Prevalence of TRD against response to the postal screening questionnaire for each of the 73 GP practices
[weighted according to number of responses (the size of the dot in the graph represents the number of responses per
practice: the larger the dot, the greater the number of responses)].
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Among those with TRD, SSRIs were the most common type of antidepressants taken (79%) (Table 71). The
two most common medications were citalopram and ﬂuoxetine. Together they accounted for 67% of all
antidepressants prescribed, in line with prescribing ﬁgures for England for 2011.5 Most patients were
taking one antidepressant (monotherapy), with < 2% of those with TRD receiving combined treatment.
Augmented antidepressant treatment was very rare (see Table 71). A further 57 patients were taking a
second antidepressant medication but at a dose below our deﬁnition of ‘adequate’.113
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TABLE 71 Prescribed antidepressant medication among patients with TRD
Antidepressant Dose (mg) Class n % Percentage of ADs issued in England in 2011a
Citalopram 20–80 SSRI 448 38.0 28.9
Fluoxetine 20–80 SSRI 334 28.3 11.8
Venlafaxine 75–450 SNRI 93 7.9 5.9
Mirtazapine 30–60 Other 82 6.9 8.3
Paroxetine 20–60 SSRI 73 6.2 3.3
Sertraline 100–400 SSRI 39 3.3 7.8
Escitalopram 10–40 SSRI 25 2.1 2.6
Lofepramine 140–350 TCA 24 2.0 0.7
Dosulepin 150–225 TCA 9 0.8 3.3
Trazodone 150–300 TCA related 8 0.7 2.1
Duloxetine 60–90 SNRI 8 0.7 1.7
Amitriptyline 150–200 TCA 6 0.5 20.5
Reboxetine 8–12 NARI 3 0.3 0.09
Clomipramine 250 TCA 1 0.1 0.7
Imipramine 150 TCA 1 0.1 0.4
Moclobemide 600 MAOI 1 0.1 0.04
Trimipramine 150 TCA 1 0.1 0.2
Combined AD treatmentb 19 1.6
Augmented AD treatmentc 2 0.2
MAOI, monoamine oxidase inhibitor.
a Data taken from prescribing data for England for 2011: www.ic.nhs.uk/webﬁles/publications/007_Primary_Care/
Prescribing/PCA_ENG_2011/PrescriptionCostAnalysis2011_report.pdf.
b Combined treatment: patients taking two antidepressant medications at an adequate dose.
c Augmented treatment: patients taking another non-antidepressant medication along with their antidepressant.
THE PREVALENCE OF TREATMENT-RESISTANT DEPRESSION IN PRIMARY CARE
114Characteristics of patients with treatment-resistant depression
Sociodemographic and clinical variables were compared for those with TRD, for those who had signiﬁcant
depressive symptoms but who had not adhered to their medication (not adherent) and for those with
minimal symptoms (Table 72). Differences were evident for a number of variables but tended to reﬂect
differences between those with minimal symptoms compared with the other two groups. For example,
those with minimal symptoms were more likely to be married, working (full/part time) and were less likely
to be living in rented accommodation or experiencing ﬁnancial difﬁculty than the other two groups
(see Table 72). Almost 70% of patients had been taking their current antidepressant for > 12 months. This
was a consistent ﬁnding among the three groups of patients described: those with TRD (67.2%); those
non-adherent to their antidepressants (67.2%); and those with minimal symptoms (71.9%) (see Table 72).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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THE PREVALENCE OF TREATMENT-RESISTANT DEPRESSION IN PRIMARY CARE
116DiscussionSummary
More than three-quarters of primary care patients taking antidepressants for at least 6 weeks had
signiﬁcant residual depressive symptoms. Fifty-ﬁve per cent of patients who had taken an adequate dose
of antidepressant medication for at least 6 weeks were classiﬁed as having TRD, clearly showing that
inadequate response to antidepressant medication is an important problem in UK primary care.
Most of these patients (70%) reported having taken their current medication for > 12 months. This ﬁnding
highlights the chronic nature of depression among many of those treated in primary care, and gives rise to
concern about the systematic reassessment and treatment of those on long-term antidepressant therapy.
The frequency of the different types of antidepressant taken by those with TRD, in the main, reﬂected
national prescribing data for England.5 Amitriptyline was frequently prescribed at low doses that were not
regarded as an effective therapeutic dose for depression, which accounted for the lower ranking of this
medication among those with TRD in our sample. Venlafaxine was slightly more frequently used compared
with national prescribing data,5 suggesting that GPs may have initially prescribed an SSRI in line with NICE
recommendations for the treatment of depression, and switched to venlafaxine as an alternative because
of a lack of response.Strengths and limitations
We used data from the recruitment phase of the CoBalT RCT based in UK primary care. The large number
of practices covering urban, rural and semi-rural settings across the three centres (Bristol, Exeter and
Glasgow) has enabled us to estimate a ﬁgure for the prevalence of TRD in UK primary care with a high
degree of precision.
Unlike other studies such as STAR*D,127 we distinguished between non-response and non-adherence to
medication in deﬁning our treatment-resistant group. Non-adherence to medication is known to be
common in depressed patients130 but is difﬁcult to measure. Other studies have relied upon clinician report
to gather this information,128 but we know that patients ﬁnd it difﬁcult to be honest with health
professionals about whether they are taking their medication as prescribed.131 We relied upon a self-report
measure of medication use,48 which has been validated against electronic monitoring bottles.49
There are a number of limitations to our study. Only 43% of those invited to participate responded to the
letter from the GP, with 54% subsequently returning a completed postal questionnaire. Our estimates of
prevalence may be biased by this non-response. However, there was no difference in estimates of
prevalence that were or were not weighted for non-response by practice, suggesting that our estimates
were robust.
Our data are cross-sectional and we acknowledge that individuals may have experienced a change in their
depressive symptoms between the initial prescription and the time that the questionnaire was completed.
A longitudinal study of patients newly starting an antidepressant could help make ﬁner distinctions in
terms of deﬁning treatment responders, partial responders and non-responders. Furthermore, although the
BDI-II measures severity of depressive symptoms, it is not a diagnostic instrument. Nonetheless, those with
TRD had a mean BDI-II score of 29.1, which is indicative of severe depression.
As highlighted earlier, there are many deﬁnitions of treatment resistance. The deﬁnition of TRD used in the
CoBalT study is pragmatic and directly relevant to UK primary care, given the uncertainty about what
treatments to recommend to those who do not respond after 4–6 weeks of antidepressant medication.13NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Reports suggest that the management of TRD is an area that has been poorly investigated, with few
robust data to guide treatment.14,132,133 Although non-response to antidepressants is frequently cited as a
key issue in the management of patients with depression, few studies have quantiﬁed the magnitude of
this problem and, prior to this study, no evidence has existed for UK primary care. Estimates of the
prevalence of TRD range from 30%127 to 50%.128 Our estimate of 55% is at the upper end of this range.
It is difﬁcult to compare the estimates of prevalence between studies directly because of differing
deﬁnitions of treatment resistance, including whether or not diagnostic criteria have been applied to
identify those with depression.128 Nonetheless, our data clearly demonstrate that TRD represents a
signiﬁcant burden for patients and primary care clinicians in the UK.Clinical implications and directions for future research
Based on our data, the scale of inadequate response to antidepressants in UK primary care is worrying,
particularly in the context of the continued increase in prescribing. Little is known about the treatment
received by patients with depression after an antidepressant has been prescribed. It is not clear what
constitutes usual care. Although the Quality Outcomes Framework has incentivised primary care clinicians
to record the severity of depressive symptoms at the start of treatment (DEP6) and again within 12 weeks
(DEP7), no incentives are in place with respect to longer-term management.134 A large number of patients
may receive long-term antidepressants without being adequately assessed for treatment response. Our
data suggest that the NICE guidelines13 for sequencing treatments after initial inadequate response are not
widely followed, as there is very little evidence in our sample of combining or augmenting antidepressant
treatments.
Given the lack of motivation that is common among depressed patients, it has been suggested that a
more proactive clinician-led approach to the management of this patient population could be of beneﬁt.135
We would urge repeated monitoring of symptoms, together with recording of medication adherence, at
regular reviews. Such an approach may help identify those patients whose symptoms have not responded
to medication at an earlier stage when it might be possible to intervene to prevent chronicity and to
improve patient outcome.117
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therapy on depression outcomesIntroductionThe theory underpinning CBT posits that dysfunctional attitudes (also referred to as ‘rules for living’ or
conditional beliefs) are a risk factor for both the onset and maintenance of depression.62,63 When a person
experiences an event (e.g. their partner threatens to leave) that is congruent with a dysfunctional attitude
(e.g. ‘If I am not in a relationship, I am unlovable’) this activates the belief and triggers the onset of, and
then exacerbates, depression. CBT focuses on behavioural activation and identifying/challenging negative
automatic thoughts to provide symptom relief. As therapy progresses, the emphasis switches to identifying
and modifying the dysfunctional attitudes (or ‘rules for living’) that underpin the longer-term risk of
depression as a way of ensuring longer-term resilience.62,64 However, although there has been much
work on dysfunctional attitudes in depression, there is little evidence that changes in dysfunctional
attitudes are speciﬁc to CBT.136 Others have suggested that CBT and other psychotherapies involve a
shift in how the individual relates to negative thoughts, such that they relate these thoughts in a different
way (a ‘decentring’ approach).137,138 Rather than viewing such thoughts as a reﬂection of reality or a
representation of themselves, they learn to see these thoughts as mental events (otherwise referred to as
increased metacognitive awareness). These arguments suggest that changes in dysfunctional attitudes
or metacognitive awareness mediate some or all of the therapeutic beneﬁt of CBT.
Increasingly in the context of pragmatic trials, we are interested in establishing the extent to which proposed
mediators, such as dysfunctional attitudes, underpin the effects of treatments, such as CBT, on health
outcomes, such as depressive symptoms. Based on such knowledge, it may then be possible to reﬁne
interventions to improve efﬁcacy and ultimately patient outcomes.139 To date, although a number of RCTs
have examined how CBT works, there is little evidence that cognitive factors, such as dysfunctional attitudes,
act as mediators.140,141 Moreover, a number of studies have shown that changes in cognitive factors are not
speciﬁc to CBT interventions [e.g. also being seen in patients receiving pharmacotherapy,141,142 with some
attributing such non-speciﬁc effects as being a consequence (rather than cause) of treatment143].
Much of the previous work in this area used the Baron and Kenny144 approach to mediation, the
limitations of which are now well recognised,145 and others have proposed modiﬁed criteria or guidelines
for identifying mediators139,146,147 that can be applied using structural equation modelling.139 Nonetheless,
there are difﬁculties in establishing that a factor is a mediator on the causal pathway between intervention
and outcome, even when data from a RCT are available. The key difﬁculty is that both the proposed
mediator and outcome act after the point of random allocation, and so the observed association between
the two can be subject to ‘hidden confounding’. The commonly used structural equation modelling
approach to evaluating potential mediators does not address this possible confounding. More recent
developments in the ﬁeld are based on the ‘causal inference approach’. These include the potential
outcomes framework148,149 and the use of instrumental variable methods150 but the latter is the subject of
ongoing development.
In this chapter we analyse data collected in the CoBalT trial, using the structural equation and potential
outcomes approaches, to investigate whether or not dysfunctional attitudes and metacognitive awareness
mediate the effect of CBT on depression outcomes. Therapists in the CoBalT trial used the seminal CBT for
depression manuals62,63 and elaborations designed to address treatment resistance.64 The latter manual
emphasises the cognitive elements of treatment, including focusing on the dysfunctional attitudes. Hence,
such mediators may be more relevant in this trial than in prior studies of CBT for less chronic depression.119
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MEDIATED EFFECT OF COGNITIVE BEHAVIOURAL THERAPY ON DEPRESSION OUTCOMES
120This chapter will ﬁrst describe the background to causal inference with reference to the original criteria put
forward by Baron and Kenny,144 before proceeding to describe the potential outcomes model that will also
be used in these analyses.Causality and mediation analysis
Causal inference is a key objective in most scientiﬁc research where RCTs are considered the gold standard
for estimating the effectiveness of interventions.151 Randomisation is crucial for ensuring comparable
groups (intervention and comparator) to obtain causal estimates by eliminating selection bias and
minimising confounding. Although pragmatic trials evaluate the effectiveness of an intervention under
‘real-life’ conditions, in practice we are often interested in efﬁcacy as a measure of the beneﬁt under ‘ideal
conditions’ as well as how the intervention works.
Examining a cause–effect process may provide better information towards understanding the mechanisms
connecting an intervention with the outcome, as in the case of the CoBalT trial. The mechanisms,
measured as intervening variables on a causal pathway linking intervention and outcome, are commonly
referred to as mediators. With regards to the CBT intervention delivered in the CoBalT trial, the speciﬁc
variables of interest are measures of dysfunctional attitudes and metacognitive awareness. Mediation
analysis aims to establish the role of such potential mechanisms that connect interventions and outcomes.
In essence, although causality reveals if a relationship exists, mediation analysis goes further to explain the
nature (the ‘how’) of the causal relationship.
In the absence of mediation, a simple model (Figure 8a) relates intervention Z (CBT) to outcome
Y (depression). However, a simple mediation model (see Figure 8b) may be schematically presented as
a mediator M (e.g. dysfunctional attitudes) in the causal path between intervention Z (CBT) and outcome
Y (depression).
The seminal approach originally proposed by Baron and Kenny144 used the simple mediation model
schema above to develop a basic approach to testing for empirical evidence of mediation using a set of
related (structural) equations to ﬁt three regression models:
M ¼ α1 þ aZ þ ε1 ð1Þ
Y ¼ α2 þ cZ þ ε2 ð2Þ
Y ¼ α3 þ c,Z þ bM þ ε3 ð3Þ(a)
c
YZ
(b) a b
c’
M
Z Y
FIGURE 8 The total effect of Z on Y (a); simple mediation model (b).
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regression coefﬁcients that provide the magnitudes of the associations between the three key variables.
The Baron and Kenny framework144 proposed three necessary and sufﬁcient conditions for evidence of
mediation – a signiﬁcant association between:
1. the intervention and the mediator, i.e. a statistically signiﬁcant regression coefﬁcient a in equation (1)
2. the intervention and the outcome, i.e. a statistically signiﬁcant regression coefﬁcient c in equation (2)
3. the mediator and the outcome, and also a signiﬁcant association between the intervention and the
outcome, i.e. statistically signiﬁcant regression coefﬁcients b and c′ in equation (3).
In regression analysis terminology, a statistically signiﬁcant value of c in equation (2) implies a direct
association between intervention and outcome, whereas a statistically signiﬁcant c′ in equation (3) implies
a direct association between intervention and outcome that is independent of mediation (association not
mediated by M). On the other hand, b captures the strength and/or direction of association between
mediator and outcome while adjusting for intervention.
Total, direct and indirect effects
As illustrated above, mediation is an intermediate step in the causal pathway between intervention and
outcome. The relationships between the three variables of interest (intervention, mediator and outcome)indirectmay be better understood by decomposing the cause–effect relationship into total, direct and
effects. To help visualise the decomposition, we reproduce the basic mediation schema (Figure 9).
We observe that a statistically non-signiﬁcant regression coefﬁcient for a or b implies no mediation. For the
CoBalT trial such a scenario would imply no association between CBT and dysfunctional attitudes or no
association between dysfunctional attitudes and depression. As the CoBalT trial showed CBT to be an
effective treatment, it is plausible to consider that the partial mediation-provided conditions (1)–(3) above
hold. We can then rule out the possibility of a perfect mediation, which can be inferred only if, in addition
to conditions (1)–(3), there was no direct association between intervention and outcome.
In the presence of no mediation, c provides the magnitude of total effect of intervention on outcome.
On the other hand c
,
provides the direct effect of intervention on outcome after adjusting for the
potential mediator. The product ab captures the indirect effect of intervention on outcome through
the mediator. Hence, if all three variables are observed then c = c
,
+ ab so that the indirect effect ab
(mediation) is obtainable as the difference between the total (c) and direct effect (c
,
) of intervention on
outcome: ab = c – c
,
.a b
C’
C
Z
M
Y
FIGURE 9 Simple mediation model.
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MEDIATED EFFECT OF COGNITIVE BEHAVIOURAL THERAPY ON DEPRESSION OUTCOMES
122However, the simple product rule cannot be extended to situations when either the mediator and/or
outcome are not continuous. But this may be addressed by standardising the estimates to help obtain the
proportion of effects mediated, i.e. rescaling using the SD of the underlying latent variable for the binary
variable.152 However, the resulting standardised indirect/mediation effect computed as a product of two
estimates may not be back transformed to make meaningful inference on individual estimates.
The seminal work by Baron and Kenny144 provided the foundation for empirical analysis of mediation.
Analysis using the Baron and Kenny method144 provides the magnitude of association between the
variables but fails to account for the order in which the variables occur, meaning that it is not possible to
make causal inferences. Temporality, which is an integral component of causal inference is also a deﬁning
concept in evaluating mediation, i.e. the mediator precedes the outcome as highlighted in the well-known
conceptual framework of mediation analysis.139 Recent advances in this ﬁeld are based on instrumental
variables methods150 and the potential outcomes framework.148 The latter method can be extended to
binary outcomes and has been implemented in a widely used statistical software package but has not, to
date, been used to examined mediators within the context of a pragmatic trial of CBT for depression. It is
this method that we adopt for the mediation analysis of the CoBalT data.
Potential outcomes framework
The potential outcomes framework is most easily explained using an example. If we consider the two-arm
CoBalT trial, then the potential outcome model presupposes that individuals under study have two
theoretical (i.e. potential) outcomes, one of which would be observed if they were randomised to the CBTusual careintervention (Y1) and the other one that would be observed if they were to be randomised to
(Y0). A causal estimate Y may then be deﬁned as the comparisons of the potential outcomes that would
have been observed under the two different exposures of units to treatments: Y = Y1 – Y0.
In our RCT set-up for CoBalT, in which Z denotes a randomisation indicator, such that Z = 1 indicates
assignment to CBT and Z = 0 assignment to usual care, each subject has two potential outcomes, Y1 and
Y0 (for outcome under CBT and usual care respectively), but at most, only one of the potential outcomes
can be realised and observed for any unit. The potential outcomes (for both Y1 and Y0) are generated from
the observed outcomes by comparison with the most similar values of other baseline characteristics. A
causal estimate is then obtained by comparing the potential outcomes that would have been observed
under different exposure of units to treatment.153 Most statistical software algorithms implementing
potential outcomes framework use matching to generate such variables. However, other methods like
propensity scores are also applicable.
Unlike in standard statistical practice that ordinarily compares two independent experimental units, causal
effects are obtained by comparing two different potential outcomes for the same experimental unit under
different treatment levels. But the fact that we can only observe one outcome and not both presents what
is often referred to as the ‘fundamental problem of causal inference’, which posits that we can never
know the individual-level causal effects.154 This predicament makes it impossible to make causal inference
without making assumptions, for example, by taking expectations over the whole population to provide an
average (aggregate) causal effect. However, most of these causal assumptions are not testable using
observed data and hence the validity of any causal inference is premised on the plausibility of its
considered assumptions.
Estimating mediation effects
A fundamental difference between analysis using observed outcomes (such as in Baron and Kenny;144
Kraemer et al.139) and potential outcomes in identifying mediators is that although the former focuses on
the observed mediator status, the latter approach focuses on the potential mediator status, which permitshe observedcausal interpretation. As mediator status and outcome are both realised post randomisation, t
association between them can be distorted by ‘hidden confounders’, such as contextual variables, which
promote high levels of mediator and outcome in the same individuals. Although they are generated post
randomisation, potential variables are not susceptible to selection bias because they are not affected byNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31the factors determining treatment actually received. As a result, adjustment using potential mediators
provides valid causal interpretation.
In the potential outcomes framework, the average causal mediated effects (ACMEs) can be deﬁned as the
mean difference in effect between two counterfactual states of a mediator, assuming no change in the
intervention. Similarly, the average direct effect (ADE) is the mean difference between two counterfactual
states of intervention, assuming no change in the mediator. In comparison with the Baron and Kenny
method,144 ADE may be viewed as an estimate of c’ [see equation (3)]. The ACME enables us to
understand the underlying causal mechanisms between an intervention and outcome via the mediator.
However, because the counterfactual states are not simultaneously observable, additional assumptions
must be made to allow ACME and ADE to be estimated without bias.
A deﬁning assumption for identifying ACME and ADE is the sequential ignorability assumption.149 First,
the treatment assignment is assumed to be unrelated to potential confounders, which is plausible in RCTs
owing to random allocation of treatment. Next, the observed mediator is assumed to be unrelated to
potential confounders once the actual treatment status and pre-treatment confounders are taken into
account. A violation of the latter assumption leads to correlation between the two resulting error terms
(residuals) from regression models ﬁtting mediator and outcome as outcomes, i.e. no correlation implies
the sequential ignorability assumption is valid.155 So given the crucial role of the (untestable) sequential
ignorability assumption, it is necessary to conduct a sensitivity analysis to examine the robustness of the
results for different degrees of violation of this key assumption.
Aims
The aim of this secondary analysis was to examine whether dysfunctional attitudes and metacognitive
awareness (measured at 6 months) are mediators of the effect of CBT on depression outcomes at
12 months in the CoBalT trial using a ‘causal inference’ approach.Methods
We used data from the CoBalT trial (described in Chapter 2) for these analyses.s. This
Outcomes at 12 months
The BDI-II46 score at 12 months post randomisation was used as the outcome for these analyse
outcome was analysed both as a continuous variable and as two binary variables denoting ‘response’
(primary outcome for the trial), which was deﬁned as at least a 50% reduction in depressive symptoms
compared with baseline, and ‘remission’ (BDI-II score of < 10).Mediators at 6 months
As outlined in the main description of the trial methods (see Chapter 2, Secondary outcomes), participants
in both groups were asked to complete the DAS and MAQ as part of the 6-month follow-up assessment.
We used a short version of the original 40-item DAS,68 the DAS-SF2, which was developed using itemearchersresponse theory as an efﬁcient method of capturing such data for more widespread use by res
and clinicians.58 The DAS-SF2 has been shown to be a valid and reliable measure of dysfunctional
attitudes.58 The measure of metacognitive awareness was developed to examine whether or not CBT
involves a shift in how the individual relates to their thoughts and has been shown to be associated a
greater likelihood of relapse in a RCT of CBT for residual depression.59 For both instruments, a total score
is generated (range 9–63), with higher scores indicating more dysfunctional attitudes or greater
metacognitive awareness. Scores on the DAS and MAQ at 6 months (as continuous variables) were
explored as potential mediators of the treatment effect.123
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124Statistical analysisn and Kenny
on of theBaron and Kenny method
To evaluate mediation for continuous BDI scores outcome, initially we ﬁtted the standard Baro
set of equations144 (see Causality and mediation analysis, above). For the binary outcome versi
Baron and Kenny method,144 the Stata command binary_mediation was used to compute the proportion
of mediated (indirect) effects. The program provides standardised coefﬁcients for both the linear and
the logistic models used. Although the binary_mediation command permits adjustment for multiple
mediators, it does not compute standard errors or CIs directly. Therefore, bootstrapping was performed to
determine the signiﬁcance of mediation effects and compute the proportion of the total
variance mediated.
Potential outcomes framework
The method of ‘potential outcomes’148 as implemented in the Stata statistical software156 will be used tommandestimate the ACME and ADE. Under the potential outcomes framework, we used the Stata co
medeff, with the medsens command used to conduct sensitivity analyses to explore violation of the key
assumption of sequential ignorability that permits valid causal inference.148,149 We speciﬁed ordinary
least-squares regression for the continuous BDI-II outcome as a check on the results obtained from the
Baron and Kenny method.144 We speciﬁed logistic regression for the binary outcomes. Of note, unlike the
binary_mediation command used to implement the Baron and Kenny method144 for the binary
outcomes, the medeff command does not have the option to adjust for multiple mediators. ADE and
ACME for binary outcomes are produced as standardised estimates, which may not be meaningfully
back-transformed to estimates of ORs or similar statistics. Therefore, our analysis will report the proportion
of total effects mediated and their corresponding 95% CIs.
All analyses adjusted for the stratiﬁcation and minimisation (design) variables (baseline BDI-II score, centre,
GP practice access to counselling, prior use of antidepressants and duration of depression) as well as the
baseline measure of the mediator (DAS or MAQ). The latter variable was included in the model to ensure
that the model examined the effect of change in the potential mediator from baseline to 6 months on
later depression outcome (measured at 12 months).
Resultss in each of
comes forA total of 469 patients were randomised into the CoBalT trial, with an equal number of patient
the two treatment arms. Tables 73–75 provide descriptive statistics summarising depression out
each treatment arm and mediator (dysfunctional attitudes scale and metacognitive awareness questionnaire)
scores at baseline, 6 and 12 months. On average, those in the usual-care group had higher BDI-II scores
than those who received the intervention over the duration of follow-up.
Descriptive statistics (see Tables 74 and 75) also show that both DAS and MAQ scores were similar at
baseline and reduced with time, more so for the intervention arm. Overall, the mean MAQ scores were
higher with corresponding smaller SDs compared with DAS scores.
There was moderate to strong correlation between the measures of dysfunctional attitudes, metacognitive
awareness and BDI-II scores across the study (Table 76).NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 73 Descriptive statistics of BDI-II scores over the duration of the study
Time point
Intervention Usual care
n Mean (SD) n Mean (SD)
Baseline 234 31.8 (10.5) 235 31.8 (10.9)
6 months 206 18.9 (14.2) 213 24.5 (13.1)
12 months 197 17.0 (14.0) 198 21.7 (12.9)
TABLE 74 Descriptive statistics for scores on dysfunctional attitudes scalea at baseline and over follow-up
Time point
Intervention Usual care
n Mean (SD) n Mean (SD)
Baseline 234 35.8 (11.0) 235 36.9 (10.6)
6 months 204 31.7 (11.4) 213 34.1 (11.6)
12 months 196 29.8 (12.4) 198 33.2 (10.9)
a Lower scores denote fewer dysfunctional attitudes.
TABLE 75 Descriptive statistics for scores on metacognitive awareness questionnairea at baseline and over follow-up
Time point
Intervention Usual care
n Mean (SD) n Mean (SD)
Baseline 233 37.5 (7.7) 235 37.4 (7.6)
6 months 204 42.8 (8.7) 213 40.0 (8.2)
12 months 196 44.2 (9.1) 198 40.7 (7.8)
a Higher scores denote greater metacognitive awareness.
TABLE 76 Correlation between measures of dysfunctional attitudes, metacognitive awareness and BDI-II scores over
the study (for n = 385 with data at all three time points)
Measure Baseline 6 months 12 months
DAS: MAQ –0.33 –0.40 –0.46
DAS: BDI-II 0.34 0.50 0.52
MAQ: BDI-II –0.23 –0.41 –0.50
Note: For DAS, higher scores indicate more dysfunctional attitudes; for MAQ, higher scores denote greater metacognitive
awareness; for BDI-II, higher scores indicate more depressive symptoms.
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126The Baron and Kenny approach to mediation
Beck Depression Inventory (second version) scores as a continuous outcome
We start by considering a continuous BDI-II score outcome to explore mediation using the standardventionBaron and Kenny144 set of equations. As expected, a linear regression of the effect of the inter
on depression outcome at 12 months [see Causality and mediation analysis, condition (ii), above]
demonstrated the effectiveness of the intervention. Those randomised to receive the intervention had, on
average, a BDI-II score that was 5 points lower at 12 months than those randomised to continue with
usual care (c = –4.96, 95% CI –7.33 to –2.59, p = 0.001).
The dysfunctional attitudes scale score at 6 months was also signiﬁcantly related to the intervention [see
Causality and mediation analysis, equation (1)], such that those who were allocated to CBT scored, on
average, 2 points lower on the DAS than those who continued with usual care (a = –1.96, 95% CI –3.82
to –0.10, p = 0.039). Although the effect of the intervention on BDI-II outcome at 12 months reduced
slightly after adjusting for dysfunctional attitudes measured at 6 months, the effect of the intervention
remained signiﬁcant (c
,
= –4.06, 95% CI –6.34 to –1.78, p = 0.001), indicating that there may be other
mediators of the intervention effect besides dysfunctional attitudes. Similarly, the association between DAS
and BDI-II scores at 12 months after adjusting for CBT was signiﬁcant (b = 0.39, 95% CI 0.27 to 0.51,
p = 0.001). As expected for continuous outcomes the results show that c = c
,
+ ab and we can conclude
that dysfunctional attitudes measured at 6 months mediated about 16% (ab/c) of the effect on the
intervention on depression outcome at 12 months (Table 77).
For comparison, results for metacognitive awareness as a potential mediator of the effect of the
intervention on depression are also given in Table 77 below. As would be predicted, a reversal in the
direction of effect was observed, for example the effect of intervention on MAQ at 6 months (a) is now
such that those who received the intervention scored, on average, 3 points higher on the MAQ than those
who continued with usual care (a = 2.98, 95% CI 1.50 to 4.47, p < 0.001), reﬂecting a positive outcome of
increased metacognitive awareness (as opposed to a reduction in dysfunctional attitudes seen previously).
After adjusting for the intervention, the effect of MAQ reduced BDI-II outcome by, on average, 0.4 points
(b = –0.43, 95% CI –0.58 to –0.28, p < 0.001). Overall, a higher proportion of intervention effect was
mediated by MAQ (25%) (see Table 77).TABLE 77 Continuous BDI-II scores outcome: mediated effects owing to DAS and MAQ scores
Mediator Total effects (c) Direct effect (c′)
Intervention-
mediator (a)
Mediator-
outcome (b)
Proportion
mediated,
% (ab/c)
DAS –4.96 (–7.33 to –2.59) –4.06 (–6.34 to –1.78) –1.96 (–3.82 to –0.10) 0.39 (0.27 to 0.51) 16
MAQ –5.13 (–7.48 to –2.78) –3.80 (–6.14 to –1.47) 2.98 (1.50 to 4.47) –0.43 (–0.58, –0.28) 25Beck Depression Inventory (second version) scores as binary outcomes of
response and remissionﬁcant.
nse’ andResults from bootstrapping showed that both direct and indirect effects were statistically signi
Table 78 shows the proportion of total mediated effects for the two binary outcomes of ‘respo
‘remission’ for the two postulated mediators (DAS and MAQ).In general, the proportion of total effect of the intervention mediated was slightly higher for the response
outcome compared with the remission outcome, although such effects were only marginal. Adjusting for
both mediators resulted in greater proportion of mediated effects than for individual mediators. However,
the higher proportion of mediated effect in the model including both mediators was estimated with less
precision (higher proportion of variance).NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 78 Binary outcomes: proportion of total mediated effects and variances
Binary outcome
DAS:
proportion of total
mediated (%)
MAQ:
proportion of total
mediated (%)
DAS +MAQ:
proportion of total
mediated (%)
Effects Variance Effects Variance Effects Variance
Response 20 12 23 12 31 19
Remission 21 12 19 11 28 15
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31Estimating average causal mediation effects and average direct effects
under the potential outcomes frameworker the
at 6 months
BTContinuous outcome and continuous mediators
Mediation analysis of linear models (continuous outcomes) for both mediator and outcome und
potential outcomes framework produced a mean average direct effect (ADE) for DAS measured
of –4.05 and ACME of –1.23 (Table 79). The estimate of the ACME indicated that the effect of C
intervention that was mediated by DAS equated, on average, to a reduction of 1 point in the BDI-II score.
This compares with a total treatment effect of, on average, a reduction of 5 points in the BDI-II score (total
effect). Hence, overall, the proportion of the total effect of the intervention mediated by dysfunctional
attitudes measured at 6 months was 24% (see Table 79).
We observe that, on average, the results for total effect and ADE are similar to the total effect c and the
direct effect of CBT on BDI-II scores c
,
, respectively, as obtained from the standard Baron and Kenny
method144 above. As expected for linear models, under the sequential ignorability assumption, the ACME
estimate, on average, approximates the product of effects ab (i.e. ACME = –1.23, ≈ –3.18 × 0.39).
A sensitivity analysis of the results suggested that the sequential ignorability assumption would be violated
(ACME≠0) in the presence of a positive correlation of 0.31 between the two error terms for regression
models ﬁtting dysfunctional attitudes and BDI-II scores as outcomes. This may be interpreted to mean that
the presence of hidden confounders, which are moderately correlated to both BDI-II scores and DAS,
would confound the causal pathway by introducing dependence in the two error terms.
Table 79 also gives the corresponding results for the MAQ as the postulated mediator. This shows a
slightly larger ACME of –1.50 compared with an ACME of –1.23 for DAS as the mediator. A slightly higher
proportion of the effect of the intervention was mediated by MAQ at 28% compared with DAS (24%),
although the CIs for the proportion of mediated effect for MAQ were relatively wider (see Table 79).
A sensitivity analysis suggested that only a modest degree of ‘hidden’ confounding (a negative correlation
of –0.27 between the error terms for regression models with MAQ and BDI-II scores as outcomes) would
result in the sequential ignorability assumption being violated.TABLE 79 Mediated effects under potential (continuous) outcomes framework
Outcome at
12 months
Mediator
measured at
6 months ADE (95% CI) ACME (95% CI) Total effect (95% CI)
Proportion
of effect
mediated, %
(95% CI)
BDI-II score
(continuous)
DAS –4.05 (–6.33 to –1.84) –1.23 (–2.18 to –0.48) –5.29 (–7.69 to –3.02) 24 (16 to 41)
MAQ –3.80 (–6.12 to –1.54) –1.50 (–2.39 to –0.76) –5.30 (–7.58 to –2.88) 28 (20 to 52)
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128Binary depression outcomes (response and remission)
and continuous mediators
A mediation analysis considering a binary ‘response’ outcome (at least a 50% reduction in BDI-II scoreoportion of
, the averagerelative to baseline) and continuous dysfunctional attitudes (mediator) produced an average pr
total effects mediated of 19% (Table 80). For a continuous metacognitive awareness mediator
proportion of total effects mediated was slightly higher, 23%, although this estimate was accompanied by
a wider 95% CI (see Table 80).
In general, for a binary ‘response’ outcome, the proportion of total mediated effects were slightly
higher for MAQ compared with DAS albeit with a corresponding wider 95% CI. On the other hand, the
proportion of total mediated effects were, on average, similar for the remission outcome regardless of
the mediator considered (MAQ or DAS). Sensitivity analyses for the binary outcomes were not conducted
as the results may not be meaningfully interpreted, as the resulting correlation values are based on the
standardised coefﬁcients from both linear and logistic models.TABLE 80 Binary outcomes: proportion of total mediated effects
Binary outcome
DAS: proportion of total
mediated effects, % (95% CI)
MAQ: proportion of total
mediated effects, % (95% CI)
Response 19 (14 to 30) 23 (17 to 38)
Remission 20 (15 to 32) 19 (14 to 32)Discussions was
. ThisOur results suggest that approximately 20–25% of the treatment effect observed at 12 month
mediated through changes in dysfunctional attitudes or metacognitive awareness at 6 months
equated, on average, to a one-point reduction in the difference in mean BDI-II scores between treatment
groups. However, these ﬁndings need to be interpreted with caution as sensitivity analyses suggested that
any hidden confounders with a fairly weak correlation (rho 0.3) with both the mediator (scores on the DAS
or MAQ) and outcome (depressive symptoms on the BDI-II) would be an alternative explanation of our
observed results.
We used the potential outcomes framework, which is part of the ‘causal inference approach’, to examine
mediated treatment effects. To the best of our knowledge, this is the ﬁrst time that this methodology has
been used to examine mediators within the context of a pragmatic trial of CBT for depression. This
methodology explicitly permits testing of the assumptions required for making valid causal inferences.
Strengths and limitations
We used data from a large multicentre RCT based in UK primary care to examine potential mediators oft has beenthe observed treatment effect. When examining mediated treatment effects, one key issue tha
highlighted139,146,157 is ensuring the temporal sequencing of the intervention, mediator and outcome. The
Baron and Kenny approach144 does not incorporate information about the temporal sequence of variables
and hence relies on the study design to establish this sequence in order to permit causal inference. For the
analyses conducted using the potential outcomes framework, a priori, we speciﬁed our outcome as
depressive symptoms at 12 months and our mediators as scores on the DAS and MAQ at 6 months post
randomisation. We also adjusted for the baseline score of the mediator (DAS or MAQ) in these models in
order to ensure that we focused on change in the postulated mediator that preceded the depression
outcome measured at 12 months. However, it proved difﬁcult to be certain about the temporal sequence
of changes in the proposed mediators and the outcome measure.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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correlated with depressive symptoms,158 and data from the CoBalT trial supported this (rho 0.34 to 0.52).
In the context of a CBT intervention, which takes place over a period of several months, the therapist would
hope to observe a shift in the postulated mediator (e.g. dysfunctional attitudes) during the course of therapy
and simultaneously to observe a decrease in depressive symptoms. Therefore, although it is possible to
use data collected at speciﬁed time points in order, at face value, to satisfy the conditions of temporality,
it is possible that the changes in mediator and outcome will be occurring more closely in time, and even
co-varying depressive symptoms will not truly address this issue. In the case of the CoBalT trial, we also need
to acknowledge the fact that the treatment effect was already observed at the 6-month time point, making
it more difﬁcult to ensure temporal separation.
A strength of the potential outcomes framework is that it uses counterfactuals in order to identify causal
effects. Hence the model compares the observed outcome with that which would have been observed had
the individual been randomly allocated to the other treatment group (= potential outcome). Such ‘potential
outcomes’ are not susceptible to selection bias because they are not affected by factors determining actual
treatment received, unlike approaches that rely solely on observed outcomes.139,144
Previous approaches to testing for mediated effects (e.g. Baron and Kenny;144 Kraemer et al.139) implicitly
assume that there is no ‘hidden’ (unmeasured) confounding between the observed mediator and outcome
but do not address this issue.159 Although the same issue of ‘hidden confounding’ applies when estimating
the ACME under the potential outcomes framework, the latter approach makes explicit this assumption
and permits sensitivity analyses to test the plausibility of this assumption. In our study, such sensitivity
analyses (for the mediated effects of DAS and MAQ) suggested that a relatively modest correlation
(rho 0.3) between error terms for the models with mediator and BDI-II score as the outcome would mean
that this assumption was violated and hence that ‘hidden’ confounding could explain the mediated effect.
Such a formal test of this assumption is key in enabling researchers to draw robust conclusions regarding
potential mediated effects.
Other methodological issues
Implementation of the Baron and Kenny approach144 for binary outcomes (binary_mediation) permitsediated byadjustment for multiple mediators, and we found that 20–25% of the treatment effect was m
either dysfunctional attitudes or metacognitive awareness. When the effect of both mediators was
modelled simultaneously, a slightly higher percentage (approximately 30%) of the treatment effect was
explained. Although, on technical grounds, it is currently not possible within the potential outcomes
framework to replicate this ﬁnding, this multivariable mediator model provides only weak evidence that
both dysfunctional attitudes and metacognitive awareness independently contribute to explaining how
CBT works.
The modest increase in percentage of mediated effect for the model including both factors suggests that
there may be substantial overlap (or measurement error) in the constructs measured by the two instruments.
Scores on the scales measuring dysfunctional attitudes and metacognitive awareness were moderately
correlated (rho –0.33 to –0.46), as has been noted previously.59 This raises the question of how well we are
measuring the cognitive factors that are thought to result in the improvements in outcome seen following a
course of CBT. Although others have suggested that individual styles of responding to questionnaires can
also lead to correlation between questionnaire measures of quite different phenomena.160
We used a short version of the 40-item DAS,68 the DAS-SF2, which was developed using
item response theory as a valid and reliable approach to efﬁciently measuring dysfunctional attitudes.58
The measure of metacognitive awareness (MAQ) was developed to examine whether or not CBT involves a
shift in how the individual relates to their thoughts and was associated with greater likelihood of relapse in
a previous RCT of CBT for residual depression.59 Nonetheless, there is likely to be substantial error in our
measurement of the mediator but this issue is difﬁcult to resolve given the nature of the mediators
of interest.129
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130Causal inference approaches to mediation analysis make explicit the assumption of no ‘hidden’
confounding that has, so far, been implicit but not addressed by many key papers in this ﬁeld.139,144,146,147
However, to date, there has been little discussion about what such confounding factors might be. A
greater understanding of these confounders, in terms of both identifying and measuring such factors,
would help us to draw more robust conclusions when interpreting the results of sensitivity analyses,
particularly when the mediated effects are modest. Methods have been developed to allow for hidden
confounding (using instrumental variables);150 however, these cannot easily be applied using standard
statistical software.
Conclusions
Increasingly, in the context of pragmatic trials, we are interested in whether or not a treatment is effective
and how it works. Recent methodological developments have permitted us to begin to unravel the ‘how’in cognitiveby using approaches based on causal inference. Using such methods, we found that changes
variables that we studied (dysfunctional attitudes and metacognitive awareness) accounted for about
20–25% of the observed treatment effect of the CBT intervention. However, sensitivity analyses showed
that only a relatively modest degree of ‘hidden’ (unmeasured) confounding between the mediator and
outcome would explain the mediated effect. Furthermore, when the proposed mediators are correlated, as
are dysfunctional attitudes and depressive symptoms, it is very difﬁcult to establish the temporal order of
change in the different variables, leaving conclusions susceptible to ‘reverse causality’. This reinforces the
view140,141 that there is little robust evidence for the role of cognitive factors as the mechanism through
which CBT works.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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cognitive behavioural therapyIntroduction
Clinical problem
Depression is a major contributor to the global burden of disease and is projected to be the leading
cause of disability in high-income countries by 2030.161 There is good evidence that CBT is an effective
treatment in previously untreated episodes of depression.162,163 However, there is considerable variation in
patient response to CBT, with signiﬁcant proportions responding either not at all or only partially. It is
therefore clinically useful to identify which patients will respond well to which treatments. Reliable
evidence informing this issue remains elusive, however, and clinicians often decide which patients to refer
to which treatment, based on implicit beliefs about patient suitability.164 In line with the current drive
towards stratiﬁed medicine that aims to target interventions at subgroups of patients who are likely to
respond,165,166 research is needed to identify reliable moderators or effect modiﬁers of treatment response.
It is important to distinguish between predictors and moderators. Predictors are prognostic factors
associated with disease outcomes irrespective of treatment, whereas moderators or effect modiﬁers are
associated with different treatment responses.139 In other words, a moderator will lead to a smaller or
larger difference between active and comparator groups. Understanding of potential moderators is
clinically useful as this would enable clinicians to base treatment choices on the individual’s likelihood of
beneﬁting from a given treatment. A variable is established as a moderator by testing for interactions
between that variable and two or more treatment options, ideally within the context of a controlled
trial.167 Studies designed speciﬁcally to test for interactions are large, expensive, and therefore rare.
Using existing data from good-quality and well-controlled clinical trials is an efﬁcient and cost-effective
alternative.168 Although such secondary analyses suffer from low statistical power, they are prone to
false-positive ﬁndings owing to multiple testing. Caution is therefore required when interpreting ﬁndings
from a single study. Consistent ﬁndings across studies are required before we can consider moderators as
clinically informative and, ideally, the ﬁeld should aim for meta-analyses of randomised studies using
individual patient data to achieve sufﬁcient statistical power.169
To date, studies reporting moderators of response to CBT in controlled trials have used small sample
sizes, randomising fewer than 63 patients per CBT arm,170–174 or have compared CBT to antidepressant
treatment,172,173 or have focused on adolescent or elderly populations.175–177 With such small sample
sizes these studies were almost certainly underpowered,167 and although understanding which of
two treatment options is likely to produce the best outcomes is important, antidepressants and CBT are
often prescribed together in practice. In most health services, antidepressants are widely available and
access to psychotherapy is limited. CBT is often reserved for those patients who have not responded to
antidepressant medication. We have previously reported effect modiﬁers for online CBT as an adjunct
to usual care, which included the option of antidepressants where prescribed, and just over half the
sample were taking antidepressants at baseline.168 However, to date, no research has examined
moderators of response to CBT as a ‘next-step’ treatment for primary care patients who have not
responded to antidepressants. Identifying reliable moderator variables in this population will inform
treatment options for depressed patients who do not respond to antidepressants. To date, the existing
literature in this area is based on studies of CBT in populations without TRD.131
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132Demographic factors
A few studies have examined whether or not demographic variables such as age, gender, education and
marital status are moderators of response to CBT in adults using appropriate tests for interaction in
controlled studies.168,172,174 In a stepwise regression, Fournier and colleagues172 found that being married,
unemployed or having more antecedent life events were associated with better response to CBT than
antidepressants. However, patients often receive CBT as an adjunct treatment in addition to antidepressant
medication. In a previous study168 with a sample twice the size of that reported by Fournier and
colleagues,172 we found that being separated, widowed or divorced or having fewer recent stressful life
events were associated with better responses to CBT compared with a waiting list control. In our study,
both arms received care as usual, including antidepressants if prescribed by the GP,168 which may account
for the discrepant ﬁndings. Furthermore, in contrast with Fournier et al.172 we divided our ‘unmarried’
participants, into ‘single’ or ‘separated/widowed/divorced’.168 Educational attainment and age were not
found to modify response to CBT.168,172Illness characteristics
To date, pre-treatment severity of depression is the most reliable moderator of response to CBT, with the
more severely depressed beneﬁting most.168,177–179 The evidence suggests that mild depression seems to
recover well irrespective of treatment, whereas severe depression gains most from CBT.168 However,
meta-analytic ﬁndings that rely on aggregate data179,178 and issues of scaling confuse these severity
ﬁndings, which may be an artefact of assessing outcomes using continuous measures. For example, a
5-point reduction in scores for someone whose baseline score was 50 is a proportionally smaller
improvement than 5 points for someone with a baseline score of 15.
There is no evidence that history, chronicity and type of depression are moderators of CBT response.168,172
The literature on comorbidity is also mixed. Patients in the STAR*D study with anxious depression who
were partial or non-responders to citalopram responded less well to either CBT or an alternative
antidepressant as a second-line treatment but there was no evidence for effect modiﬁcation.171 Asarnow
et al.180 identiﬁed comorbidity, including anxiety, as a moderator, with increased comorbidity associated
with increased response to combined CBT and antidepressants relative to antidepressants alone. However,
anxiety did not modify response to CBT in a study of depressed adolescents.175Personality traits, cognitions and psychological mindedness
Assessing individuals’ suitability for therapy is an important part of clinical practice, which often focuses
on interpersonal skills, personality and psychological mindedness.164 The lack of clear evidence of effect
modiﬁcation from appropriately controlled studies, however, illustrates that this practice is not evidence
based. Indeed, few studies have investigated these variables as moderators. To date, there is no evidence
that the personality trait neuroticism is a moderator.172,181 Patients with lower dysfunctional attitudes have
been found to do better in treatment arms (CBT and antidepressants) relative to pill placebo,174 whereas
other studies found no evidence for effect modiﬁcation.172,176 Clinicians believe it is important to
individualise treatment in line with particular patient presentations,182 and it seems likely that
cognitive-based therapies will be most effective in those with high levels of psychological awareness.
However, no studies have directly investigated metacognitive awareness as a moderator in an
appropriately controlled trial.Aims
The aim of the present analysis was to examine potential moderators of response to CBT given as an
adjunct to usual care that included pharmacotherapy as a ‘next-step’ treatment for patients whose
depression had not responded to treatment with antidepressants using data from the CoBalT trial. By
examining moderators in this group, we aim to inform decisions of whether or not to refer such patients
for CBT. We examined the modifying effects of demographic, life events, illness, comorbidity, personality
traits and cognitive variables.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Participants
This was a secondary analysis of data collected as part of the CoBalT trial, which has been described in
detail earlier (see Chapter 2). Brief details are outlined below.
Individuals were eligible for the trial if they were aged between 18 and 75 years, were currently taking
antidepressant medication and had been doing so at an adequate dose for at least 6 weeks, scored ≥ 14
on the BDI-II46 and met the ICD-10 criteria for depression (assessed using the CIS-R47,183). Participants were
randomised to one of two groups: (1) usual care or (2) CBT in addition to usual care. Treatment allocation
was stratiﬁed by recruitment centre and minimised by baseline BDI-II score, whether participant’s general
practice had a counsellor (yes/no), prior treatment with antidepressants (yes/no) and duration of their
current episode of depression (< 1 year; 1–2 years; ≥ 2 years) in order to achieve balance in these
important (design) variables across the treatment arms. Participants were followed up at intervals of
3 months for 1 year, with the BDI-II being completed at baseline, 6 and 12 months.Outcome
The outcome variable used in this secondary analysis was BDI-II score treated as a continuous variable at
6 and 12 months’ follow-up analysed as a repeated measure. We treated BDI-II score as a continuous
variable in this exploratory study to retain maximum power and ensure comparability of ﬁndings with
previous studies of moderation.168,172 This is in contrast with the main trial, where the primary outcome
was a binary variable representing a reduction in BDI-II score of at least 50% compared with baseline
(see Chapter 2, Primary outcome).Moderators
All data on potential moderators were collected as part of the baseline assessment, prior to randomisation.
The potential moderators were grouped into three general classes: (1) demographic and life factors;
(2) illness characteristics; and (3) personality, cognition and psychological mindedness.Demographic and life factors
Age was categorised into the following groups: (1) < 30 years; (2) 30–39 years; (3) 40–49 years;
and (4) > 49 years. Level of education was deﬁned as highest educational qualiﬁcation and categorised
as (1) ‘A-level/Higher Grade or above’; (2) ‘Other qualiﬁcations – GCSE or equivalent’; and (3) ‘No formal
qualiﬁcations’. A-levels are UK national qualiﬁcations that are generally taken at age 18 years, and
qualiﬁcations at this level are usually required for entry to university or higher education. GCSEs are also
national qualiﬁcations generally taken at age 16 years. Marital status was categorised as (1) ‘Single’;
(2) ‘Married/living as married’; and (3) ‘Separated/Widowed/Divorced’. Eight questions selected from the
Social and Readjustment Rating Scale,184 dealing with bereavement, separation or divorce, serious illness
or injury, victim of crime, problems with the police resulting in a court appearance, debt, disputes with
friends, relatives and/or neighbours and redundancy within the 6 months prior to randomisation were used
to measure adverse life events. The number of life events were summed and categorised as: (1) 0 events;
(2) 1–2 events; and (3) ≥ 3 events.Illness characteristics
Two measures of pre-treatment depression severity were measured: (1) baseline BDI-II score,
dichotomised as (i) severe (BDI-II score of > 28) and (ii) less severe (BDI-II score of < 29); and (2) baseline
CIS-R depression severity as a continuous variable, generated by summing the depression, depressive ideas,
fatigue, concentration and sleep sections of the CIS-R to produce a score ranging from 0 to 21. History of
depression was assessed in terms of the number of previous episodes of depression reported and
the duration of the current episode. Number of prior episodes of depression was categorised as
(1) 0–1 episodes; (2) 2–4 episodes; and (3) ≥ 5 episodes. The duration of the current episode of depression
was categorised as (1) < 1 year; (2) 1–2 years; and (3) > 2 years. Anxiety was measured as the score of133
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134the CIS-R anxiety section, range 0–4. PTSD was scored as an additive count of symptoms on the
PC-PTSD,51 with a possible range of 0–4. Physical comorbidity was investigated based on self-report of
participants’ other illnesses: (1) no chronic illness; (2) diabetes; (3) asthma; (4) arthritis; (5) heart disease;
(6) high blood pressure; (7) lung disease; (8) more than one of the above; and (9) none of the above
but other.Personality, cognition and psychological mindedness
Dysfunctional attitudes and metacognitive awareness were measured as continuous variables by summing
participants’ responses to the DAS-SF258 and MAQ59 respectively. Neuroticism was measured using the
neuroticism subscale of the ‘Big Five’ Inventory (BFI)52 and examined as a continuous variable as the mean
score of the eight test items.Statistical analysis
Treatment effect was deﬁned as the (adjusted) difference in mean BDI-II outcome score (as a continuous
variable) between the usual care and intervention arms. Separate repeated measures linear regression
models were carried out for each potential moderator. The model included an interaction term between
the moderator and treatment allocation, and adjusted for the design variables (including baseline BDI-II
score) and time. Further models, containing a three-way interaction (moderator by treatment allocation by
time) were carried out to investigate whether or not effect modiﬁcation varied across time. Repeated
measures regression models were also stratiﬁed by each level of the potential moderators to illustrate any
interaction effects.Results
Baseline characteristics
As reported earlier (see Table 19), the randomised groups were similar in terms of the stratiﬁcation and
minimisation variables (baseline BDI-II score, whether participant’s general practice had a counsellor, prior
treatment with antidepressants, and duration of their current episode of depression), age, gender and
demographic factors. The two groups were also similar in terms of the other potential treatment
moderators investigated (Table 81) that were not reported earlier.
Adherence to the intervention
The level of adherence to the intervention (deﬁned as the mean number of CBT sessions attended) were
generally very similar across the levels of the potential moderators investigated (Table 82).
Effect modification by potential moderators
The results obtained from the repeated measures regression models suggested that age was the only
variable for which there was any evidence of an interaction between a potential moderator and the
intervention, implying that age may modify the effectiveness of CBT. The interaction coefﬁcients became
more negative the higher the age category, suggesting that the higher the age category the greater the
beneﬁt of treatment (p-value for interaction effect = 0.012; Table 83). When age was used as a continuous
variable the conclusion was the same, evidence for greater treatment derived beneﬁt the older the subject
(interaction coefﬁcient = –0.20, 95% CI = –0.37 to –0.02, p = 0.027).
The regression analyses were also carried out separately at each level of the potential moderator variables
in order to illustrate the ﬁndings. The adjusted differences in mean BDI-II scores between the levels of the
investigated variables were similar, had overlapping CIs and did not show any clear trends except for age,
in which older individuals had a larger treatment response (see Tables 84 and 85). The three-way
treatment × moderator × time interactions suggested that there was no evidence that the relationships
between any of the investigated potential moderators and the intervention varied over time (Table 83).NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 81 Comparison of additional baseline characteristics between randomised groups
Characteristic Intervention (n = 234) Usual care (n = 235)
Demographic and life factors
Age (categories, years): n (%)
< 30 20 (8.6) 11 (4.7)
30–39 29 (12.4) 32 (13.6)
40–49 64 (27.4) 69 (29.4)
> 49 121 (51.7) 123 (52.3)
Life events in the past 6 months: n (%)
0 62 (26.5) 71 (30.2)
1–2 138 (59.0) 135 (57.5)
≥ 3 34 (14.5) 29 (12.3)
Illness characteristics
BDI severity group: n (%)
Less severe 102 (43.6) 103 (43.8)
Severe 132 (56.4) 132 (56.2)
CIS-R depression severity score: mean (SD) 14.8 (3.1) 14.9 (2.9)
Anxiety score: mean (SD) 2.5 (1.5) 2.4 (1.5)
PTSD score: mean (SD) 2.0 (1.5) 2.1 (1.5)
Illnesses: n (%)
No chronic illness 64 (27.4) 54 (23.0)
Diabetes 10 (4.3) 6 (2.6)
Asthma 11 (4.7) 17 (7.2)
Arthritis 19 (8.1) 19 (8.1)
Heart disease 5 (2.1) 4 (1.7)
High blood pressure 11 (4.7) 16 (6.8)
Lung disease 1 (0.4) 4 (1.7)
More than one of the above 35 (15) 44 (18.7)
None of the above but other 78 (33.3) 71 (30.2)
Personality, cognition and psychological mindedness
Dysfunctional attitudes score: mean (SD) 35.8 (11.0) 36.9 (10.6)
Metacognitive awareness score: mean (SD) 37.5 (7.7) 37.4 (7.6)
Neuroticism score: mean (SD) 4.0 (0.7) 4.1 (0.6)
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TABLE 82 Adherence to CBT intervention
Moderator No. of CBT sessions attended: mean (SD)
Demographic and life factors
Age (years)
< 30 11.0 (6.4)
30–39 10.7 (6.6)
40–49 11.0 (6.3)
> 49 11.6 (6.2)
Highest level of educationa
A-level/Higher Grade or above 12.5 (5.9)
Other qualiﬁcations – GCSE or equivalent 11.5 (5.9)
No formal qualiﬁcations 8.6 (6.5)
Marital status
Single 9.9 (6.6)
Married/living as married 11.6 (6.4)
Separated/divorced/widowed 11.5 (5.8)
Life events in the past 6 months
0 11.0 (6.2)
1–2 11.5 (6.2)
≥ 3 10.7 (6.8)
Illness characteristics
Baseline BDI severity
Less severe 10.8 (6.0)
Severe 11.6 (6.4)
Baseline CIS-R depression severityb
Low 11.1 (6.0)
High 11.3 (6.5)
No. of prior episodes of depression
0–1 10.5 (6.4)
2–4 10.7 (6.4)
≥ 5 11.9 (6.1)
Duration of current episode of depression:
< 1 year 10.2 (6.6)
1–2 years 12.0 (6.1)
> 2 years 11.5 (6.1)
Anxiety scorec
Low 11.3 (5.9)
High 11.2 (6.4)
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TABLE 82 Adherence to CBT intervention (continued )
Moderator No. of CBT sessions attended: mean (SD)
PTSD scoreb
Low 10.7 (6.5)
High 11.6 (6.0)
Illnesses
No chronic illness 10.8 (6.3)
Diabetes 7.8 (7.2)
Asthma 11.5 (5.6)
Arthritis 10.7 (7.6)
Heart disease 16.0 (2.9)
High blood pressure 12.4 (4.1)
Lung disease 4.0 (NA)
More than one of the above 10.7 (6.4)
None of the above but other 12.0 (6.0)
Personality, cognition and psychological mindedness
Dysfunctional attitudes scoreb
Low 10.4 (6.5)
High 12.1 (5.9)
Metacognitive awareness scoreb
Low 11.7 (6.2)
High 10.8 (6.3)
Neuroticism scoreb
Low 10.4 (6.5)
High 12.0 (5.9)
NA, not applicable.
a A-level are UK national qualiﬁcations generally taken at age 18 years, and qualiﬁcations at this level or equivalent are
usually required for entry to university/higher education.
b Continuous variables were median split to produce low and high categories.
c Low and high categories deﬁned as a score of < 2 and ≥ 2 respectively.
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TABLE 85 Results from repeated measures regression models when carried out separately for each level of the
potential moderator
Moderator ba 95% CI
Demographic and life factors
Age (years)
< 30 –2.4 –8.1 to 3.3
30–39 –0.5 –7.0 to 6.0
40–49 –5.0 –8.9 to –1.1
> 49 –6.6 –9.4 to –3.9
Highest level of education
A-level/Higher Grade or above –4.6 –7.5 to –1.7
Other qualiﬁcations: GCSE or equivalent –3.3 –7.7 to 1.1
No formal qualiﬁcations –7.5 –12.0 to –3.0
Marital status
Single –2.5 –7.3 to 2.4
Married/living as married –6.1 –8.8 to –3.3
Separated/divorced/widowed –5.0 –9.2 to –0.7
Life events in the past 6 months
0 –5.0 –9.0 to –1.0
1–2 –5.7 –8.4 to –3.1
≥ 3 –6.9 –12.2 to –1.5
Illness characteristics
Baseline BDI severity
Less severe –5.8 –8.1 to –3.5
Severe –4.6 –7.8 to –1.3
Baseline CIS-R depression severityb
Low –5.4 –8.0 to –2.8
High –5.1 –8.2 to –2.0
No. of prior episodes of depression
0–1 –5.2 –10.2 to –0.2
2–4 –5.5 –9.1 to –1.9
≥ 5 –4.7 –7.7 to –1.7
Duration of current episode of depression (years)
< 1 –6.1 –10.2 to –2.0
1–2 –3.5 –8.4 to 1.4
> 2 –5.2 –7.9 to –2.5
Anxiety scorec
Low –4.6 –7.9 to –1.3
High –5.3 –7.9 to –2.8
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TABLE 85 Results from repeated measures regression models when carried out separately for each level of the
potential moderator (continued )
Moderator ba 95% CI
PTSD scoreb
Low –3.5 –6.6 to –0.5
High –5.9 –8.7 to –3.2
Illnesses
No chronic illness –2.4 –6.8 to 2.0
Diabetes 1.5 –8.9 to 11.9
Asthma –8.4 –18.5 to 1.7
Arthritis –1.3 –8.7 to 6.1
Heart disease –15.4 –34.5 to 3.7
High blood pressure –10.1 –22.8 to 2.5
Lung disease 0 Omitted
More than one of the above –9.6 –15.0 to –4.2
None of the above but other –4.9 –8.2 to –1.6
Personality, cognition and psychological mindedness
Dysfunctional attitudes scoreb
Low –5.6 –8.4 to –2.8
High –4.7 –7.7 to –1.7
Metacognitive awareness scoreb
Low –8.2 –11.5 to –4.8
High –3.0 –5.7 to –0.3
Neuroticism scoreb
Low –3.3 –6.2 to –0.4
High –6.4 –9.4 to –3.3
a Values represent differences in mean BDI-II scores between randomisation groups. Negative values represent more
desirable outcomes (i.e. greater treatment-derived beneﬁt) relative to the reference subgroup.
b Continuous variables were median split to produce low and high categories.
c Low and high categories deﬁned as a score of > 2 and ≥ 2 respectively.
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31DiscussionSummary of main findings
This is the ﬁrst study testing for moderators of response to CBT as a ‘next-step’ treatment for primary care
patients who have not responded to antidepressants. Of the 14 variables assessed, age was the only
variable with some statistical evidence for effect modiﬁcation, with older patients beneﬁting the most from
CBT. We found no evidence of effect modiﬁcation by any other demographic, life, illness, personality trait
or cognitive variable. Insufﬁcient power prevents conclusive interpretation of such null ﬁndings. However,
our ﬁndings suggest that it would be premature to adopt a stratiﬁed approach to prescribing CBT as a
‘next-step’ treatment for individuals who have not responded to antidepressants.145
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Wiles et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
MODERATORS OF TREATMENT RESPONSE TO COGNITIVE BEHAVIOURAL THERAPY
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The limitations associated with post hoc subgroup analyses should be borne in mind when interpreting our
ﬁndings.167 Although the sample size (n = 469) is one of the largest RCTs of CBT to date, it is small for
testing interactions, creating uncertainty about the reliability of the estimates. In addition, multiple testing
increases the likelihood of chance ﬁndings. However, we tested 14 different variables and found evidence
for only one moderator. Given the move towards stratiﬁed medicine,165 it is important to discern for which
patients CBT is likely to work and for what reasons. Pragmatically, CBT is often reserved for the patients
who have not responded to antidepressants. Hence, identifying moderators of CBT response in this
population is clearly clinically important, and ours is the ﬁrst large-scale controlled study to examine effect
modiﬁers of CBT offered as a ‘next-step’ treatment for non-responders to pharmacotherapy.Demographic and life factors
Age was the only variable with evidence for effect modiﬁcation, with older patients beneﬁting the most
from CBT. There is no precedent for age as a moderator in previous studies of CBT in populations without
TRD,168,172 so we treat our result with caution, and it may be a type I error. In contrast with RCTs of
previously untreated episodes of depression, the mean age of patients in CoBalT was higher, with over
half of the sample being ≥ 50 years when they entered the study. We would not expect this in itself to
inﬂuence the ﬁndings in terms of the pattern of coefﬁcients, especially given the good balance between
the trial arms with respect to age. Yet it may have increased our power to detect this particular interaction
compared with other studies with a younger age distribution. Alternatively, it may reﬂect something
speciﬁc to the treatment-resistant population. CBT was most effective for patients over 40 years, and least
effective in patients aged 30–39 years. It is unclear why CBT was not beneﬁcial in this younger subgroup,
but it is worth noting that given the small numbers (n = 61) the CIs around the estimate are wide,
providing no evidence for either treatment beneﬁt or harm. Further research is required to assess whether
this ﬁnding is replicated.
In contrast with previous research,168,172,174 we did not identify marital status or stressful life events as
moderators. The point estimates for marital status were consistent with single individuals gaining least
from CBT, but there was no statistical evidence for effect modiﬁcation (p = 0.34). The estimates for life
events showed no evidence or even a suggestion of support for previous ﬁndings in non-TRD
samples.168,172Illness characteristics and comorbidity
In contrast with previous studies,168,177–179 pre-treatment severity of depression did not moderate response
to CBT. This may reﬂect the nature of our treatment-resistant sample; in CoBalT patients were selected
for their non-response to antidepressants. In our previous study, mild depression seemed self-limiting,
improving equally well irrespective of receiving CBT or waiting list control. By contrast, CBT was particularly
effective for severe depression, which did not improve in the waiting list arm. By deﬁnition, the depression
in patients recruited to CoBalT was not self-limiting as we selected patients through the resistance of their
symptoms to pharmacotherapy. This may explain the absence of effect modiﬁcation by severity in this
group. It is of note, however, that baseline severity in CoBalT was similar to other RCTs of depression in
the UK.109,185,186 The CoBalT sample was nevertheless more ill in terms of chronicity, number of previous
episodes, comorbidities and non-response to medication. This suggests that to capture the extent of illness
that we see clinically then we need to account for both severity and chronicity, especially in those whose
symptoms are resistant to antidepressants. However, an a priori subgroup analysis conducted in the main
trial found no evidence that the degree of treatment-resistance modiﬁed response to CBT (see Chapter 3,
Subgroup analyses).Personality, cognitions and psychological mindedness
The literature on assessing individuals’ suitability for CBT is based more on clinical opinion164 than empirical
evidence, and often focuses on interpersonal skills (which we were unable to investigate), personality and
psychological mindedness. Consistent with previous research assessing personality traits in untreated
episodes of depression,172,181 we found no evidence that neuroticism was a moderator of response to CBTNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18310 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 31in treatment-resistant individuals. Furthermore, dysfunctional attitudes and metacognitive awareness were
not associated with differential response. The practice of selecting patients for CBT based on assessments
of personality and psychological dysfunction and awareness remains empirically unsupported. Indeed, such
practice might be harmful, preventing individuals, who might actually beneﬁt, from receiving CBT.Clinical implications
Cognitive behavioural therapy as an adjunct to usual care is an effective ‘next-step’ treatment for patients
whose depression has not responded to treatment with antidepressants. This is an important ﬁnding, as, in
practice, limited availability means that referral for CBT often only follows non-response to ﬁrst-line
treatment with antidepressants. However, to further improve patients outcomes by tailoring treatment in
line with stratiﬁed medicine165 it is helpful to understand if there are any factors associated with differential
treatment response. We found that response to CBT differed with age, with older age groups beneﬁting
more. Given the small numbers of patients and wide CIs in this subgroup, we caution against using age to
inform treatment decisions until further research replicates this effect. We found no evidence to suggest
that non-response varied systematically with other patient characteristics. Until research replicates the age
ﬁnding, and in the absence of other clear and reliable moderators, consideration should be given to
offering CBT to all individuals where antidepressant medication has failed. Not all patients will respond,
but, as we have only preliminary evidence as to whom these might be, consideration should be given to
offering CBT to all patients in this severely ill group.ConclusionsCognitive behavioural therapy as an adjunct to usual care is an effective ‘next-step’ treatment for patients
whose depression has not responded to treatment with antidepressants. To move from a stepped care
towards a stratiﬁed approach requires evidence of reliable and informative moderators of CBT response.
To date, the evidence does not support a stratiﬁed approach to prescribing CBT in depressed patients who
have not responded to antidepressants, and we suggest, therefore, that consideration should be given to
offering CBT to all patients in this group. Future studies to investigate moderators of clinical importance
will require much larger sample sizes and this may need individual patient data meta-analyses.147
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Adequate Doses 
NAME TRADE NAME TYPE BNF* 
CODE 
 
 
MINIMUM 
ADEQUATE  
DAILY DOSE (MG) 
AMITRIPTYLINE N/A TRICYCLIC 4.3.1 150 
CITALOPRAM CIPRAMIL SSRI 4.3.3 20 
CLOMIPRAMINE ANAFRANIL TRICYCLIC 4.3.1 150 
DOSULEPIN PROTHIADEN TRICYCLIC 4.3.1 150 
DOXEPIN SINEPIN TRICYCLIC 4.3.1 150 
DULOXETINE CYMBALTA / 
YENTREVE 
SNRI 4.3.4 60 
ESCITALOPRAM CIPRALEX SSRI 4.3.3 10 
FLUOXETINE PROZAC SSRI 4.3.3 20 
FLUVOXAMINE FAVERIN SSRI 4.3.3 100 
IMIPRAMINE N/A TRICYCLIC 4.3.1 150 
LOFEPRAMINE FEPRAPAX / 
LOMONT 
TRICYCLIC 4.3.1 140 
MIANSERIN N/A TRICYCLIC-
RELATED 
4.3.1 60 
MIRTAZAPINE ZISPIN SolTab OTHER 4.3.4 30 
MOCLOBEMIDE MANERIX MAOI 4.3.2 600 
NORTRIPTYLINE ALLEGRON TRICYCLIC 4.3.1 75 
PAROXETINE SEROXAT SSRI 4.3.3 20 
REBOXETINE EDRONAX NaRI 4.3.4 8 
SERTRALINE LUSTRAL SSRI 4.3.3 100 
TRAZODONE MOLIPAXIN TRICYCLIC-
RELATED 
4.3.1 150 
TRIMIPRAMINE SURMONTIL TRICYCLIC 4.3.1 150 
VENLAFAXINE EFEXOR SNRI 4.3.4 75 
*Source: BNF No.55 (March 2008) for BNF code and dosage165
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Service user input was sought during the original application for funding for this study. We asked userrepresentatives to provide feedback on trial documentation and questionnaires during the preparatory
phase of the study. A user representative was a member of our independent TSC. The newsletter to
participants giving feedback on the study ﬁndings was developed in collaboration with the service user
member of our TSC.167
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